Public Meeting Agenda



Thursday, October 24, 2024 9:00 A.M.

BOARD ROOM

4800 Fournace Place, Bellaire, TX 77401

The meeting may be viewed online: http://harrishealthtx.swagit.com/live.

*Notice: Some Board Members may participate by videoconference.

Mission

Harris Health is a community-focused academic healthcare system dedicated to improving the health of those most in need in Harris County through quality care delivery, coordination of care and education.

AGENDA

I.	Call to Order and Record of Attendance	Dr. Andrea Caracostis	1 min
II.	Approval of the Minutes of Previous Meeting	Dr. Andrea Caracostis	1 min
	 Board Meeting – September 26, 2024 		
III.	Announcements / Special Presentations	Dr. Andrea Caracostis	15 min
	A. CEO Report Including Special Announcements – Dr. Esmaeil Porsa		(10 min)
	B. Board Member Announcements Regarding Board Member Advocacy and Community Engagements		(5 min)
IV.	Public Comment	Dr. Andrea Caracostis	3 min
V.	Executive Session	Dr. Andrea Caracostis	40 min
	A. Report Regarding Quality of Medical and Healthcare, Pursuant to Tex. Health & Safety Code Ann. §161.032, Tex. Occ. Code Ann. §160.007, and Tex. Occ. Code Ann. §151.002 to Receive Peer Review and/or Medical Committee Report, Including Report of the Medical Executive Board in Connection with the Evaluation of the Quality of Medical and Healthcare Services, Including the Harris Health Quality, Safety Performance Measures, Good Catch Recipients, Centers for Medicare and Medicaid Services Quality Reporting and Possible Action Regarding this Matter Upon Return to Open Session – Dr. Andrea Caracostis, Dr. Steven Brass and Dr. Yashwant Chathampally		(20 min)
	B. Medical Executive Board Report and Credentialing Discussion, Pursuant to Tex. Occ. Code Ann. §151.002, Tex. Occ. Code Ann. §160.007 and Tex. Health & Safety Code Ann. §161.032 to Receive Peer Review and/or Medical Committee Report, Including Consideration of Approval of Credentialing Changes for Members of Harris Health Medical Staff – Dr. Martha Mims and Dr. Bradford Scott		(10 min)

Board of Trustees I Board Meeting Agenda

October 24, 2024

Page 2 of 4

C. Report Regarding Harris Health Correctional Health Quality of Medical and Healthcare, Including Credentialing Discussion and Operational Updates, Pursuant to Tex. Occ. Code Ann. §151.002, Tex. Occ. Code Ann. §160.007, Tex. Health & Safety Code Ann. §161.032 and Tex. Gov't Code Ann. §551.071 to Receive Peer Review and/or Medical Committee Report with Possible Action Upon Return to Open Session - Dr. Otis Egins

(10 min)

VI. Reconvene to Open Meeting

Dr. Andrea Caracostis 2 min

VII. General Action Item(s)

Dr. Andrea Caracostis

Dr. Andrea Caracostis

4 min

- A. General Action Item(s) Related to Quality: Medical Staff
 - 1. Consideration of Approval of Credentialing Changes for Members of Harris Health Medical Staff – Dr. Martha Mims

(2 min)

- B. General Action Item(s) Related to Quality: Correctional Health Medical Staff
 - 1. Consideration of Approval of Credentialing Changes for Members of Harris Health Correctional Health Medical Staff - Dr. Otis Egins

(2 min)

VIII. New Items for Board Consideration

A. Consideration of Approval of the Appointment of Mr. Jim Robinson as a Member of the Board of Trustees Compliance and Audit Committee

(5 min)

10 min

B. Consideration of Approval of the Appointment of Ms. Libby Viera-Bland as a Member of the Board of Trustees Diversity Equity and Inclusion Committee and the Ambulatory Surgical Center at LBJ Governing Body

(5 min)

IX. Strategic Discussion

Dr. Andrea Caracostis 50 min

- A. Harris Health Strategic Plan Initiatives
 - 1. Presentation Regarding the Harris Health 2021-2025 Strategic Plan Update - Ms. Maria Cowles

(30 min)

2. Review and Consideration of Approval Regarding the Naming and Launch of the Sheila Jackson Lee Center for Accelerating Health Equity

(10 min)

- Dr. Chethan Bachireddy

(10 min)

- B. October Committee Reports:
 - Quality Committee Dr. Andrea Caracostis
 - DEI Committee Ms. Ingrid Robinson

X. Consent Agenda Items

Dr. Andrea Caracostis 5 min

- A. Consent Purchasing Recommendations
 - 1. Consideration of Approval of Purchasing Recommendations (Items A1 through A3 of the Purchasing Matrix) - Ms. Paige McInnis and Mr. Jack Adger, Harris County Purchasing Office

(See Attached Expenditure Summary: October 24, 2024)

2. Consideration of Approval of the Harris Health Premier Spend Report for Quarter 3 of Fiscal Year 2024 - Ms. Paige McInnis and Mr. Jack Adger, **Harris County Purchasing Office**

- **B.** Consent Committee Recommendations
 - Consideration of Approval of the 2025 DEI Reporting Schedule [DEI Committee]
- C. Consent Grant Recommendations
 - Consideration of Approval of Grant Recommendation (Item C1 of the Grant Matrix) – Mr. Jeff Baker

(See Attached Expenditure Summary: October 24, 2024)

- D. New Consent Items for Board Approval
 - Consideration of Approval of the Re-Appointment of Dr. Sandeep
 Markan as Chief of Staff for Ben Taub Hospital
 Dr. Glorimar Medina
 - Consideration of Approval of a Second Amendment to the Interlocal Subrecipient Agreement Between Harris County and Harris Health for Funds to Support Expansion of Harris Health's Food Rx and Food Farmacy Program – Dr. Chethan Bachireddy
 - 3. Consideration of Approval of a Second Amendment to the Population Health Collaboration Agreement between The University of Texas MD Anderson Cancer Center and Harris Health *Dr. Chethan Bachireddy*
 - Consideration of Approval to Amend the Lease with Houston Business
 Development, Inc. for the Dental Center located at 5220-5250 Griggs Rd.,
 Houston, Texas 77021 Mr. Patrick Casey
- E. Consent Reports and Updates to the Board
 - Updates Regarding Pending State and Federal Legislative and Policy Issues Impacting Harris Health – Mr. R. King Hillier

{End of Consent Agenda}

XI. Item(s) Related to the Health Care for the Homeless Program

- A. Review and Acceptance of the Following Reports for the Health Care for the Homeless Program (HCHP) as Required by the United States Department of Health and Human Services, which Provides Funding to the Harris County Hospital District d/b/a/Harris Health to Provide Health Services to Persons Experiencing Homelessness under Section 330(h) of the Public Health Service Act Dr. Jennifer Small and Ms. Tracey Burdine
 - HCHP October 2024 Operational Update
- B. Consideration of Approval of the HCHP Consumer Advisory Report

 Dr. Jennifer Small and Ms. Tracey Burdine

Consideration of Approval of the HCHP Revised Legislative Mandate Policy
 Dr. Jennifer Small and Ms. Tracey Burdine

Consideration of Approval of the HCHP HIV Prevention Funding
 Dr. Jennifer Small and Ms. Tracey Burdine

Dr. Andrea Caracostis 15 min

(11 min)

(1 min)

(1 min)

Board of Trustees I Board Meeting Agenda

October 24, 2024

Page 4 of 4

E. Consideration of Approval of the HCHP Quality Management Report

— Dr. Jennifer Small and Ms. Tracey Burdine

(1 min)

XII.	Executive Session	Dr. Andrea Caracostis	70 min
	D. Review of the Community Health Choice, Inc. and Community Health Choice Texas, Inc. Organizational Update and the Year-to-Date August 2024 Financial Performance, Pursuant to Tex. Gov't Code Ann. §551.085 – Ms. Lisa Wright, CEO and Ms. Anna Mateja, CFO, Community Health Choice		(10 min)
	E. <u>Discussion Regarding Expansion of Clinical Service Lines, Pursuant to Tex Gov't Code Ann. §551.072 and Tex. Gov't Code Ann. §551.085</u> – <i>Mr. Louis Smith and Mr. Cole Rasmussen, Capital Healthcare Planning</i>		(20 min)
	F. Consultation with Attorney Regarding Settlement of Claim with Johnston LLC, Pursuant to Tex. Gov't Code Ann. §551.071 and Possible Action Upon Return to Open Session – Ms. Ebon Swofford and Mr. Michael Fritz		(10 min)
	G. Report by the Executive Vice President, Chief Compliance and Risk Officer Regarding Compliance with Medicare, Medicaid, HIPAA and Other Federa and State Health Care Program Requirements, Including Status of Fraud and Abuse Investigations, Pursuant to Tex. Health & Safety Code Ann. §161.032 – Ms. Carolynn Jones and Mr. Anthony Williams		(10 min)
	H. Consultation with Attorney Regarding Jail Interlocal Agreement, Pursuant to Tex. Gov't Code §551.071 – Ms. Sara Thomas		(10 min)
	 Consultation with Attorney Regarding Council-at-Large Bylaws, Pursuant to Tex. Gov't Code §551.071 – Ms. Sara Thomas 		(10 min)
XIII.	Reconvene	Dr. Andrea Caracostis	1 min
XIV.	Adjournment	Dr. Andrea Caracostis	1 min



MINUTES OF THE HARRIS HEALTH SYSTEM BOARD OF TRUSTEES

Board Meeting Thursday, September 26, 2024 9:00 a.m.

AGENDA ITEM	DISCUSSION	ACTION/RECOMMENDATION
I. Call to Order and Record of Attendance	The meeting was called to order at 9:01 a.m. by Dr. Caracostis, Chair. It was noted that a quorum was present and the attendance was recorded. Dr. Caracostis stated while some of Board members are in the room with us today, others will participate by videoconference as permissible by state law and the Harris Health Videoconferencing Policy. Only participants scheduled to speak have been provided dial in information for the meeting. All others who wish to view the meeting may access the meeting online through the Harris Health website: http://harrishealthtx.swagit.com/live .	A copy of the attendance is
II. Approval of the Minutes of Previous Meeting	Fiscal Year 2025 Budget Workshop Meeting – August 1, 2024	Motion No. 24.09-127 Moved by Mr. Jim Robinson, seconded by Dr. Cody Pyke, and unanimously passed that the Board approve the minutes of the August 1, 2024 Fiscal Year 2025 Budget Workshop meeting. Motion carried.
	Special Call Board Meeting – August 22, 2024	Motion No. 24.09-128 Moved by Dr. Cody Pyke, seconded by Mr. Jim Robinson, and unanimously passed that the Board approve the minutes of the August 22, 2024 Special Call Board meeting. Motion carried.
	Board Meeting – August 29, 2024	Motion No. 24.09-129 Moved by Ms. Carol Paret, seconded by Ms. Afsheen Davis, and unanimously passed that the Board approve the minutes of the August 29, 2024 meeting. Motion carried.

III. Announcements/ Special Presentations	A. CEO Report Including Special Announcements	As Presented.
openia i continuo	Budget & Tax Rates Update	
	Public Art Project on the Lyndon B. Johnson Hospital (LBJ) Campus	
	Update Regarding Underground Power Lines on the LBJ Campus	
	 Dr. Esmaeil Porsa, President and Chief Executive Officer (CEO), presented the CEO Report and provided the following updates: Last week, the Harris County Commissioners Court approved Harris Health's revised FY25 budget and tax rate. Harris Health is requesting seasoned and emerging artists residing in Harris County to submit their qualifications for the LBJ Campus Expansion – Garage Façade Project (Phase I). Dr. Porsa expressed his deepest gratitude to CenterPoint Energy and its CEO, Mr. Jason Wells, for their support in enhancing resilience at our LBJ campus by undergrounding the power lines from the nearest electrical substation, located four miles away. Harris Health 2024 Physician Engagement Survey is currently in progress, and the 2024 Employee Engagement Survey will take place this November. Dr. Porsa also highlighted upcoming events, including a collaboration with the American Heart Association (AHA) to host the world's largest CPR training event on October 16, 2024 for World AIDS Day, along with our annual "Celebrate You" event on Saturday, November 9, 2024, from 9:00 AM to 7:00 PM at 4800 Fournace Place, Bellaire, Texas. 	
	B. Board Member Announcements Regarding Board Member Advocacy and Community Engagements There were no announcements made by the Board members.	As Presented.
	·	
IV. Public Comment	There were no public speakers registered to appear before the Board.	As Presented.
V. Executive Session	At 9:08 a.m., Dr. Caracostis stated that the Board would enter into Executive Session for Items V. 'A through D' as permitted by law under Tex. Health & Safety Code Ann. §161.032, Tex. Occ. Code Ann. §§151.002, 160.007 and Tex. Gov't Code Ann. §551.071.	
	A. Report Regarding Quality of Medical and Healthcare, Pursuant to Tex. Health & Safety Code Ann. §161.032, Tex. Occ. Code Ann. §160.007, and Tex. Occ. Code Ann. §151.002 to Receive Peer Review and/or Medical Committee Report, Including Report of the Medical Executive Board in Connection with the Evaluation of the Quality of Medical and Healthcare Services, Including the Harris Health Quality, Safety Performance Measures, and Possible Action Regarding this Matter Upon Return to Open Session	No Action Taken.

	B. Medical Executive Board Report and Credentialing Discussion, Pursuant to Tex. Occ. Code Ann. §151.002, Tex. Occ. Code Ann. §160.007 and Tex. Health & Safety Code Ann. §161.032 to Receive Peer Review and/or Medical Committee Report, Including Consideration of Approval of Credentialing Changes for Members of the Harris Health System Medical Staff	No Action Taken.
	C. Report Regarding Harris Health System Correctional Health Quality of Medical and Healthcare, Including Credentialing Discussion and Operational Updates, Pursuant to Tex. Occ. Code Ann. §151.002, Tex. Occ. Code Ann. §160.007, Tex. Health & Safety Code Ann. §161.032 and Tex. Gov't Code Ann. §551.071 to Receive Peer Review and/or Medical Committee Report with Possible Action Upon Return to Open Session	No Action Taken.
	D. Consultation with Attorney Regarding Interlocal Agreement between Harris County and Harris Health Related to Correctional Health Services, Pursuant to Tex. Gov't Code Ann. §551.071 and Possible Action Upon Return to Open Session	No Action Taken.
Meeting	At 9:46 a.m., Dr. Caracostis reconvened the meeting in open session; she noted that a quorum was present, and that no action was taken in Executive Session.	
VII. General Action Item(s)		
	A. General Action Item(s) Related to Quality: Medical Staff	
	 Approval of Credentialing Changes for Members of the Harris Health System Medical Staff Dr. Martha Mims, Chair, Medical Executive Board, presented the credentialing changes for members of the Harris Health System Medical Staff. For September 2024, there were forty – six (46) initial appointments, ninety – one (91) reappointments, three (3) change/add privileges, fourteen (14) resignations, eighteen (18) temporary privileges and fourteen (14) urgent patient care need privileges. A copy of the credentialing report is available in the permanent record. 	unanimously passed that the Board approve agenda item
	B. General Action Item(s) Related to Quality: Correctional Health Medical Staff	
	 Approval of Credentialing Changes for Members of the Harris Health System Correctional Health Medical Staff Dr. Otis Egins, Chief Medical Officer, Harris Health Correctional Health, presented the credentialing changes for members of the Harris Health System Correctional Health Medical Staff. For September 2024, there were two (2) initial appointments and two (2) reappointments. A copy of the credentialing report is available in the permanent record. 	Moved by Ms. Carol Paret, seconded by Ms. Jennifer Tijerina, and unanimously passed that the Board approve
	Approval of the Harris Health Correctional Health Medical Staff Bylaws Dr. Caracostis noted that this item has been pulled and will be revisited next month.	PULLED

VIII. New Items for Board Consideration		
	County Hospital District d/b/a Harris Health for Correctional Healthcare	Motion No. 24.09-132 Moved by Ms. Afsheen Davis, seconded by Ms. Jennifer
	Ms. Sara Thomas, Chief Legal Officer, Harris County Attorney's Office, indicated that this agreement extends the Interlocal Agreement (ILA) until December 31, 2024 to allow Harris County and Harris Health time to finalize the terms of a new ILA that updates the current arrangements. A copy of	Tijerina, and unanimously passed that the Board approve agenda item VIII.A. Motion carried.
	Ms. Victoria Nikitin, Executive Vice President & Chief Financial Officer, presented the Revised Harris Health Fiscal Year 2025 Operating and Capital Budget, reflecting the new VAR tax rate of \$0.16348 approved by the Harris County Commissioners Court. A copy of the Revised Harris Health	Motion No. 24.09-133 Moved by Ms. Jennifer Tijerina, seconded by Dr. Cody Pyke, and unanimously passed that the Board approve agenda item VIII.B. Motion carried.
	C. Approval to Enter into a New Sublease Agreement between Harris Health and Harris County for Clinical Space at Centrico Pasadena Development, 100 Pasadena Blvd., Pasadena, TX 77506	Motion No. 24.09-134 Moved by Dr. Cody Pyke, seconded by Mr. Jim Robinson,
	Dr. Jennifer Small, Executive Vice President, Ambulatory Care Services, shared that Harris Health plans to consolidate and relocate the Monroe Same Day Clinic, Strawberry Health Center, and the	and unanimously passed that the Board approve agenda item VIII.C. Motion carried.

IX. Strategic Discussion		
	A. Presentation Regarding New Hospital Construction and Costs Mr. Casey delivered a presentation on New Hospital Construction and Costs. He outlined a timeline for the LBJ campus expansion, summarizing the projected construction costs from groundbreaking in May 2024 to the first quarter of 2029. He also emphasized three (3) key categories contributing to these construction costs. Mr. Smith indicated that the Board will receive updates during each phase of the construction process. A copy of the presentation is available in the permanent record.	
	 B. September Committee Reports Quality Committee Dr. Pyke stated that the Quality Committee met on September 10, 2024 and the following topics were covered: The monthly High Reliability Organization (HRO) Video "Antibiotics Before Surgery" was displayed. The Red Rule Policy was updated to ensure all staff operate within a just and accountable culture. The review focused on defining, differentiating, and responding to the three behaviors that can lead to risk and patient harm: (1) human error; (2) at-risk behavior; and (3) reckless behavior. The changes were effective August 26, 2024. Compliance & Audit Committee 	As Presented.
	 Ms. Carol Paret stated that the Compliance & Audit Committee met on September 10, 2024 and the following topics were covered: Board Education: The Committee received compliance education from the Chief Compliance and Risk Officer on Compliance Program Infrastructure: The Seven Elements. Internal Audit Quarterly Update:	
	 Summary of outstanding management action plans (MAPs) – There were eleven (11) outstanding MAPs from six (6) prior engagements (UT Provider Invoicing; Medical Device Security; M/WBE Program and Policy; Business Continuity and 	

		1
	Disaster Recovery; HIPAA Privacy Controls; Vendor Payment Timeliness). This included five past-due, high-priority MAPs to be discussed in Executive Session.	
	 Joint Conference Committee Dr. Caracostis stated that the Joint Conference Committee met on September 12, 2024 and the following topics were covered: The Committee received an update from Dr. Martha Mims, Chair, Medical Executive Board, regarding the MEB. The Committee received an update from Dr. Tien Ko, Chief of Staff, LBJ and Dr. Sandeep Markan, Chief of Staff, BT, related to System pavilions. The Committee received an update from Dr. Fareed Khan, Assistant Chief of Staff, BT and Dr. Mohammad Zare, Assistant Chief of Staff, UT, related to Ambulatory Care Services. 	
X. Consent Agenda Items		
	A. Consent Purchasing Recommendations	
	 Approval of Purchasing Recommendations (Items A1 through A9) Ms. Paige McInnis, Purchasing Agent, Harris County, noted that the total expenditures at the bottom of the purchasing matrix was amended from \$52,798,220 to reflect \$22,798,220. A copy of the purchasing agenda is available in the permanent record. 	<u>-</u>
	B. Consent Committee Recommendations	
	Ms. Tijerina requested to have consent agenda item X.C.1. (Item C4) pulled from the consent agenda for discussion.	
	Approval of the Annual Reports Regarding Neonatal and Maternal Health Programs for Ben Taub and LBJ Hospitals Discussed at the September 10, 2024 Quality Committee	Motion No. 24.09-136 Moved by Dr. Cody Pyke, seconded by Ms. Jennifer Tijerina, and unanimously passed that the Board approve agenda items X.B.1. through X.D.1., with the exception of X.C.1. (Item C4) of the Grant Matrix. Motion carried. *NOTE: This motion substituted the previous motion, which incorrectly excluded all of Items X.C.1. (C1-C4) of the Grant Matrix.

C. Consent Grant Recommendations	
	Motion No. 24.09-136
1. Approval of Grant Recommendations (Items C1 through C4)	Moved by Dr. Cody Pyke,
	seconded by Ms. Jennifer
Ms. Tijerina inquired about grant related to the Harris Health Strategic Fund. Dr. Porsa clarified	Tijerina, and unanimously
that while the Strategic Fund Board was established to raise funds for the strategic facilities	passed that the Board approve
plan, it can also accept and distribute grants. This award, presented by EPIC, is designated for	agenda items X.B.1. through
correctional health for various purposes. A copy of the grant matrix is available in the	_ =
permanent record.	item X.C.1. (Item C4) of the Grant
	Matrix. Motion carried.
	*NOTE: This motion substituted the
	previous motion, which incorrectly
	excluded all of Items X.C.1. (C1-C4)
	of the Grant Matrix.
	Motion No. 24.09-137
	Moved by Dr. Cody Pyke,
	seconded by Ms. Afsheen Davis,
	and unanimously passed that the
	Board approve agenda item
	X.C.1. (Item C4) of the Grant
	Matrix. Motion carried.
	*Note: this item was taken out of
	order after it was pulled from the
	consent agenda.
D. New Consent Items for Board Approval	
Acceptance of the Harris Health August 2024 Financial Report Subject to Audit	Motion No. 24.09-136
	Moved by Dr. Cody Pyke,
	seconded by Ms. Jennifer
	Tijerina, and unanimously
	passed that the Board approve
	agenda items X.B.1. through
	X.D.1., with the exception of
	item X.C.1. (Item C4) of the Grant
	Matrix. Motion carried.
	*NOTE: This motion substituted the
	previous motion, which incorrectly
	excluded all of Items X.C.1. (C1-C4) of
	the Grant Matrix.
E. Consent Reports and Updates to the Board	

	Updates Regarding Pending State and Federal Legislative and Policy Issues Impacting Harris Health System	For Information Only
	{End of Consent Agenda}	
XI. Item(s) Related to the Health Care for the Homeless Program		
	 A. Review and Acceptance of the Following Reports for the Health Care for the Homeless Program (HCHP) as Required by the United States Department of Health and Human Services, which Provides Funding to the Harris County Hospital District d/b/a/Harris Health System to Provide Health Services to Persons Experiencing Homelessness under Section 330(h) of the Public Health Service Act HCHP September 2024 Operational Update HCHP C8E Capital Grant Extension HCHP Service Area Competition Grant Budget HCHP Patient Satisfaction Report 	Motion No. 24.09-138 Moved by Ms. Afsheen Davis, seconded by Dr. Cody Pyke, and unanimously passed that the Board approve agenda item XI.A. Motion carried.
	Dr. Nelson Gonzalez, Grants Project Manager, Health Care for the Homeless Program, presented the September 2024 Operational Update. This included details on the HCHP C8E Capital Grant Extension, the HCHP Service Area Competition Grant Budget, and the HCHP Patient Satisfaction Report. He reported that HCHP has provided care to 4,902 unduplicated patients and conducted a total of 18,403 visits year – to – date. In August of 2024, HCHP served 1,240 unduplicated patients, with 805 receiving family practice services. Dr. Gonzalez noted an increase in services compared to the previous year, reporting a total of 2,681 completed visits for the month of August of 2024. He gave an overview of the American Rescue Plan for health center construction and capital improvements, detailing the award date, funding amount, and services offered. He also outlined the budget for the Service Area Competition Grant Application, along with the services provided. Finally, Dr. Gonzalez presented the trending data for HCHP Patient Satisfaction for the second quarter. A copy of the presentation is available in the permanent record.	
	B. Approval of the HCHP C8E Capital Grant Extension	Motion No. 24.09-139 Moved by Dr. Cody Pyke, seconded by Ms. Jennifer Tijerina, and unanimously passed that the Board approve agenda item XI.B. Motion carried.

	C. Approval of the HCHP Service Area Competition Grant Budget	Motion No. 24.09-140 Moved by Ms. Carol Paret, seconded by Ms. Jennifer Tijerina, and unanimously passed that the Board approve agenda item XI.C. Motion carried.
	D. Approval of the HCHP Patient Satisfaction Report	Motion No. 24.09-141 Moved by Ms. Afsheen Davis, seconded by Ms. Jennifer Tijerina, and unanimously passed that the Board approve agenda item XI.D. Motion carried.
XII. Executive Session	At 10:48 a.m., Dr. Andrea Caracostis stated that the Board would enter into Executive Session for Items XII. 'E through H' as permitted by law under Tex. Health & Safety Code Ann. §161.032 and Tex. Gov't Code Ann. §§551.071, 551.074, and 551.085.	
	E. Review of the Community Health Choice, Inc. and Community Health Choice Texas, Inc. Organizational Update and the Year-to-Date July 2024 Financial Performance, Pursuant to Tex. Gov't Code Ann. §551.085	No Action Taken.
	F. Consultation with Attorney Regarding Settlement of Claim with Clark Linbeck, Pursuant to Tex. Gov't Code Ann. §551.071 and Possible Action Upon Return to Open Session	Motion No. 24.09-142 Moved by Dr. Cody Pyke, seconded by Mr. Jim Robinson, and unanimously passed that the Board approve agenda item XII.F. Motion carried.
	G. Report by the Executive Vice President, Chief Compliance and Risk Officer, Regarding Compliance with Medicare, Medicaid, HIPAA and Other Federal and State Health Care Program Requirements, Including Status of Fraud and Abuse Investigations, Pursuant to Tex. Health & Safety Code Ann. §161.032	No Action Taken.

	H. Discussion Regarding the Chief Executive Officer (CEO) Evaluation, Pursuant to Tex. Gov't Code Ann. §551.074 and Possible Action Upon Return to Open Session	Motion No. 24.09-143 Moved by Ms. Carol Paret, seconded by Mr. Jim Robinson, and majority passed that the Board approve agenda item XII.H. Ms. Jennifer Tijerina opposed the motion. Motion carried. *NOTE: This motion was moved to approve the 2024 Evaluation of the President/CEO as presented in Executive Session. Motion No. 24.09-144 Moved by Dr. Cody Pyke, seconded by Ms. Carol Paret, and majority passed that the Board approve agenda item XII.H. Ms. Jennifer Tijerina abstained from the vote. Motion carried. *NOTE: This motion was moved to approve the first amendment to the employee agreement between Dr. Esmaeil Porsa and Harris Health. Motion No. 24.09-145 Moved by Dr. Cody Pyke, seconded by Ms. Carol Paret, and majority passed that the Board approve agenda item XII.H. Ms. Jennifer Tijerina abstained from the vote. Motion carried. *NOTE: This motion was moved to approve the Fiscal Year 2025 CEO Evaluation metrics as presented in
XIII. Reconvene	At 12:34 p.m., Dr. Andrea Caracostis reconvened the meeting in open session; she noted that a quorum was present, and that no action was taken in Executive Session. Dr. Caracostis stated that the	Executive Session.
XIV. Adjournment	Board will now take action on items XII. 'F and H' of the Executive Session agenda. There being no further business to come before the Board, the meeting adjourned at 12:37 p.m.	

Minutes of the Board of Trustees Board Meeting – September 26, 2024 Page 11 of 11

I certify that the foregoing are the Minutes of the Harris Health System Board of Trustees Meeting held on September 26, 202	I certify	that the foregoin	g are the Minutes of	the Harris Health Sv	stem Board of Trustees N	leeting held on Septembe	er 26, 2024.
--	-----------	-------------------	----------------------	----------------------	--------------------------	--------------------------	--------------

Respectfully Submitted,

Andrea Caracostis, MD, MPH, Chair

Carol Paret, BS, Secretary

Minutes transcribed by Cherry A. Pierson, MBA

Thursday, September 26, 2024 Harris Health System Board of Trustees Board Meeting – Attendance

Note: For Zoom meeting attendance, if you joined as a group and would like to be counted as present, please submit an email to:

BoardofTrustees@harrishealth.org before close of business the day of the meeting.

BOARD MEMBERS PRESENT	BOARD MEMBERS ABSENT
Afsheen Davis	
Dr. Andrea Caracostis (Chair)	
Carol Paret (Secretary)	
Dr. Cody M. Pyke (Vice Chair)	
Ingrid Robinson	
Jennifer Tijerina	
Jim Robinson	
Libby Viera-Bland	
Sima Ladjevardian	

EXECUTIVE LEADERSHIP/STAFF/ SPECIAL INVITED GUESTS							
Alexander Yaffe (Pearl Meyer)	Jerry Summers						
Dr. Amy Smith	Jessey Thomas						
Anna Mateja (Community Health Choice, CFO)	John Matcek						
Anthony Williams	Dr. Joseph Kunisch						
Dr. Anwar Mohammad Sirajuddin	Dr. Kunal Sharma						
Carolynn Jones	Lindsey "Katie" Rutherford (Harris County Attorney's Office)						
Cherry Pierson	Lisa Wright (Community Health Choice, CEO)						
Daniel Smith	Louis Smith						
Derek Curtis	Maria Cowles						
Ebon Swofford (Harris County Attorney's Office)	Dr. Martha Mims						
Elizabeth Hanshaw Winn (Harris County Attorney's Office)	Maureen Padilla						
Dr. Esmaeil Porsa (Harris Health System, President & CEO)	Micah Rodriguez						
Esperanza "Hope" Galvan	Michael Fritz (Harris County Attorney's Office)						
Dr. Glorimar Medina	Dr. Michael Nnadi						
Holly Gummert (Harris County Attorney's Office)	Nathan Bac (Harris County Attorney's Office)						
Jack Adger (Harris County Purchasing Office)	Dr. Nelson Gonzalez						
Dr. Jackie Brock	Nicholas J. Bell						
Jay Aiyer (Harris County Attorney's Office)	Olga Rodriguez						
Dr. Jennifer Small	Omar Reid						
Jennifer Zarate	Dr. O. Reggie Egins						

EXECUTIVE LEADERSHIP/STAFF/ SPECIAL INVITED GUESTS						
Paige McInnis (Harris County Purchasing Office)	Dr. Sandeep Markan					
Pamela Russell	Sara Thomas (Harris County's Attorney's Office)					
Patricia Darnauer	Sharon Brantley-Smith					
Patrick Casey	Shawn DeCosta					
R. King Hillier	Dr. Steven Brass					
Randy Manarang	Tekhesia Phillips					
Ron Fuschillo	Dr. Tien Ko					
Sam De Leon	Victoria Nikitin					
Sam Karim	Vivian Ho-Nguyen					



Public Comment Request and Registration Process

Pursuant to Texas Government Code §551.007, members of the public are invited to attend the regular meetings of the Harris Health System Board of Trustees and may address the Board during the Public Comment segment regarding an official agenda item that the Board will discuss, review, or take action upon, or regarding a subject related to healthcare or patient care rendered at Harris Health System. Public Comment will occur prior to the consideration of all agenda items. If you have signed up to attend as a Public Speaker virtually, a meeting link will be provided. Note: Public Speakers will be removed from the meeting after speaking and have the option to join the meeting live via http://harrishealthtx.swagit.com/live.

How to Request to Address the Board of Trustees

Members of the public must register in advance to speak at the Harris Health System Board of Trustees meetings. To register, members of the public must contact the Board of Trustees Office during core business hours, Monday through Friday between 8:00 a.m. to 5:00 p.m. Members of the public must submit the registration no later than 4:00 p.m. on the day before the scheduled meeting and may only register in one of the following manners:

- Providing the requested information located in the "Speak to the Board" tile found at: https://www.harrishealth.org/about-us-hh/board/Pages/public-comment-request-and-registration-process.aspx.
- 2. Printing and completing the downloadable registration form found at: https://www.harrishealth.org/about-us-hh/board/Pages/public-comment-request-and-registration-process.aspx.
 - A hard-copy may be scanned and emailed to <u>BoardofTrustees@harrishealth.org.</u>
 - 2b. Mailing the completed registration form to 4800 Fournace Pl., Ste. E618, Bellaire, TX 77401.
- 3. Contacting staff at (346) 426-1524.

Prior to submitting a request to address the Harris Health System Board of Trustees, please take a moment to review the rules to be observed during the Public Comment Period.

Rules During Public Comment Period

The presiding officer of the Board of Trustees or the Board Secretary shall keep the time for speakers.

Three Minutes

A speaker, whose subject matter, as submitted, relates to an identifiable item of business on the agenda, will be requested by the presiding officer to come to the podium where they will be provided three (3) minutes to speak. A speaker, whose subject matter, as submitted, does not relate to an identifiable item of business on the agenda, will also be provided three (3) minutes to speak. A member of the public who addresses the body through a translator will be given at least twice the amount of time as a member of the public who does not require the assistance of a translator.

harrishealth.org



Meeting of the Board of Trustees

- Page 19 Was Intentionally Left Blank -



Meeting of the Board of Trustees

Thursday, October 24, 2024

Executive Session

Report Regarding Quality of Medical and Healthcare, Pursuant to Tex. Health & Safety Code Ann. §161.032, Tex. Occ. Code Ann. §160.007, and Tex. Occ. Code Ann. §151.002 to Receive Peer Review and/or Medical Committee Report, Including Report of the Medical Executive Board in Connection with the Evaluation of the Quality of Medical and Healthcare Services, Including the Harris Health Quality, Safety Performance Measures, Good Catch Recipients, Centers for Medicare and Medicaid Services Quality Reporting and Possible Action Regarding this Matter Upon Return to Open Session.

Dr. Yashwant Chathampally

Associate Chief Medical Officer, Senior Vice President – Quality & Patient Safety



Meeting of the Board of Trustees

- Pages 21-34 Were Intentionally Left Blank -

BOARD OF TRUSTEES Meeting of the Board of Trustees



Thursday, October 24, 2024

Executive Session

Medical Executive Board Report and Credentialing Discussion, Pursuant to Tex. Occ. Code Ann. §151.002, Tex. Occ. Code Ann. §160.007 and Tex. Health & Safety Code Ann. §161.032 to Receive Peer Review and/or Medical Committee Report, Including Consideration of Approval of Credentialing Changes for Members of the Harris Health System Medical Staff.

Dr. Yashwant Chathampally

Associate Chief Medical Officer, Senior Vice President – Quality & Patient Safety



Meeting of the Board of Trustees

- Pages 36-59 Were Intentionally Left Blank -



Meeting of the Board of Trustees

Thursday, October 24, 2024

Executive Session

Report Regarding Harris Health System Correctional Health Quality of Medical and Healthcare, Including Credentialing Discussion and Operational Updates, Pursuant to Tex. Occ. Code Ann. §151.002, Tex. Occ. Code Ann. §160.007, Tex. Health & Safety Code Ann. §161.032 and Tex. Gov't Code Ann. §551.071 to Receive Peer Review and/or Medical Committee Report with Possible Action Upon Return to Open Session.

Otis R. Egins

Otis R. Egins, MD, CCHP-P Chief Medical Officer of Correctional Health



Meeting of the Board of Trustees

- Pages 61-65 Were Intentionally Left Blank -



Meeting of the Board of Trustees

Thursday, October 24, 2024

Consideration of Approval Regarding Credentialing Changes for Members of the Harris Health System Medical Staff

The Harris Health System Medical Executive Board approved the attached credentialing changes for the members of the Harris Health System Medical Staff on October 8, 2024.

The Harris Health System Medical Executive Board requests the approval of the Board of Trustees.

Thank you.

Dr. Yashwant Chathampally

Associate Chief Medical Officer, Senior Vice President – Quality & Patient Safety

Board of Trustees



October 2024 Medical Staff Credentials Report

Medical Staff Initial Appointments: 33	
BCM Medical Staff Initial Appointments - 17	
UT Medical Staff Initial Appointments - 16	
HCHD Medical Staff Initial Appointments - o	
Medical Staff Reappointments: 270	
BCM Medical Staff Reappointments - 125	
UT Medical Staff Reappointments - 138	
HCHD Medical Staff Reappointments - 7	
BCM/UT/Harris County Hospital District (Harris Health) Medical Staff Changes in Clinical Privileges: 12	
BCM/UT/HCHD Medical Staff Resignations: 31	
DCM/01/ncno Medical Staff Resignations: 31	
Other Business	
Other pushiess	
For Information	
Temporary Privileges Awaiting Board Approval - 18	
Urgent Patient Care Need Privileges Awaiting Board Approval - 8	
BCM/UT/Harris County Hospital District (Harris Health) Medical Staff Files for Discussion: 3	
Medical Staff Initial Appointment Files for Discussion - 2	
Medical Staff Reappointment Files for Discussion - 1	
Medical Staff Reappointment Files for Discussion - 1	
Medical Staff Reappointment Files for Discussion - 1	



Meeting of the Board of Trustees

Thursday, October 24, 2024

Consideration of Approval of Credentialing Changes for Members of the Harris Health

Correctional Health Medical Staff

The Harris Health Correctional Health Medical Executive Committee approved the attached credentialing changes for the members of the Harris Health Medical Staff on September 23, 2024.

The Harris Health Correctional Health Medical Executive Committee requests the approval of the Board of Trustees.

O. Reggie Egins

O. Reggie Egins, MD, CCHP-P
Chief Medical Officer of Correctional Health

Board of Trustees



October 2024 Correctional Health Credentials Report

Medical Staff Initial Appointments: 2
Medical Staff Reappointments: 7
Medical Staff Resignations: 3
Medical Staff Files for Discussion: 1
Wedical Staff Files for Discussion: 1

2024 Strategic Discussion Reporting Schedule

Strategic Pillar	Executive Owner	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
NAME OF THE PROPERTY OF THE PR		2024	2024	2024	2024	2024	2024	2024	2024	2024	2024	2024	2024
Pillar 1: Quality & Patient Safety	Dr. Steven Brass												
Rollout of HRO Progress (Presented in Quality Committee)	Dr. Steven Brass			×	1								
Physician Engagement Survey (Presented in Joint Conference Committee)	Dr. Steven Brass			×									
Pillar 2: People	Omar Reid/ Dr. Jackie Brock										×		
Employee Engagement Survey	Omar Reid/ Gary Marsh				×	î.							
Pillar 3: One Harris Health	Louis Smith										×		
Hospital at Home - Program Operations	Dr. Amy Smith/ Dr. Shazia Sheikh					×							
Pillar 4: Population Health Management	Dr. Jennifer Small/ Dr. Chethan Bachireddy												
Systematizing Screening & Referrals for Health-Related Social Needs (HRSN) (Presented in Quality Committee)	Hope Galvan/ Denise LaRue	×											
Community Health Worker Home Visit Program (Presented in DEI Committee)	Hope Galvan				×								
Social Determinants of Health: Medical Legal Partnership (Presented in Quality Committee)	Dr. Chethan Bachireddy/ Hope Galvan								×				
Access to Care as a Social Determinant of Health (Will be presented in DEI Committee)	Dr. Chethan Bachireddy/ Hope Galvan										×		
Pillar 5: Infrastructure Optimization	Louis Smith												
New LBJ Hospital and LBJ Campus Planning	Louis Smith/ Trish Darnauer					×							
IT Technology Governance	Louis Smith/ Ron Fuschillo						×						
New Hospital Construction and Costs	Louis Smith/ Patrick Casey									×			
Pillar 6: Diversity & Inclusion	Omar Reid				1								
Minority Women Owned Business Enterprise (Presented in DEI Committee)	Dr. Jobi Martinez/ Derek Holmes				×								
M/WBE Annual Report (Presented in DEI Committee)	Dr. Jobi Martinez/ Derek Holmes								×				

*Subject to Change Revised: 9.19.24



Meeting of the Board of Trustees

Thursday, October 24, 2024

Presentation Regarding the Harris Health 2021-2025 Strategic Plan Update

Maria M. Cowles


EVP, Chief Strategy Officer and Chief of Staff

2021 – 2025 Strategic Plan Update

Maria Cowles Chief Strategy Officer

HARRISHEALTH

Harris Health Leadership Team Timeline



HARRISHEALTH

Setting the Stage: Harris Health From 2019 – 2020

- In 2019, an adverse safety event leads to an HHSC survey and letter of termination from CMS.
- Harris Health hires two consultants to assist with driving organizational change: Alvarez & Marsal and RFLIA.
- Two additional adverse safety events drive more organizational change.
- Harris Health undergoes an intense CMS validation survey with issues identified and plans of correction created.



March 2020: Dr. Esmaeil Porsa joins Harris Health as President & CEO

- Harris Health completes CMS validation survey and deemed status is restored. Harris Health undergoes a full CLIA
- survey with issues identified and plans of correction created.
- Harris Health resolves CLIA findings and restores status.
- COVID pandemic begins.
- Strategic planning for 2021 2025 begins.
- A steam line bursts at LBJ, resulting in patient and staff injury.
- Harris Health's Board of Trustees approves Harris Health's 2021 – 2025 strategic plan.



2021 – 2025 Strategic Plan

Many thanks to:

- Dr. Kim Monday, Chair
- Linda Morales, Vice Chair
- Elena Marks, Secretary
- Dr. Art Bracey
- Dr. Andrea Caracostis
- Anne Clutterbuck
- Larry Finder
- Dr. Ewan Johnson
- Alicia Reyes

- The 2021 2025 Strategic Plan took 8 months to complete, with another 2 months spent executing the communications plan.
- Feedback was obtained from via an all-employee/medical staff survey, 36 individuals, and 4 subgroups.
- Updates were provided at 5 Board meetings.
- 3 dedicated Board retreats provided a forum for more in-depth discussion.
- The plan was designed to address:
 - Quality and patient safety
 - ☐ Aging and deteriorating infrastructure
 - ☐ Primary and specialty care access
 - Non-medical determinants of health
 - ☐ Correctional health care
- The strategic facilities plan and strategic financial plan were developed in support of the strategic plan imperatives.


HARRISHEALTH


2021 – 2025 Strategic Plan

Pillar 1	Quality and Patient Safety	Harris Health will become a high-reliability organization (HRO) with quality and patient safety as a core value where zero patient harm is not only a possibility but an expectation.
Pillar 2	People	Harris Health will enhance the patient, staff and provider experience by actively listening to feedback and developing strategies to address high impact areas of opportunity. Moreover, Harris Health will develop a culture of respect, recognition and trust with its patients, staff and providers.
Pillar 3	One Harris Health	Harris Health will act as one system in its approach to management and delivery of healthcare.
Pillar 4	Population Health	Harris Health will measurably improve patient health outcomes by optimizing a cross-continuum approach to health that is anchored in high-impact preventive, virtual, and community-based services, deployed in coordination with clinical and social services partners, and underwritten by actionable population health analytics and technology.
Pillar 5	Infrastructure Optimization	Harris Health will invest in and optimize infrastructure related to facilities, information technology (IT), telehealth, information security, health informatics & Data Science strategies to increase value, ensure safety and meet the current and future needs of the population we serve.
Pillar 6	Diversity, Equity, and Inclusion	Harris Health will ensure equitable access to high-quality care for our patients, foster a diverse and inclusive workplace, cultivate and sustain strategic relationships with suppliers and community partners, and broaden our reach and our understanding of the communities we serve.

HARRISHEALTH

Pillar 2: People





ACS score: "Would Recommend Facility" BT& LBJ score: HCAHPS Overall Rating

QUARTERLY ANNUALIZED TURNOVER RATE CY 2022, CY 2023 AND CY 2024 (JAN-SEP) SYSTEM-WIDE



Employee Engagement

- BT and LBJ achieved ANCC Magnet Status in 2020
- ACS achieves Pathways to Excellence in 2023
- Implemented executive rounding program
- Launched eMBA program
- Expanded student debt repayment program
- Two minimum/living wage increases
- Developed Patient Care Assistant and Medical Assistant Programs in partnership with Houston Community College
- Developed Licensed Vocational Nurse Residency Program in ACS and Correctional Health
- Focus on additional residencies: nursing residency and fellowship, nurse externs, diagnostic medical imaging, physical therapy, clinical pastoral education

HARRISHEALTH

6

Pillar 3: One Harris Health System

72%

Voter Approval Rate

Bond Proposal



- 65 admissions todate
- 195 bed days saved to-date

Hospital at Home



- 11 specialties performing econsults with 45,664 performed
- 1,202,369 virtual visits
- Creation of services lines
- Deployment of huddle boards
- Creation of vertical care units and observation units

Additional Efficiency and Throughput Efforts



- Significant focus on labor productivity benchmarking
- Timely vendor payment percentage increased from 73% in FY23 to 86% FY24 YTD.
- Expansion of 340B program to HCJ and ASC

Financial Stability



Pillar 4: Population Health Management



Strawberry Health Center May 2019



LBJ Hospital Campus May 2021



Food Farmacy @ Settegast, El Franco, Gulfgate & MLK Community Redemption @ Squatty Lyons & Cypress Food Lockers @ Casa and Thomas Street at Quentin Mease Coming Soon 2024 / 2025





April 2023 Baytown Health Center - Hearts and Hands of Baytown Partnership



Food Farmacy Metrics May 28, 2019 – June 30, 2024



Pillar 4: Population Health Management

Multi-Visit Patient (MVP) Program

- During the first two years of the program, annual MVP Emergency Department (ED) visits decreased more than 10% each year while total ED visits were increasing 4-5% per year.
- Three years into the program, the annual MVP visit count is down 23.2% (more than 1,500 visits per year) from baseline.
- These decreases in MVP visits have been mirrored by similarly substantial decreases in total length-of-stay hours among MVP patients, which have decreased 16,000 hours per year, down 36% from baseline.

Community Health Worker Program

Lives Impacted	Baseline A1c	Endline A1c	Change in A1c	% Reengaged with PCP	% Reengaged with Ancillary Services
520 Unique Patients	11.1%	8.7%	-2.4%	78% of patient	71% of patients

HealthyConnect Remote Patient Monitoring

- Since April 2022, HealthyConnect has enrolled 3,384 patients who have received over 294,000 automated text messages and 34,000 phone calls.
- HealthyConnect enrolled historically marginalized patients – 49% Black and 45% Hispanic patients taking a step towards addressing the inequities in blood pressure control rates between Hispanic and Black patients compared to our White patients.
- Since program launch, 1,587 patients have graduated with an average engagement of seven months. At baseline, the average blood pressure was 150/84 mmHg. After graduation, the average blood pressure was 128/75 mmHg.
- HealthyConnect initially launched in the three lowest-performing clinics, all of which had blood pressure control rates ranging from 44.2-55.9%. Now those three clinics have greatly improved their blood pressure control, with rates ranging from 61.3 68.7%.

HARRISHEALTH

October 2023 – September 2024

Pillar 5: Infrastructure Optimization

LBJ Campus

Estimated Scope	Start Design/Assessment	Start Procurement	Start Construction	Estimated Duration
LBJ Hospital Expansion Project	2022 Q4	2023 Q4	2024 Q2	48 months
LBJ Legacy Project	2025 Q1	2026 Q4	2027 Q2	60 months
LBJ New Outpatient MOB	2028 Q3	2029 Q3	20230 Q1	24 months

Ben Taub Campus

Estimated Scope	Start Design/Assessment	Start Procurement	Start Construction	Estimated Duration
BT ICUs - 4 Phases	2023 Q4	2024 Q3	2025 Q1	48 months
BT Ancillary/Operation Support Areas	2023 Q4	2024 Q3	2025 Q1	30 months
BT Infrastructure (Mechnical, Electrial, Plumbing)	2023 Q4	2024 Q2	2024 Q4	36 months
BT Sanitary Sewer Pipe	2024 Q1	2024 Q3	2025 Q1	30 months
BT Expand Telemetry Capability for all Beds	2024 Q1	2024 Q2	2024 Q4	12 months
BT Women and Infant Services	2024 Q4	2025 Q3	2026 Q1	36 months
BT Bed Tower (120 Beds)	2025 Q4	2026 Q4	2027 Q2	36 months

Ambulatory Care Services

Estimated Scope	Start Design/Assessment	Start Procurement (Bidding)	Start Construction	Estimated Duration
Roofing/HVAC Refresh through all the ACS Facilities (Over 10 years)	2023 Q3	2023 Q4	2024 Q1	120 months
Sunset Heights Same Day Clinic (Expansion Build on Casa Property)	2024 Q1	2024 Q4	2025 Q2	24 months
Radiology/Radiation Therapy Modality refresh (Smith Clinic)	2024 Q4	2025 Q1	2025 Q2	96 months
Health Center Pasadena (Centrico) (Already in motion in partnership with Harris County)	2024 Q1	2024 Q4	2025 Q2	24 months
Vallbona Main Renovation, Campus, Annex/Robindell Same Day Clinic	2025 Q1	2025 Q4	2026 Q2	24 months
Harris Health Garage (Serving BT, QM, Smith)	2025 Q4	2026 Q4	2027 Q2	22 months
Net New Health Center (Number 1)*	2026 Q1	2026 Q4	2027 Q2	24 months
Health Center (Cypress) (Renovation/Expansion)	2026 Q3	2027 Q2	2027 Q4	14 months
Age Facility Replacement/Expansion - Acres Home	2027 Q1	2027 Q4	2028 Q2	24 months
Net New Health Center (Number 2)*	2028 Q2	2029 Q1	2029 Q3	24 months
Net New Health Center (Number 3)*	2029 Q1	2029 Q4	2030 Q2	24 months
Mobile Mammo Van (Refresh in 7-8 years)	2029 Q4	2030 Q1	2030 Q3	12 months
Age Facility Replacement - Gulfgate	2030 Q3	2031 Q3	2032 Q1	24 montas D

*Net New Health Centers will be located one each in precincts 2, 3 and 4 in the Harris Health Identified Area of Need

Pillar 5: Infrastructure Optimization







Ben Taub Expansion





Pillar 5: Infrastructure Optimization

New Central Fill Pharmacy: 10/24 Kickoff



New Pasadena Clinic (Centrico): In Design



Sunset Heights (Casa Campus): In Validation



Vallbona/Robindell: In Validation



HARRISHEALTH

12

Pillar 6: Diversity, Equity and Inclusion





66 outreach events

MWBE Awards

FY 23: \$45,810,075 FY 24 through June: \$70,744,899 **MWBE Payments**

FY 23: \$17,672, 998 FY 24 through June: \$14,930,597

DEI Program Highlights

- Hired first Chief Diversity Officer
- Launched DEI Grand Rounds in partnership with Baylor College of Medicine
- Implemented Health Equity Speaker Series
- Developed 7 Employee Resource Groups
- Formed DEI Board Committee

2023 Employee Engagement Survey




HARRIS**HEALTH**

13

Ongoing Strategic Efforts

6 People Quality & Patient Safety Continued HRO Continued One Harris Health Continued efforts Population Health Management •Focus on Heart nfrastructure Optimization •Increase bed Inclusion •Staff training on deployment and **Retention Efforts** to improve Health and Heart capacity reduction of SSE Health Equity throughput Workforce Execution of Continued and HRE Development •Expansion of Expansion of strategic facilities Support of Food Farmacy Continued **Programs** Hospital at Home Employee plan improvement in program Program Resource Groups Workplace Safety Cybersecurity 8 Leapfrog and •MWBE Initiatives Service Line Continued focus posture Equity other publicly **Expansion** on Multi Visit improvement Community Continued reported Patient, Remote outreach evaluation of Position LBJ for Big Rocks programs Patient increases to Level 1 Trauma Technology Reduction in Support of Monitoring & and Enhanced minimum/living Strategy contracts exempt Diversity, Correctional Community wage Services due to procured Development of **Health Quality** Health Worker prior to MWBE Continued **Urgent Care** Improvement programs program improvement in strategy **Efforts** • REGAL data name recognition •Focus on collection and brand Philanthropy Center for awareness Accelerating **Health Equity**

2026 – 2030 Strategic Planning Process





Meeting of the Board of Trustees

Thursday, October 24, 2024

October Committee Reports

October Committee Meetings:

- Quality Committee October 8, 2024
 A summary was attached for your review.
 - o HRO Safety Message Video: Clostridioides difficile (C. diff)
 - o Workplace Safety & Violence Prevention
 - Keeping Our Workforce Safe and Informed
- <u>Diversity, Equity and Inclusion (DEI) Committee October 11, 2024</u>
 - Presentation Regarding Partnering with Patients and Communities to Advance Access to Care
 - Presentation Regarding DEI Employee Engagement Analysis: Finding Statistical Significance
 - o Discussion Regarding the 2025 DEI Reporting Schedule



Board of Trustees – Executive Summary
Patient Safety & Quality Programs – Open Session Presentations
October 24, 2024

Please refer to the reports presented at the Quality Committee Executive Session on October 8, 2024 for additional details.

HRO Safety Message - Video: Clostridioides difficile (C. diff)

High-reliability Organizations (HROs) are those that successfully complete their missions despite massive complexity and high risk. Examples include the Federal Aviation Administration's Air Traffic Control system, aircraft carriers, and nuclear power plants. In each case, even a minor error could have catastrophic consequences. Yet, adverse outcomes in these organizations are rare. Five principles of a High Reliability Organization (HRO) are: (1) Preoccupation with failure; (2) Reluctance to simplify interpretations; (3) Sensitivity to operations; (4) Commitment to resilience; and (5) Deference to expertise.

Workplace Safety & Violence Prevention

Harris Health's commitment to the safety of employees and patients is unwavering and continues to evolve as conditions change. Some of the current efforts and opportunities for future improvements include getting the message to people through videos, website communication, email communication, flyers and monthly meetings. The current video was presented. It summarized current efforts related to staff training; utilizing escalation techniques, important tools, identifying early recognition and de-escalation management (BARS). There is a Workplace Safety & Violence Prevention Committee to help navigate and assist with events.

October 6, 2024

Board of Trustees Office Harris Health

RE: Board of Trustees Meeting - October 24, 2024 **Budget and Finance Agenda Items**

The Office of the Harris County Purchasing Agent recommends approval of the attached procurement actions. All recommendations are within the guidelines established by Harris County and Harris Health.

> Sincerely, Paige MoInnis

Paige McInnis Purchasing Agent

JA/ea Attachments

Budget and Finance Agenda Items for the Harris County Hospital District dba Harris Health System - Board of Trustees Report Expenditure Summary: October 24, 2024 (Approvals)

No.	Vendor	Description Justification Contract	Action Basis of Recommendation Term	Project Owner	Previous Amount	Current stimated Cost
A1	W. L. Gore & Associates, Inc (HCHD-1279 & 1280) MWBE Goal: Exempt Sole Source	Endoprosthesis Stents - A consignment and pricing agreement for endoprosthesis stents. Public Health or Safety Exemption	Award Public Health or Safety Exemption One (1) year initial term with one (1) one-year renewal options	Charles Motley		\$ 470,820
A2	Benco Dental Supply Co. MWBE Goal: 5%	Dental Supplies & Equipment for Harris Health - To provide dental products and equipment used for dental services provided to Harris Health patients. Job No. 230380	Award Lowest priced proposal meeting requirements One (1) year initial term with five (5) one-year renewal options	Charles Motley		*
A3	ConMed (HCHD 1364) MWBE Goal: Exempt Sole Source	Distribution of Cover Stents - Sole distributor of W.L Gore's product VialBil. Sole Source Exemption	Award Sole Source Exemption One (1) year initial term with four (4) one-year renewal options	Charles Motley		\$ 259,200
		,		-	Total Expenditures	\$ 1,130,020
					Total Revenue	\$ (0)



Meeting of the Board of Trustees

Thursday, October 24, 2024

Consideration of Approval of the Harris Health Premier Spend Report for Quarter 3 of Fiscal Year 2024

HARRIS HEALTH PREMIER Q3 SPEND FY2024	
SUPPLIER	Q3 SPEND FY2024
CARDINAL HEALTH 200, LLC	\$15,661,581
AMN HEALTHCARE, INC.	\$14,007,342
MCKESSON PHARMACEUTICAL	\$3,880,910
MORRIS & DICKSON CO., LTD.	\$3,559,195
US FOODS, INC.	\$3,218,397
STRYKER SALES, LLC DBA STRYKER ENDOSCOPY	\$2,121,529
PHILIPS HEALTHCARE	\$2,054,683
JOHNSON & JOHNSON HEALTH CARE SYSTEMS INC.	\$1,694,699
SANOFI PASTEUR	\$1,258,656
BOSTON SCIENTIFIC CORPORATION	\$1,250,576
BAXTER HEALTHCARE CORPORATION	\$1,192,575
MEDLINE INDUSTRIES, LP	\$1,170,792
ABBOTT LABORATORIES INC.	\$1,111,062
COVIDIEN SALES LLC	\$1,053,805
BECTON, DICKINSON AND COMPANY	\$1,019,197
FFF ENTERPRISES, INC.	\$1,015,622
CAREFUSION SOLUTIONS, LLC	\$992,508
LABORATORY CORPORATION OF AMERICA HOLDINGS	\$750,987
BECKMAN COULTER, INC.	\$679,732
PC CONNECTION, INC.	\$520,024
SMITH & NEPHEW INC - ORTHOPAEDIC DIVISION	\$512,760
HILL-ROM COMPANY, INC.	\$503,098
INSIGHT DIRECT USA, INC.	\$501,528
NEUROLOGICA CORP	\$397,825
ODP BUSINESS SOLUTIONS, LLC	\$396,834
CSL BEHRING	\$394,836
ABBVIE INC. DBA ABBVIE US LLC	\$392,174
NETWORK SERVICES COMPANY DBA NETWORK DISTRIBUTION	\$363,209
CAREFUSION 303, INC.	\$352,799
MASIMO AMERICAS, INC.	\$334,492
AMGEN INC.	\$327,943
PARTSSOURCE, INC.	\$323,913
ICU MEDICAL SALES, INC.	\$303,900
CDW	\$296,768
STRYKER SALES, LLC DBA STRYKER INSTRUMENTS	\$294,230
OLYMPUS AMERICA, INC.	\$291,849
S2S GLOBAL	\$279,197
GETINGE USA SALES, LLC	\$278,714
SYSMEX AMERICA, INC.	\$277,820
MEDTRONIC, INC.	\$263,511
W.W. GRAINGER, INC.	\$257,722
KIMBALL INTERNATIONAL BRANDS, INC.	\$257,625
WELCH ALLYN, INC.	\$252,039
3M HEALTHCARE US OPCO LLC	\$233,204
COOK MEDICAL LLC	\$229,288
KCI USA, INC. DBA 3M MEDICAL SOLUTIONS	\$218,446
STERIS CORPORATION	\$214,041
BIOMERIEUX, INC.	\$205,926
	\$203,920
CLEAN HARBORS ENVIRONMENTAL SERVICES, INC.	\$201,427

HARRIS HEALTH PREMIER Q3 SPEND FY2024	
SUPPLIER	Q3 SPEND FY2024
KARL STORZ ENDOSCOPY-AMERICA, INC.	\$196,526
ARUP LABORATORIES, INC.	\$193,926
GEORGIA-PACIFIC CONSUMER PRODUCTS LP	\$191,200
PENUMBRA INC	\$187,190
PFIZER (GENERIC)	\$185,399
SAGE PRODUCTS, LLC	\$182,055
EDWARDS LIFESCIENCES LLC	\$177,903
TELEFLEX LLC	\$169,396
MUSCULOSKELETAL TRANSPLANT FOUNDATION	\$167,894
ASTELLAS PHARMA US, INC.	\$158,422
LSL INDUSTRIES, INC.	\$158,006
HOLOGIC SALES AND SERVICE, LLC	\$155,417
JUBILANT DRAXIMAGE INC.	\$154,800
QUVA PHARMA, INC.	\$153,480
INARI MEDICAL, INC.	\$149,700
ORTHO-CLINICAL DIAGNOSTICS, INC.	\$143,465
B. BRAUN MEDICAL INC.	\$143,222
ZOLL MEDICAL CORPORATION	\$139,026
MERCK SHARP & DOHME LLC	\$132,893
LANTHEUS MEDICAL IMAGING, INC.	\$127,072
CHIESI USA, INC	\$124,116
MYLAN INSTITUTIONAL	\$123,221
LINDE GAS & EQUIPMENT INC.	\$121,083
STRYKER SALES, LLC DBA STRYKER CRANIOMAXILLOFACIAL	\$119,810
ZIMMER BIOMET	\$118,190
FISHER SCIENTIFIC HEALTHCARE	\$113,786
APPLIED MEDICAL RESOURCES CORPORATION	\$111,500
SHARED IMAGING, LLC	\$109,950
EHOB INC	\$109,927
GE HEALTHCARE INC.	\$109,194
VERITIV CORPORATION	\$106,761
BAYER HEALTHCARE LLC	\$102,477
AMERICAN HEALTH PACKAGING	\$102,474
WIELAND	\$102,155
ACUMED LLC	\$102,043
ENCOMPASS GROUP, LLC	\$101,607
ECOLAB USA, INC.	\$100,784
STANDARD TEXTILE CO., INC.	\$100,481
BARD PERIPHERAL VASCULAR, INC.	\$96,569
VYAIRE MEDICAL 211, INC.	\$96,303
DAVOL INC.	\$96,271
PERFORMANCE HEALTH SUPPLY, LLC	\$95,701
ARAMARK UNIFORM AND CAREER APPAREL	\$95,587
AESCULAP, INC.	\$93,522
SILENTIA INC.	\$93,428
BAUSCH HEALTH US, LLC	\$92,425
I.B.S. SOLUTIONS CORPORATION	\$90,700
CARRIER CORPORATION	\$84,000
SHOCKWAVE MEDICAL, INC.	\$83,550
SHOCK VVAVE IVIEDICAL, IIVC.	\$65,550

HARRIS HEALTH PREMIER Q3 SPEND FY2024	
SUPPLIER	Q3 SPEND FY2024
MANNINGTON MILLS INC.	\$83,151
DIAGNOSTICA STAGO, INC.	\$76,516
FAGRON COMPOUNDING SERVICES, LLC DBA FAGRON STERILE SERVICES	\$75,578
PDC HEALTHCARE (PRECISION DYNAMICS CORPORATION)	\$74,369
FRESENIUS KABI USA, LLC	\$73,530
US FOODS CULINARY EQUIPMENT & SUPPLIES	\$72,716
ANDWELL LLC	\$70,724
LYFT	\$69,262
US MED-EQUIP, LLC	\$69,259
VERATHON INC.	\$68,981
STRYKER SALES, LLC DBA STRYKER MEDICAL	\$66,524
ADVANCED STERILIZATION PRODUCTS SERVICES INC.	\$66,255
MGC DIAGNOSTICS CORPORATION	\$66,193
SUNMED GROUP HOLDINGS, LLC DBA AIRLIFE	\$66,040
DIVERSEY, INC.	\$64,431
PEPSICO FOODSERVICE	\$63,939
BARD MEDICAL DIVISION	\$62,052
KERECIS LLC	\$60,858
HENRY SCHEIN, INC.	\$60,598
SANOFI-AVENTIS U.S. LLC	\$60,284
TIDI PRODUCTS, LLC	\$59,600
TEVA PHARMACEUTICALS USA (BRAND)	\$59,037
HIKMA PHARMACEUTICALS USA INC.	\$58,593
PACTIV CORPORATION	\$58,509
SCA PHARMACEUTICALS, LLC	\$57,528
LEICA BIOSYSTEMS A DIVISION OF LEICA MICROSYSTEMS INC.	\$56,778
CARESTREAM HEALTH, INC.	\$56,542
REMEL INC.	\$56,506
FISHER & PAYKEL HEALTHCARE, INC.	\$55,579
AGILITI HEALTH, INC.	\$55,511
MOLNLYCKE HEALTH CARE US, LLC	\$54,217
CONVATEC INC	\$53,430
MEDELA LLC	\$53,349
ASTRAZENECA PHARMACEUTICALS LP	\$52,803
DOLE PACKAGED FOODS COMPANY	\$51,750
KIMBERLY CLARK GLOBAL SALES LLC	\$50,602
AVANOS MEDICAL, INC.	\$49,353
WELLS PHARMA OF HOUSTON, LLC	\$48,920
WNA INC	\$48,675
CARCO GROUP, INC. DBA PRECHECK	\$48,114
LUMINEX CORPORATION	\$48,048
RADIOMETER AMERICA INC.	\$47,336
SOFIE CO.	\$47,332
STANCE HEALTHCARE INC.	\$46,664
HEALTHMARK INDUSTRIES CO., INC.	\$46,437
TRI-ANIM HEALTH SERVICES, INC.	\$46,266
MICHAEL FOODS, INC.	\$46,265
BOEHRINGER LABORATORIES, LLC	\$45,819
·	
AMBU INC.	\$45,455

HARRIS HEALTH PREMIER Q3 SPEND FY2024	
SUPPLIER	Q3 SPEND FY2024
ZYDUS PHARMACEUTICALS USA INC	\$43,702
COUNTRY PURE FOODS, INC.	\$42,716
CAREFUSION 2200, INC.	\$42,363
AMPHASTAR PHARMACEUTICALS, INC.	\$41,839
AT&T MOBILITY NATIONAL ACCOUNTS, LLC	\$41,239
AMERICAN REGENT, INC.	\$40,231
NEOGENOMICS LABORATORIES, INC.	\$39,589
KURIN, INC.	\$38,500
HORMEL FOODS CORPORATION	\$34,198
PROFESSIONAL DISPOSABLES INTERNATIONAL, INC.	\$33,942
LOGIQUIP L.L.C.	\$32,239
COLOPLAST CORP.	\$32,125
INTEGRA LIFESCIENCES CORPORATION	\$31,767
PEPSICO INC.	\$31,465
MAJOR PHARMACEUTICALS	\$31,253
RAULAND-BORG CORPORATION	\$30,891
DR. REDDY'S LABORATORIES, INC.	\$30,615
KRAFT HEINZ FOODS COMPANY, FOODSERVICE DIVISION	\$29,598
AVKARE, LLC.	\$28,917
NOVARTIS PHARMACEUTICALS CORPORATION	\$28,405
HEALTH CARE LOGISTICS, INC.	\$28,371
SMITH & NEPHEW INC - WOUND MANAGEMENT DIVISION	\$27,664
HAMILTON MEDICAL, INC.	\$26,845
BIO-RAD LABORATORIES, INC.	\$26,656
STERIS INSTRUMENT MANAGEMENT SERVICES, INC.	\$26,589
ADVANCE MEDICAL DESIGNS, INC.	\$26,463
INTEGRA LIFESCIENCES SALES, LLC	\$25,857
PAR STERILE PRODUCTS, LLC	\$25,839
DEROYAL INDUSTRIES, INC.	\$25,125
SWISSLOG HEALTHCARE	\$25,035
CONAGRA FOODS INC	\$25,020
GLOBUS MEDICAL, INC.	\$24,735
BIOTISSUE HOLDINGS INC.	\$24,638
SUN PHARMACEUTICAL LABORATORIES, LTD.	\$24,172
NOVO SURGICAL, INC.	\$23,566
TYSON FOODS, INC.	\$23,085
SABERT CORPORATION	\$22,952
INTERNATIONAL BIOMEDICAL, LTD.	\$22,871
BAUSCH & LOMB AMERICAS INC.	\$22,720
SMITHS MEDICAL ASD, INC.	\$22,532
FREEDOM MEDICAL, INC.	\$22,154
TEVA PHARMACEUTICALS USA (GENERIC)	\$21,864
THE J. M. SMUCKER COMPANY	\$21,549
MCKESSON MEDICAL-SURGICAL INC.	\$21,537
PAI HOLDINGS, LLC DBA PAI PHARMA	\$21,398
ANGIODYNAMICS, INC.	\$21,398
HETTICH INSTRUMENTS, LP	\$21,336
RICHARD-ALLAN SCIENTIFIC	\$21,272
CONMED CORPORATION	\$21,112

HARRIS HEALTH PREMIER Q3 SPEND FY2024	
SUPPLIER	Q3 SPEND FY2024
SMITH & NEPHEW INC - BIOTHERAPEUTICS	\$21,039
EMERGENCY CARE RESEARCH INSTITUTE DBA ECRI INSTITUTE	\$20,850
OWENS & MINOR DISTRIBUTION, INC.	\$20,751
EXELA PHARMA SCIENCES, LLC	\$20,486
VAPOTHERM, INC.	\$20,244
GLAXOSMITHKLINE INC.	\$20,223
AMNEAL PHARMACEUTICALS LLC	\$20,004
MXR IMAGING, INC.	\$19,498
SLMP, LLC DBA STATLAB MEDICAL PRODUCTS	\$19,430
GENERAL MILLS	\$19,203
NESTLE HEALTH SCIENCES	\$19,192
SAGENT PHARMACEUTICALS, INC.	\$18,916
CAMPBELL FOODSERVICE COMPANY	\$18,664
KOCH FOODS	\$18,524
O&M HALYARD, INC.	\$18,451
DART CONTAINER CORPORATION	\$18,416
MERIT MEDICAL SYSTEMS, INC.	\$17,732
ANCHOR PACKAGING	\$17,146
SOMERSET PHARMA LLC	\$17,052
THE COCA-COLA COMPANY	\$16,817
PACIRA PHARMACEUTICALS, INC.	\$16,798
MEDEGEN MEDICAL PRODUCTS, LLC	\$16,299
EXEMPLIS LLC	\$16,034
HOWMEDICA OSTEONICS CORP. DBA STRYKER ORTHOPAEDICS	\$15,389
BRACCO DIAGNOSTICS INC.	\$15,076
CAMFIL USA, INC	\$14,806
HORMEL HEALTHLABS, INC.	\$14,781
SECURITAS HEALTHCARE LLC	\$14,476
TENNANT SALES AND SERVICE COMPANY	\$14,366
FLOWERS BAKERIES LLC	\$14,353
MONDELEZ INTERNATIONAL, INC.	\$14,118
ELI LILLY AND COMPANY	\$13,999
WG CRITICAL CARE, LLC	\$13,699
DJO GLOBAL, INC.	\$13,255
BSN MEDICAL, INC.	\$13,119
DANONE NORTH AMERICA	\$12,992
CORDIS US CORP.	\$12,855
INTERMETRO INDUSTRIES CORPORATION	\$12,739
IRRAS USA, INC.	\$12,600
FEDERAL EXPRESS CORPORATION	\$12,236
PROGRESSIVE MEDICAL, INC.	\$12,196
NESTLE PROFESSIONAL NORTH AMERICA	\$12,005
CARLISLE FOODSERVICE PRODUCTS	\$11,716
PHARMA LOGISTICS	\$11,593
UCB PHARMA, INC.	\$11,591
FLEXICARE INCORPORATED	\$11,585
URGO MEDICAL NORTH AMERICA	\$11,429
INTERSURGICAL INCORPORATED	\$11,283
VENTURA FOODS, LLC	\$11,283
VERTORA I GODO, ELC	\$11,227

HARRIS HEALTH PREMIER Q3 SPEND FY2024	
SUPPLIER	Q3 SPEND FY2024
KEDRION BIOPHARMA INC.	\$11,205
STERICYCLE, INC.	\$10,901
SENSOSCIENTIFIC, INC.	\$10,890
KLS MARTIN LP	\$10,501
BRISTOL MYERS SQUIBB US PHARM	\$10,495
BELIMED, INC.	\$10,406
SARA LEE FROZEN BAKERY, LLC	\$10,360
GOJO INDUSTRIES, INC.	\$10,293
HUB PHARMACEUTICALS, LLC	\$10,242
TZ MEDICAL, INC.	\$10,200
SPECGX LLC	\$10,182
RETRACTABLE TECHNOLOGIES, INC.	\$10,161
WELLS DAIRY, INC.	\$10,143
PILGRIM'S PRIDE CORPORATION	\$10,137
STRATUS PHARMACEUTICALS, INC.	\$9,649
SOLAIRE MEDICAL STORAGE, LLC DBA INNERSPACE H.C.	\$9,624
LITTLE RAPIDS HOLDING CORPORATION DBA GRAHAM MEDICAL	\$9,433
MICROGENICS CORPORATION	\$9,379
KOCH FILTER CORPORATION	\$8,925
KNOUSE FOODS CO-OP INC	\$8,833
ALADDIN TEMP-RITE	\$8,358
TETRA MEDICAL SUPPLY CORP.	\$8,293
THE CLOROX SALES COMPANY	\$8,160
EUGIA US LLC	\$7,961
W. L. GORE & ASSOCIATES, INC.	\$7,782
Z-MEDICA, LLC	\$7,766
MARS FOOD US, LLC	\$7,445
MIDMARK SALES CORPORATION	\$7,426
FERNDALE LABORATORIES, INC.	\$7,330
PULMODYNE	\$7,216
UPSHER-SMITH LABORATORIES, LLC	\$7,153
GRACE MEDICAL, INC.	\$6,899
BREG, INC	\$6,620
OHIO MEDICAL, LLC	\$6,555
PELSTAR, LLC DBA HEALTH O METER	\$6,550
MILLERKNOLL, INC. DBA HERMAN MILLER, INC.	\$6,511
SHASTA FOODSERVICE	\$6,510
CUSTOM CULINARY, INC.	\$6,497
GREINER BIO-ONE NORTH AMERICA, INC.	\$6,490
TELA BIO, INC.	\$6,480
QUEST DIAGNOSTICS INCORPORATED	\$6,465
TRILLIANT SURGICAL, LLC	\$6,371
HEALTH O METER PROFESSIONAL	\$6,016
ACCUVEIN INC.	\$6,000
ASPIRE BAKERIES LLC	\$5,992
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.	\$5,812
CHOBANI LLC	\$5,787
STELLEX/CF BUYER (US) LLC	\$5,700
HOLLISTER INCORPORATED	\$5,647
*****	Ŧ-/ 0

HARRIS HEALTH PREMIER Q3 SPEND FY2024	
SUPPLIER	Q3 SPEND FY2024
LABORIE MEDICAL TECHNOLOGIES CORP.	\$5,485
PRECISION DOSE, INC.	\$5,402
NORDIC PHARMA, INC.	\$5,396
HOVERTECH INTERNATIONAL	\$5,202
ARYZTA, LLC	\$5,122
PRINT MEDIA, INC.	\$5,063
SUGAR FOODS LLC	\$4,920
LANDAUER, INC.	\$4,899
PFIZER (BRAND)	\$4,879
ASPEN SURGICAL PRODUCTS, INC.	\$4,863
SMITHFIELD FOODS, INC.	\$4,852
WERFEN USA, LLC	\$4,790
TB&A HOSPITAL TELEVISION, INC.	\$4,640
STEELCASE INC.	\$4,616
SWEET STREET DESSERTS, INC.	\$4,512
PHILIPS DS NORTH AMERICA LLC	\$4,496
PADAGIS US LLC	\$4,385
BASIC AMERICAN FOODS	\$4,384
ENERGIZER BATTERY COMPANY	\$4,375
BRECKENRIDGE PHARMACEUTICAL INC.	\$4,308
RISING PHARMACEUTICALS, INC.	\$4,188
HOFFMASTER GROUP, INC.	\$4,129
MEAD JOHNSON & COMPANY, LLC	\$4,108
GE MEDICAL SYSTEMS INFORMATION TECHNOLOGIES, INC.	\$4,063
ABBOTT NUTRITION	\$4,018
NEPHRON PHARMACEUTICALS CORPORATION	\$3,970
STAQ PHARMA, INC.	\$3,966
KELLANOVA	\$3,951
J.R. SIMPLOT COMPANY	\$3,921
ALLEN MEDICAL SYSTEMS, INC.	\$3,871
OLE MEXICAN FOODS, INC.	\$3,871
CYGNUS MEDICAL L.L.C.	\$3,840
J & J SNACK FOODS CORP	\$3,762
RICH PRODUCTS CORPORATION	
	\$3,759 \$3,706
SCHWAN'S FOOD SERVICE, INC. MEDICAL COMPONENTS, INC.	\$3,680
·	
JOHNSONVILLE, LLC OCEAN SPRAY	\$3,671 \$3,668
MEITHEAL PHARMACEUTICALS, INC.	\$3,636
SMITH & NEPHEW INC - ENDOSCOPY DIVISION	\$3,628
POSITIVE PROMOTIONS, INC.	\$3,625
ARMSTRONG WORLD INDUSTRIES, INC.	\$3,451
LIFENET HEALTH	\$3,443
GE PRECISION HEALTHCARE LLC	\$3,431
CHICKEN OF THE SEA INTERNATIONAL	\$3,387
OBP SURGICAL CORPORATION	\$3,375
BLUETRITON BRANDS, INC.	\$3,369
HALEON US INC.	\$3,316
WK KELLOGG SALES LLC	\$3,308


TARRY MEDICAL PRODUCTS DBA DANDLELION MEDICAL \$3,102 BPI LABS, LLC \$3,102 RESER'S FINE FOODS, INC. \$3,094 GREENSTONE LLC \$3,044 MCCORMICK & COMPANY, INC. \$2,977 CASE MEDICAL, INC. \$2,979 HURON BIDGO, INC. DBA SECOND NATURE BRANDS \$2,909 ALCON VISION, LLC \$2,702 CARRIER ENTERPRISE, LLC \$2,702 CARBRO MANUFACTURING COMPANY \$2,702 IGSAW MEDICAL, LLC \$2,270 R D PLASTICS COMPANY, INC. \$2,63 B&G FOODS, INC. \$2,63 BEUTLICH PHARMACEUTICALS, LLC \$2,61 MELINTA THERAPEUTICS, INC. \$2,45 APOTEX CORP. \$2,45 GENDOSE PHARMACEUTICALS \$2,46 MYLAN SPECIALTY L.P. \$2,40 MYLAN SPECIALTY L.P. \$2,40 BROOKWOOD FARMS, INC. \$2,33 HARTMANN USA, INC. \$2,33 HARTMANN USA, INC. \$2,23 HARTMANN USA, INC. \$2,20 SANDOZ INC. \$2,20 SEBELA PHARMACEUTICALS DIB, INC. <t< th=""><th>HARRIS HEALTH PREMIER Q3 SPEND FY2024</th><th></th></t<>	HARRIS HEALTH PREMIER Q3 SPEND FY2024	
TARRY MEDICAL PRODUCTS DBA DANDLELION MEDICAL \$3,102 BPI LABS, LLC \$3,102 RESER'S FINE FOODS, INC. \$3,094 GREENSTONE LLC \$3,044 MCCORMICK & COMPANY, INC. \$2,977 CASE MEDICAL, INC. \$2,979 HURON BIDCO, INC. DBA SECOND NATURE BRANDS \$2,909 ALCON VISION, LLC \$2,702 CARRIER ENTERPRISE, LLC \$2,702 CAMBRO MANUFACTURING COMPANY \$2,702 IGSAW MEDICAL, LLC \$2,270 R D PLASTICS COMPANY, INC. \$2,63 B&G FOODS, INC. \$2,63 B&G FOODS, INC. \$2,63 BEUTLICH PHARMACEUTICALS, LLC \$2,61 MELINTA THERAPEUTICS, INC. \$2,45 APOTEX CORP. \$2,45 GENDOSE PHARMACEUTICALS \$2,46 MYLAN SPECIALTY L.P. \$2,40 BROOKWOOD FARMS, INC. \$2,33 HARTMANN USA, INC. \$2,33 HARTMANN USA, INC. \$2,33 HARTMANN USA, INC. \$2,20 SCEN PHARMACEUTICALS DIB, INC. \$2,20 SCEN PHARMACEUTICALS DIB, INC. <th>SUPPLIER</th> <th>Q3 SPEND FY2024</th>	SUPPLIER	Q3 SPEND FY2024
BPI LABS, LLC \$3,00 RESER'S FINE FOODS, INC. \$3,04 MCCORMICK & COMPANY, INC. \$2,97 CASE MEDICAL, INC. \$2,97 HURON BIDCO, INC. DBA SECOND NATURE BRANDS \$2,90 ALCON VISION, LLC \$2,79 CARRIER ENTERPRISE, LLC \$2,72 CAMBRO MANUFACTURING COMPANY \$2,70 IGSAW MEDICAL, LLC \$2,70 R D PLASTICS COMPANY, INC. \$2,63 B&G FOODS, INC. \$2,62 BEUTLICH PHARMACEUTICALS, LLC \$2,61 MELINITA THERAPEUTICS, INC. \$2,45 APOTEX CORP. \$2,45 GENDOSE PHARMACEUTICALS \$2,45 PAR PHARMACEUTICAL, INC. \$2,40 MYLAN SPECIALTY L.P. \$2,40 BROOKWOOD FARMS, INC. \$2,33 HARTMANN USA, INC. \$2,33 PROCTER & GAMBLE DISTRIBUTING LLC \$2,33 XEGEN PHARMACEUTICALS DIB, INC. \$2,27 JONAS SOFTWARE COMPANY \$2,27 SARDOZ INC. \$2,20 SEBLA PHARMACEUTICALS INC. \$2,20 LUPIN PHARMACEUTICALS SINC.	CONMED LINVATEC	\$3,153
BPI LABS, LLC \$3,00 RESER'S FINE FOODS, INC. \$3,04 MCCORMICK & COMPANY, INC. \$2,97 CASE MEDICAL, INC. \$2,97 HURON BIDCO, INC. DBA SECOND NATURE BRANDS \$2,90 ALCON VISION, LLC \$2,79 CARRIER ENTERPRISE, LLC \$2,72 CAMBRO MANUFACTURING COMPANY \$2,70 IGSAW MEDICAL, LLC \$2,70 R D PLASTICS COMPANY, INC. \$2,63 B&G FOODS, INC. \$2,62 BEUTLICH PHARMACEUTICALS, LLC \$2,61 MELINITA THERAPEUTICS, INC. \$2,45 APOTEX CORP. \$2,45 GENDOSE PHARMACEUTICALS \$2,45 PAR PHARMACEUTICAL, INC. \$2,40 MYLAN SPECIALTY L.P. \$2,40 BROOKWOOD FARMS, INC. \$2,33 HARTMANN USA, INC. \$2,33 PROCTER & GAMBLE DISTRIBUTING LLC \$2,33 XEGEN PHARMACEUTICALS DIB, INC. \$2,27 JONAS SOFTWARE COMPANY \$2,27 SARDOZ INC. \$2,20 SEBLA PHARMACEUTICALS INC. \$2,20 LUPIN PHARMACEUTICALS SINC.	TARRY MEDICAL PRODUCTS DBA DANDLELION MEDICAL	\$3,123
RESER'S FINE FOODS, INC. 33,09: GREENSTONE LLC 33,09: GREENSTONE LLC 52,97: MCCORMICK & COMPANY, INC. 52,97: HURON BIDCO, INC. DBA SECOND NATURE BRANDS 52,99: ALCON VISION, LLC 52,79: ALCON VISION, LLC 52,79: JIGSAW MEDICAL, LLC 52,70: BEUTLICH PHARMACEUTICALS, LLC 52,61: MELINTA THERAPEUTICS, INC. 52,63: BEUTLICH PHARMACEUTICAL, INC. 52,46: APOTEX CORP. 52,45: GENDOSE PHARMACEUTICAL, INC. 52,40: MYLAN SPECIALTY L.P. 52,40: BROOKWOOD FARMS, INC. 52,33: PROCTER & GAMBLE DISTRIBUTING LLC 52,30: XGEN PHARMACEUTICALS DIB, INC. 52,27: JONAS SOFTWARE COMPANY 52,27: JONAS FORTWARE FORTWARE TO THE TOTAL T	BPI LABS, LLC	\$3,100
GREENSTONE LLC \$3,044 MCCORMICK & COMPANY, INC. \$2,97 CASE MEDICAL, INC. \$2,97 HURON BIDCO, INC. DBA SECOND NATURE BRANDS \$2,90 ALCON VISION, LLC \$2,79 CARRIER ENTERPRISE, LLC \$2,72 CARMER DANAUFACTURING COMPANY \$2,70 IJGSAW MEDICAL, LLC \$2,62 R D PLASTICS COMPANY, INC. \$2,63 B&G FOODS, INC. \$2,62 BEUTLICH PHARMACEUTICALS, LLC \$2,61 MELINTA THERAPEUTICS, INC. \$2,45 APOTEX CORP. \$2,45 GENDOSE PHARMACEUTICAL, INC. \$2,45 MYLAN SPECIALTY L.P. \$2,40 BROOKWOOD FARMS, INC. \$2,33 HARTMANN USA, INC. \$2,33 PROCTER & GAMBLE DISTRIBUTING LLC \$2,33 YEAP PHARMACEUTICALS DIB, INC. \$2,27 JONAS SOFTWARE COMPANY \$2,27 SEBELA PHARMACEUTICALS SINC. \$2,27 LUPIN PHARMACEUTICALS INC. \$2,19 LUPIN PHARMACEUTICALS INC. \$2,19 LUPIN PHARMACEUTICALS, INC. \$2,20 HUBERT C		\$3,099
MCCORMICK & COMPANY, INC. \$2,97 CASE MEDICAL, INC. \$2,97 HURON BIDCO, INC. DBA SECOND NATURE BRANDS \$2,90 ALCON VISION, LLC \$2,79 CARRIER ENTERPRISE, LLC \$2,70 CAMBRO MANUFACTURING COMPANY \$2,70 IJGSAW MEDICAL, LLC \$2,70 R D PLASTICS COMPANY, INC. \$2,63 B&G FOODS, INC. \$2,62 BEUTLICH PHARMACEUTICALS, LLC \$2,61 MELINTA THERAPEUTICS, INC. \$2,45 APOTEX CORP. \$2,45 GENDOSE PHARMACEUTICALS \$2,45 PAR PHARMACEUTICAL, INC. \$2,40 MYLAN SPECIALTY L.P. \$2,40 MYLAN SPECIALTY L.P. \$2,40 MYLAN SPECIALTY L.P. \$2,40 MYLAN SPECIALTY L.P. \$2,20 BROOKWOOD FARMS, INC. \$2,33 PROCTER & GAMBLE DISTRIBUTING LLC \$2,33 XGEN PHARMACEUTICALS DIB, INC. \$2,27 JONAS SOFTWARE COMPANY \$2,27 SANDOZ INC. \$2,20 AERO US INC. DBA AEROGEN \$2,20 SEBELA PHARMACEUTICALS INC.		\$3,040
CASE MEDICAL, INC. \$2,97 HURON BIDCO, INC. DBA SECOND NATURE BRANDS \$2,90 ALCON VISION, LLC \$2,79 CARRIER ENTERPRISE, LLC \$2,70 CAMBRO MANUFACTURING COMPANY \$2,70 JIGSAW MEDICAL, LLC \$2,70 R D PLASTICS COMPANY, INC. \$2,62 BE&G FOODS, INC. \$2,62 BEUTLICH PHARMACEUTICALS, LLC \$2,61 MELINTA THERAPEUTICS, INC. \$2,46 APOTEX CORP. \$2,45 GENDOSE PHARMACEUTICALS \$2,40 MYLAN SPECIALTY L.P. \$2,40 BROOKWOOD FARMS, INC. \$2,35 HARTMANN USA, INC. \$2,33 PROCTER & GAMBLE DISTRIBUTING LLC \$2,33 XGEN PHARMACEUTICALS DIB, INC. \$2,27 JONAS SOFTWARE COMPANY \$2,27 SANDOZ INC. \$2,27 AERO US INC. DBA AEROGEN \$2,20 AERO US INC. DBA AEROGEN \$2,20 LAND O'LAKES, INC. \$2,19 LUPIN PHARMACEUTICALS INC. \$2,19 LUPIN PHARMACEUTICALS INC., USA \$2,02 GENORONGE HEALTHCARE SOLUT		\$2,979
HURON BIDCO, INC. DBA SECOND NATURE BRANDS ALCON VISION, LLC \$2,79 CARRIER ENTERPRISE, LLC \$2,70 IJGSAW MEDICAL, LLC \$2,70 IJGSAW MEDICAL, LLC \$2,63 B&G FOODS, INC. \$2,63 B&G FOODS, INC. \$2,61 BEUTLICH PHARMACEUTICALS, LLC APOTEX CORP. \$2,45 GENDOSE PHARMACEUTICALS \$2,45 GENDOSE PHARMACEUTICALS \$2,45 GENDOSE PHARMACEUTICAL, INC. \$2,40 MYLAN SPECIALTY L.P. \$2,40 MYLAN SPECIALTY \$2,40		
ALCON VISION, LLC CARRIER ENTERPRISE, LLC CAMBRO MANUFACTURING COMPANY \$2,70 IJGSAW MEDICAL, LLC R D PLASTICS COMPANY, INC. \$2,62 B&G FOODS, INC. BEUTLICH PHARMACEUTICALS, LLC MELINTA THERAPEUTICS, INC. 42,46 APOTEX CORP. GENDOSE PHARMACEUTICALS FAR PHARMACEUTICAL, INC. MYLAN SPECIALTY L.P. BROOKWOOD FARMS, INC. \$2,35 PROCTER & GAMBLE DISTRIBUTING LLC \$2,33 PROCTER & GAMBLE DISTRIBUTING LLC \$2,275 JONAS SOFTWARE COMPANY \$2,275 SEBELA PHARMACEUTICALS DIB, INC. \$2,275 JONAS SOFTWARE COMPANY \$2,275 SEBELA PHARMACEUTICALS INC. \$2,205 AERO US INC. DBA AEROGEN \$2,205 SEBELA PHARMACEUTICALS INC. \$2,205 SEBELA PHARMACEUTICALS INC. \$2,207 GERNDAS SOFTWARE COMPANY \$2,277 SEBELA PHARMACEUTICALS INC. \$2,19 LUPIN PHARMACEUTICALS, INC. \$2,19 LUPIN PHARMACEUTICALS, INC. \$2,19 LUPIN PHARMACEUTICALS, INC. \$2,19 CONCORDANCE HEALTHCARE SOLUTIONS LLC \$2,007 GIENMARK PHARMACEUTICALS INC. \$3,977 GENDARK PHARMACEUTICALS INC. \$1,977 MERCURY MEDICAL GIENMARK PHARMACEUTICALS INC. \$1,977 ASAHI INTECC USA, INC. \$3,977 ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES \$1,66 MONVAGHAN MEDICAL, LLC \$1,577 ROBERT BUSSE & C.O., INC. DBA BUSSE HOSPITAL DISPOSABLES \$1,66 MONVAGHAN MEDICAL, LLC \$1,577 BRASSELER U.S.A. MEDICAL, LLC \$1,577	·	
CARRIER ENTERPRISE, LLC \$2,72 CAMBRO MANUFACTURING COMPANY \$2,70 JIGSAW MEDICAL, LLC \$2,70 R D PLASTICS COMPANY, INC. \$2,63 B&G FOODS, INC. \$2,62 BEUTLICH PHARMACEUTICALS, LLC \$2,61 MELINTA THERAPEUTICS, INC. \$2,46 APOTEX CORP. \$2,45 GENDOSE PHARMACEUTICALS \$2,45 PAR PHARMACEUTICAL, INC. \$2,45 MYLAN SPECIALTY LP. \$2,40 BROOKWOOD FARMS, INC. \$2,35 HARTMANN USA, INC. \$2,33 PROCTER & GAMBLE DISTRIBUTING LLC \$2,30 XGEN PHARMACEUTICALS DJB, INC. \$2,27 JONAS SOFTWARE COMPANY \$2,27 SANDOZ INC. \$2,20 AERO US INC. DBA AEROGEN \$2,20 SEBELA PHARMACEUTICALS INC \$2,19 LUPIN PHARMACEUTICALS, INC. \$2,19 LUPIN PHARMACEUTICALS, INC. \$2,20 GENMARK PHARMACEUTICALS INC., USA \$2,05 CONCORDANCE HEALTHCARE SOLUTIONS LLC \$2,05 BIO PRODUCTS LABORATORY \$2,00 BIO PROD		
CAMBRO MANUFACTURING COMPANY \$2,70 JIGSAW MEDICAL, LLC \$2,70 R D PLASTICS COMPANY, INC. \$2,63 B&G FOODS, INC. \$2,621 BEUTLICH PHARMACEUTICALS, LLC \$2,61 MELINTA THERAPEUTICS, INC. \$2,46 APOTEX CORP. \$2,45 GENDOSE PHARMACEUTICALS \$2,45 PAR PHARMACEUTICAL, INC. \$2,40 MYLAN SPECIALTY LP. \$2,40 BROOKWOOD FARMS, INC. \$2,33 HARTMANN USA, INC. \$2,33 PROCTER & GAMBLE DISTRIBUTING LLC \$2,30 XGEN PHARMACEUTICALS DISTRIBUTING LLC \$2,30 XGEN PHARMACEUTICALS DISTRIBUTING LLC \$2,20 SANDOZ INC. \$2,27 SANDOZ INC. \$2,27 AERO US INC. DBA AEROGEN \$2,20 SEBELA PHARMACEUTICALS INC \$2,19 LAND O'LAKES, INC. \$2,19 LUPIN PHARMACEUTICALS, INC. \$2,18 HUBERT COMPANY, LLC \$2,05 GENMARK PHARMACEUTICALS INC., USA \$2,05 CONCORDANCE HEALTHCARE SOLUTIONS LLC \$2,02 BIO PRODUCTS LABORATORY \$2,00 BIO PRODUCTS LABORA		
JIGSAW MEDICAL, LLC \$2,70 R D PLASTICS COMPANY, INC. \$2,63 B&G FOODS, INC. \$2,62 BEUTLICH PHARMACEUTICALS, LLC \$2,61 MELINTA THERAPEUTICS, INC. \$2,46 APOTEX CORP. \$2,45 GENDOSE PHARMACEUTICALS \$2,45 PAR PHARMACEUTICAL, INC. \$2,40 MYLAN SPECIALTY L.P. \$2,40 BROOKWOOD FARMS, INC. \$2,33 PROCTER & GAMBLE DISTRIBUTING LLC \$2,30 XGEN PHARMACEUTICALS DJB, INC. \$2,27 JONAS SOFTWARE COMPANY \$2,27 SANDOZ INC. \$2,20 AERO US INC. DBA AEROGEN \$2,20 SEBELA PHARMACEUTICALS INC \$2,19 LUPIN PHARMACEUTICALS, INC. \$2,19 LUPIN PHARMACEUTICALS, INC. \$2,19 LUPIN PHARMACEUTICALS, INC. \$2,19 LUPIN PHARMACEUTICALS, INC. \$2,20 GIENMARK PHARMACEUTICALS INC., USA \$2,05 CONCORDANCE HEALTHCARE SOLUTIONS LLC \$2,00 BIO PRODUCTS LABORATORY \$2,00 BIO PRODUCTS LABORATORY \$2,00 <t< td=""><td>·</td><td></td></t<>	·	
R D PLASTICS COMPANY, INC. \$2,63 B&G FOODS, INC. \$2,62 BEUTLICH PHARMACEUTICALS, LLC \$2,61 MELINTA THERAPEUTICS, INC. \$2,46 APOTEX CORP. \$2,45 PAR PHARMACEUTICAL, INC. \$2,40 MYLAN SPECIALTY L.P. \$2,40 BROOKWOOD FARMS, INC. \$2,35 HARTMANN USA, INC. \$2,35 HARTMANN USA, INC. \$2,37 PROCTER & GAMBLE DISTRIBUTING LLC \$2,30 XGEN PHARMACEUTICALS DIJB, INC. \$2,27 SANDOZ INC. \$2,27 SANDOZ INC. \$2,27 SANDOZ INC. \$2,20 SEBELA PHARMACEUTICALS INC \$2,20 SEBELA PHARMACEUTICALS INC \$2,20 SEBELA PHARMACEUTICALS INC \$2,19 LUPIN PHARMACEUTICALS INC. \$2,19 LUPIN PHARMACEUTICALS INC. \$2,19 LUPIN PHARMACEUTICALS INC. \$2,19 CURNON SOFTWARE COMPANY \$2,27 SANDOZ INC. \$2,20 SEBELA PHARMACEUTICALS INC. \$2,19 LUPIN PHARMACEUTICALS, INC. \$2,19 CURNON PHARMACEUTICALS INC. \$2,00 SEBELA PHARMACEUTICALS, INC. \$2,00 SEBELA PHARMACEUTICALS INC. \$1,97 SEBELA PHARMACEUTICALS INC. \$1,97 SEBELA PHARMACEUTICALS SINC. \$1,66 MONAGHAN MEDICAL CORPORATION \$1,66 MONAGHAN MEDICAL CORPORATION \$1,66 MONOAGHAN MEDICAL CORPORATION \$1,66 MONOAGHAN MEDICAL CORPORATION \$1,66 MONOAGHAN MEDICAL CORPORATION \$1,66 SEASSELER U.S.A. MEDICAL, LLC		
B&G FOODS, INC. \$2,621 BEUTLICH PHARMACEUTICALS, LLC \$2,61 MELINTA THERAPEUTICS, INC. \$2,46 APOTEX CORP. \$2,45 GENDOSE PHARMACEUTICALS \$2,40 MYLAN SPECIALTY L.P. \$2,40 BROOKWOOD FARMS, INC. \$2,33 HARTMANN USA, INC. \$2,33 PROCTER & GAMBLE DISTRIBUTING LLC \$2,30 XGEN PHARMACEUTICALS DJB, INC. \$2,27 JONAS SOFTWARE COMPANY \$2,27 SAROU SI INC. DBA AEROGEN \$2,20 SEBELA PHARMACEUTICALS INC \$2,19 LAND O'LAKES, INC. \$2,19 LUPIN PHARMACEUTICALS, INC. \$2,19 LUPIN PHARMACEUTICALS, INC. \$2,07 GLENMARK PHARMACEUTICALS INC., USA \$2,07 CONCORDANCE HEALTHCARE SOLUTIONS LLC \$2,00 BIO PRODUCTS LABORATORY \$2,00 ENABLECV, INC. \$1,93 MERCURY MEDICAL \$1,93 CIVCO MEDICAL SOLUTIONS \$1,91 ANAPHARMACEUTICALS \$1,93 CIVCO MEDICAL SOLUTIONS \$1,91 ANI PHARMACEUTICALS \$1,77 ASAHI INTECC USA, INC. <td< td=""><td></td><td></td></td<>		
BEUTLICH PHARMACEUTICALS, LLC \$2,61 MELINTA THERAPEUTICS, INC. \$2,46 APOTEX CORP. \$2,45 GENDOSE PHARMACEUTICALS \$2,45 PAR PHARMACEUTICAL, INC. \$2,40 MYLAN SPECIALTY L.P. \$2,40 BROOKWOOD FARMS, INC. \$2,35 HARTMANN USA, INC. \$2,33 PROCTER & GAMBLE DISTRIBUTING LLC \$2,30 XGEN PHARMACEUTICALS DJB, INC. \$2,27 JONAS SOFTWARE COMPANY \$2,27 SANDOZ INC. \$2,20 AERO US INC. DBA AEROGEN \$2,20 SEBELA PHARMACEUTICALS INC \$2,19 LAND O'LAKES, INC. \$2,19 LAND O'LAKES, INC. \$2,19 LUPIN PHARMACEUTICALS, INC. \$2,96 GLENMARK PHARMACEUTICALS INC., USA \$2,07 GLENMARK PHARMACEUTICALS INC., USA \$2,05 CONCORDANCE HEALTHCARE SOLUTIONS LLC \$2,02 BIO PRODUCTS LABORATORY \$2,00 ENABLECV, INC. \$1,97 MERCURY MEDICAL \$1,93 CIVCO MEDICAL SOLUTIONS \$1,91 ANI PHARMACEUTICALS <td>·</td> <td></td>	·	
MELINTA THERAPEUTICS, INC. \$2,46. APOTEX CORP. \$2,45. GENDOSE PHARMACEUTICALS \$2,45. PAR PHARMACEUTICAL, INC. \$2,40. MYLAN SPECIALTY L.P. \$2,40. BROOKWOOD FARMS, INC. \$2,35. HARTMANN USA, INC. \$2,33. PROCTER & GAMBLE DISTRIBUTING LLC \$2,30. XGEN PHARMACEUTICALS DJB, INC. \$2,27. JONAS SOFTWARE COMPANY \$2,27. SANDOZ INC. \$2,20. AERO US INC. DBA AEROGEN \$2,20. SEBELA PHARMACEUTICALS INC \$2,19. LAND O'LAKES, INC. \$2,19. LUPIN PHARMACEUTICALS, INC. \$2,19. HUBERT COMPANY, LLC \$2,07. GLENMARK PHARMACEUTICALS INC., USA \$2,05. CONCORDANCE HEALTHCARE SOLUTIONS LLC \$2,00. BIO PRODUCTS LABORATORY \$2,00. ENABLECV, INC. \$1,97. MERCURY MEDICAL \$1,97. ANI PHARMACEUTICALS \$1,77. ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES \$1,66. MONAGHAN MEDICAL CORPORATION \$1,66. MONOLEX HOLDINGS, LLC \$1,57.		
APOTEX CORP. \$2,45 GENDOSE PHARMACEUTICALS \$2,45 PAR PHARMACEUTICAL, INC. \$2,40 MYLAN SPECIALTY L.P. \$2,40 BROOKWOOD FARMS, INC. \$2,35 HARTMANN USA, INC. \$2,35 HARTMANN USA, INC. \$2,30 XGEN PHARMACEUTICALS DIB, INC. \$2,20 XGEN PHARMACEUTICALS DIB, INC. \$2,27 JONAS SOFTWARE COMPANY \$2,27 SANDOZ INC. \$2,20 AERO US INC. DBA AEROGEN \$2,20 SEBELA PHARMACEUTICALS INC \$2,19 LAND O'LAKES, INC. \$2,19 LUPIN PHARMACEUTICALS, INC. \$2,19 LUPIN PHARMACEUTICALS, INC. \$2,19 LUPIN PHARMACEUTICALS, INC. \$2,19 CLENMARK PHARMACEUTICALS, INC. \$2,18 HUBERT COMPANY, LLC \$2,07 GLENMARK PHARMACEUTICALS INC. USA CONCORDANCE HEALTHCARE SOLUTIONS LLC BIO PRODUCTS LABORATORY \$2,00 ENABLECV, INC. \$1,97 MERCURY MEDICAL \$1,93 CIVCO MEDICAL SOLUTIONS \$1,91 ANI PHARMACEUTICALS \$1,79 ASAHI INTECC USA, INC. \$1,77 ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES MONAGHAN MEDICAL CORPORATION \$1,66 MONAGHAN MEDICAL CORPORATION \$1,66 MONAGHAN MEDICAL CORPORATION \$1,65 BRASSELER U.S.A. MEDICAL, LLC		· '
GENDOSE PHARMACEUTICALS \$2,450 PAR PHARMACEUTICAL, INC. \$2,400 MYLAN SPECIALTY L.P. \$2,400 BROOKWOOD FARMS, INC. \$2,355 HARTMANN USA, INC. \$2,331 PROCTER & GAMBLE DISTRIBUTING LLC \$2,301 XGEN PHARMACEUTICALS DJB, INC. \$2,272 JONAS SOFTWARE COMPANY \$2,277 SANDOZ INC. \$2,201 AERO US INC. DBA AEROGEN \$2,201 SEBELA PHARMACEUTICALS INC \$2,19 LAND O'LAKES, INC. \$2,19 LUPIN PHARMACEUTICALS, INC. \$2,19 HUBERT COMPANY, LLC \$2,07 GLENMARK PHARMACEUTICALS INC., USA \$2,05 CONCORDANCE HEALTHCARE SOLUTIONS LLC \$2,05 BIO PRODUCTS LABORATORY \$2,00 ENABLECV, INC. \$1,97 MERCURY MEDICAL \$1,93 CIVCO MEDICAL SOLUTIONS \$1,91 ANI PHARMACEUTICALS \$1,79 ASAHI INTECC USA, INC. \$1,79 ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES \$1,66 MONAGHAN MEDICAL CORPORATION \$1,66 MONVOLEX HOLDINGS, LLC \$1,57 <td></td> <td></td>		
PAR PHARMACEUTICAL, INC. \$2,400 MYLAN SPECIALTY L.P. \$2,400 BROOKWOOD FARMS, INC. \$2,355 HARTMANN USA, INC. \$2,330 PROCTER & GAMBLE DISTRIBUTING LLC \$2,300 XGEN PHARMACEUTICALS DJB, INC. \$2,275 JONAS SOFTWARE COMPANY \$2,277 SANDOZ INC. \$2,200 AERO US INC. DBA AEROGEN \$2,201 SEBELA PHARMACEUTICALS INC \$2,191 LAND O'LAKES, INC. \$2,192 LUPIN PHARMACEUTICALS, INC. \$2,194 HUBERT COMPANY, LLC \$2,007 GLENMARK PHARMACEUTICALS INC., USA \$2,007 GLENMARK PHARMACEUTICALS INC., USA \$2,007 GONCORDANCE HEALTHCARE SOLUTIONS LLC \$2,002 BIO PRODUCTS LABORATORY \$2,002 ENABLECV, INC. \$1,977 MERCURY MEDICAL \$1,937 CIVCO MEDICAL SOLUTIONS \$1,913 ANI PHARMACEUTICALS \$1,772 ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES \$1,666 MONAGHAN MEDICAL CORPORATION \$1,666 NOVOLEX HOLDINGS, LLC \$1,575<		
MYLAN SPECIALTY L.P. \$2,400 BROOKWOOD FARMS, INC. \$2,350 HARTMANN USA, INC. \$2,331 PROCTER & GAMBLE DISTRIBUTING LLC \$2,300 XGEN PHARMACEUTICALS DJB, INC. \$2,273 JONAS SOFTWARE COMPANY \$2,273 SANDOZ INC. \$2,201 AERO US INC. DBA AEROGEN \$2,201 SEBELA PHARMACEUTICALS INC \$2,191 LAND O'LAKES, INC. \$2,191 LUPIN PHARMACEUTICALS, INC. \$2,194 HUBERT COMPANY, LLC \$2,073 GLENMARK PHARMACEUTICALS INC., USA \$2,073 CONCORDANCE HEALTHCARE SOLUTIONS LLC \$2,002 BIO PRODUCTS LABORATORY \$2,003 ENABLECV, INC. \$1,933 MERCURY MEDICAL \$1,937 CIVCO MEDICAL SOLUTIONS \$1,937 ANI PHARMACEUTICALS \$1,772 ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES \$1,666 MONAGHAN MEDICAL CORPORATION \$1,666 NOVOLEX HOLDINGS, LLC \$1,656 BRASSELER U.S.A. MEDICAL, LLC \$1,575		
BROOKWOOD FARMS, INC. \$2,355 HARTMANN USA, INC. \$2,331 PROCTER & GAMBLE DISTRIBUTING LLC \$2,300 XGEN PHARMACEUTICALS DJB, INC. \$2,275 JONAS SOFTWARE COMPANY \$2,275 SANDOZ INC. \$2,200 AERO US INC. DBA AEROGEN \$2,200 SEBELA PHARMACEUTICALS INC \$2,195 LAND O'LAKES, INC. \$2,195 LUPIN PHARMACEUTICALS, INC. \$2,196 LUPIN PHARMACEUTICALS, INC. \$2,196 LUPIN PHARMACEUTICALS, INC. \$2,196 CONCORDANCE HEALTHCARE SOLUTIONS LLC \$2,007 GLENMARK PHARMACEUTICALS INC., USA \$2,056 CONCORDANCE HEALTHCARE SOLUTIONS LLC \$2,007 ENABLECV, INC. \$1,975 MERCURY MEDICAL \$1,936 CIVCO MEDICAL SOLUTIONS \$1,916 ANI PHARMACEUTICALS \$1,775 ASAHI INTECC USA, INC. \$1,775 ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES \$1,666 MONAGHAN MEDICAL CORPORATION \$1,666 NOVOLEX HOLDINGS, LLC \$1,575		
HARTMANN USA, INC. \$2,331 PROCTER & GAMBLE DISTRIBUTING LLC \$2,301 XGEN PHARMACEUTICALS DJB, INC. \$2,275 JONAS SOFTWARE COMPANY \$2,277 SANDOZ INC. \$2,202 AERO US INC. DBA AEROGEN \$2,202 SEBELA PHARMACEUTICALS INC \$2,199 LAND O'LAKES, INC. \$2,199 LUPIN PHARMACEUTICALS, INC. \$2,180 HUBERT COMPANY, LLC \$2,077 GLENMARK PHARMACEUTICALS INC., USA \$2,050 CONCORDANCE HEALTHCARE SOLUTIONS LLC \$2,020 BIO PRODUCTS LABORATORY \$2,000 ENABLECV, INC. \$1,975 MERCURY MEDICAL \$1,935 CIVCO MEDICAL SOLUTIONS \$1,915 ANI PHARMACEUTICALS \$1,795 ASAHI INTECC USA, INC. \$1,775 ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES \$1,666 MONAGHAN MEDICAL CORPORATION \$1,666 NOVOLEX HOLDINGS, LLC \$1,575 BRASSELER U.S.A. MEDICAL, LLC \$1,575		
PROCTER & GAMBLE DISTRIBUTING LLC \$2,30 XGEN PHARMACEUTICALS DJB, INC. \$2,27 JONAS SOFTWARE COMPANY \$2,27 SANDOZ INC. \$2,20 AERO US INC. DBA AEROGEN \$2,20 SEBELA PHARMACEUTICALS INC \$2,19 LAND O'LAKES, INC. \$2,19 LUPIN PHARMACEUTICALS, INC. \$2,18 HUBERT COMPANY, LLC \$2,07 GLENMARK PHARMACEUTICALS INC., USA \$2,05 CONCORDANCE HEALTHCARE SOLUTIONS LLC \$2,00 BIO PRODUCTS LABORATORY \$2,00 ENABLECV, INC. \$1,97 MERCURY MEDICAL \$1,93 CIVCO MEDICAL SOLUTIONS \$1,91 ANI PHARMACEUTICALS \$1,79 ANI PHARMACEUTICALS \$1,79 ASAHI INTECC USA, INC. \$1,77 ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES \$1,66 MONAGHAN MEDICAL CORPORATION \$1,66 NOVOLEX HOLDINGS, LLC \$1,57 BRASSELER U.S.A. MEDICAL, LLC \$1,57		
XGEN PHARMACEUTICALS DJB, INC. \$2,27 JONAS SOFTWARE COMPANY \$2,27 SANDOZ INC. \$2,20 AERO US INC. DBA AEROGEN \$2,20 SEBELA PHARMACEUTICALS INC \$2,19 LAND O'LAKES, INC. \$2,19 LUPIN PHARMACEUTICALS, INC. \$2,07 GLENMARK PHARMACEUTICALS INC., USA \$2,05 CONCORDANCE HEALTHCARE SOLUTIONS LLC \$2,00 BIO PRODUCTS LABORATORY \$2,00 ENABLECV, INC. \$1,97 MERCURY MEDICAL \$1,93 CIVCO MEDICAL SOLUTIONS \$1,91 ANI PHARMACEUTICALS \$1,79 ANI PHARMACEUTICALS \$1,79 ANI PHARMACEUTICALS \$1,79 ASAHI INTECC USA, INC. \$1,77 ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES \$1,66 MONAGHAN MEDICAL CORPORATION \$1,66 NOVOLEX HOLDINGS, LLC \$1,57 BRASSELER U.S.A. MEDICAL, LLC \$1,57		
JONAS SOFTWARE COMPANY \$2,27' SANDOZ INC. \$2,20' AERO US INC. DBA AEROGEN \$2,20' SEBELA PHARMACEUTICALS INC \$2,19' LAND O'LAKES, INC. \$2,19' LUPIN PHARMACEUTICALS, INC. \$2,18' HUBERT COMPANY, LLC \$2,07' GLENMARK PHARMACEUTICALS INC., USA \$2,05' CONCORDANCE HEALTHCARE SOLUTIONS LLC \$2,02' BIO PRODUCTS LABORATORY \$2,00' ENABLECV, INC. \$1,97' MERCURY MEDICAL \$1,93' CIVCO MEDICAL SOLUTIONS \$1,79' ANI PHARMACEUTICALS \$1,79' ASAHI INTECC USA, INC. \$1,77' ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES \$1,66' MONAGHAN MEDICAL CORPORATION \$1,66' NOVOLEX HOLDINGS, LLC \$1,65' BRASSELER U.S.A. MEDICAL, LLC \$1,57'		
SANDOZ INC. \$2,200 AERO US INC. DBA AEROGEN \$2,200 SEBELA PHARMACEUTICALS INC \$2,190 LAND O'LAKES, INC. \$2,190 LUPIN PHARMACEUTICALS, INC. \$2,180 HUBERT COMPANY, LLC \$2,070 GLENMARK PHARMACEUTICALS INC., USA \$2,050 CONCORDANCE HEALTHCARE SOLUTIONS LLC \$2,000 BIO PRODUCTS LABORATORY \$2,000 ENABLECV, INC. \$1,970 MERCURY MEDICAL \$1,930 CIVCO MEDICAL SOLUTIONS \$1,910 ANI PHARMACEUTICALS \$1,770 ASAHI INTECC USA, INC. \$1,770 ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES \$1,660 MONAGHAN MEDICAL CORPORATION \$1,660 NOVOLEX HOLDINGS, LLC \$1,650 BRASSELER U.S.A. MEDICAL, LLC \$1,570		
AERO US INC. DBA AEROGEN \$2,200 SEBELA PHARMACEUTICALS INC \$2,195 LAND O'LAKES, INC. \$2,196 LUPIN PHARMACEUTICALS, INC. \$2,186 HUBERT COMPANY, LLC \$2,075 GLENMARK PHARMACEUTICALS INC., USA \$2,056 CONCORDANCE HEALTHCARE SOLUTIONS LLC \$2,002 BIO PRODUCTS LABORATORY \$2,000 ENABLECV, INC. \$1,975 MERCURY MEDICAL \$1,933 CIVCO MEDICAL SOLUTIONS \$1,915 ANI PHARMACEUTICALS \$1,795 ASAHI INTECC USA, INC. \$1,775 ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES \$1,666 MONAGHAN MEDICAL CORPORATION \$1,666 NOVOLEX HOLDINGS, LLC \$1,575		
SEBELA PHARMACEUTICALS INC \$2,19 LAND O'LAKES, INC. \$2,19 LUPIN PHARMACEUTICALS, INC. \$2,18 HUBERT COMPANY, LLC \$2,07 GLENMARK PHARMACEUTICALS INC., USA \$2,05 CONCORDANCE HEALTHCARE SOLUTIONS LLC \$2,02 BIO PRODUCTS LABORATORY \$2,00 ENABLECV, INC. \$1,97 MERCURY MEDICAL \$1,93 CIVCO MEDICAL SOLUTIONS \$1,91 ANI PHARMACEUTICALS \$1,79 ASAHI INTECC USA, INC. \$1,77 ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES \$1,66 MONAGHAN MEDICAL CORPORATION \$1,66 MOVOLEX HOLDINGS, LLC \$1,575		
LAND O'LAKES, INC. \$2,194 LUPIN PHARMACEUTICALS, INC. \$2,184 HUBERT COMPANY, LLC \$2,075 GLENMARK PHARMACEUTICALS INC., USA \$2,056 CONCORDANCE HEALTHCARE SOLUTIONS LLC \$2,026 BIO PRODUCTS LABORATORY \$2,000 ENABLECV, INC. \$1,976 MERCURY MEDICAL \$1,936 CIVCO MEDICAL SOLUTIONS \$1,916 ANI PHARMACEUTICALS \$1,799 ASAHI INTECC USA, INC. \$1,776 ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES \$1,666 MONAGHAN MEDICAL CORPORATION \$1,666 NOVOLEX HOLDINGS, LLC \$1,576 BRASSELER U.S.A. MEDICAL, LLC \$1,576		
LUPIN PHARMACEUTICALS, INC. HUBERT COMPANY, LLC \$2,075 GLENMARK PHARMACEUTICALS INC., USA \$2,055 CONCORDANCE HEALTHCARE SOLUTIONS LLC BIO PRODUCTS LABORATORY \$2,005 ENABLECV, INC. \$1,975 MERCURY MEDICAL \$1,935 CIVCO MEDICAL SOLUTIONS \$1,915 ANI PHARMACEUTICALS \$1,795 ASAHI INTECC USA, INC. \$1,775 ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES MONAGHAN MEDICAL CORPORATION \$1,666 NOVOLEX HOLDINGS, LLC \$1,575		
HUBERT COMPANY, LLC \$2,075 GLENMARK PHARMACEUTICALS INC., USA \$2,056 CONCORDANCE HEALTHCARE SOLUTIONS LLC \$2,026 BIO PRODUCTS LABORATORY \$2,000 ENABLECV, INC. \$1,975 MERCURY MEDICAL \$1,936 CIVCO MEDICAL SOLUTIONS \$1,916 ANI PHARMACEUTICALS \$1,791 ASAHI INTECC USA, INC. \$1,775 ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES \$1,666 MONAGHAN MEDICAL CORPORATION \$1,666 NOVOLEX HOLDINGS, LLC \$1,656 BRASSELER U.S.A. MEDICAL, LLC \$1,575		
GLENMARK PHARMACEUTICALS INC., USA CONCORDANCE HEALTHCARE SOLUTIONS LLC BIO PRODUCTS LABORATORY ENABLECV, INC. MERCURY MEDICAL CIVCO MEDICAL SOLUTIONS ANI PHARMACEUTICALS ANI PHARMACEUTICALS S1,79 ASAHI INTECC USA, INC. ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES MONAGHAN MEDICAL CORPORATION NOVOLEX HOLDINGS, LLC BRASSELER U.S.A. MEDICAL, LLC \$2,020 \$2,020 \$2,020 \$1,979 \$2,000 \$1,979 \$1,979 \$1,660 \$1,660 \$1,660 \$1,660 \$1,660 \$1,650 \$1,650 \$1,650 \$1,650	· · · · · · · · · · · · · · · · · · ·	
CONCORDANCE HEALTHCARE SOLUTIONS LLC BIO PRODUCTS LABORATORY \$2,00° ENABLECV, INC. \$1,97° MERCURY MEDICAL CIVCO MEDICAL SOLUTIONS ANI PHARMACEUTICALS \$1,79° ASAHI INTECC USA, INC. \$1,77° ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES MONAGHAN MEDICAL CORPORATION \$1,66° NOVOLEX HOLDINGS, LLC \$1,57° ENASSELER U.S.A. MEDICAL, LLC	·	
BIO PRODUCTS LABORATORY \$2,00° ENABLECV, INC. \$1,97° MERCURY MEDICAL \$1,93° CIVCO MEDICAL SOLUTIONS \$1,91° ANI PHARMACEUTICALS \$1,79° ASAHI INTECC USA, INC. \$1,77° ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES MONAGHAN MEDICAL CORPORATION \$1,66° NOVOLEX HOLDINGS, LLC \$1,65° BRASSELER U.S.A. MEDICAL, LLC	·	
ENABLECV, INC. \$1,979 MERCURY MEDICAL \$1,933 CIVCO MEDICAL SOLUTIONS \$1,919 ANI PHARMACEUTICALS \$1,799 ASAHI INTECC USA, INC. \$1,779 ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES \$1,669 MONAGHAN MEDICAL CORPORATION \$1,669 NOVOLEX HOLDINGS, LLC \$1,659 BRASSELER U.S.A. MEDICAL, LLC \$1,579		
MERCURY MEDICAL \$1,933 CIVCO MEDICAL SOLUTIONS \$1,915 ANI PHARMACEUTICALS \$1,793 ASAHI INTECC USA, INC. \$1,777 ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES \$1,666 MONAGHAN MEDICAL CORPORATION \$1,666 NOVOLEX HOLDINGS, LLC \$1,656 BRASSELER U.S.A. MEDICAL, LLC \$1,575		\$2,007
CIVCO MEDICAL SOLUTIONS \$1,916 ANI PHARMACEUTICALS \$1,79 ASAHI INTECC USA, INC. \$1,779 ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES \$1,660 MONAGHAN MEDICAL CORPORATION \$1,660 NOVOLEX HOLDINGS, LLC \$1,650 BRASSELER U.S.A. MEDICAL, LLC \$1,579	· · · · · · · · · · · · · · · · · · ·	
ANI PHARMACEUTICALS \$1,79 ASAHI INTECC USA, INC. \$1,77 ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES \$1,66 MONAGHAN MEDICAL CORPORATION \$1,66 NOVOLEX HOLDINGS, LLC \$1,650 BRASSELER U.S.A. MEDICAL, LLC \$1,575		
ASAHI INTECC USA, INC. \$1,775 ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES \$1,666 MONAGHAN MEDICAL CORPORATION \$1,666 NOVOLEX HOLDINGS, LLC \$1,656 BRASSELER U.S.A. MEDICAL, LLC \$1,575		\$1,918
ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES \$1,660 MONAGHAN MEDICAL CORPORATION \$1,660 NOVOLEX HOLDINGS, LLC \$1,650 BRASSELER U.S.A. MEDICAL, LLC \$1,570		\$1,797
MONAGHAN MEDICAL CORPORATION \$1,660 NOVOLEX HOLDINGS, LLC \$1,650 BRASSELER U.S.A. MEDICAL, LLC \$1,570	·	\$1,775
NOVOLEX HOLDINGS, LLC \$1,650 BRASSELER U.S.A. MEDICAL, LLC \$1,570	ROBERT BUSSE & CO., INC. DBA BUSSE HOSPITAL DISPOSABLES	\$1,661
BRASSELER U.S.A. MEDICAL, LLC \$1,57		\$1,660
	·	\$1,656
SURGICAL SPECIALTIES CORPORATION \$1.52	BRASSELER U.S.A. MEDICAL, LLC	\$1,575
91,33	SURGICAL SPECIALTIES CORPORATION	\$1,537
FERRING PHARMACEUTICALS, INC. \$1,52	FERRING PHARMACEUTICALS, INC.	\$1,522
CARDINAL HEALTH 414, LLC \$1,51	CARDINAL HEALTH 414, LLC	\$1,513
GUERBET LLC \$1,47	GUERBET LLC	\$1,475
ACIST MEDICAL SYSTEMS, INC. \$1,45	ACIST MEDICAL SYSTEMS, INC.	\$1,452
MYCO MEDICAL SUPPLIES INC. \$1,44	MYCO MEDICAL SUPPLIES INC.	\$1,445

SUPPLIER Q3 SPEND FY2024 NOVA BIOMEDICAL CORPORATION \$1,420 CONTINENTAL MILLS, INC. DBA THE KRUSTEAZ COMPANY \$1,347 CANVIIY, LLC. \$1,347 ALBA BIOSCIENCE, INC. \$1,320 NOVOLEX HERITAGE BAG, LLC \$1,301 SOLCO HEALTHCARE US, LLC \$1,301 ECO-PRODUCTS, INC. \$1,286 INPRO CORPORATION \$1,260 PEDIGO PRODUCTS INC \$1,180 MCKESSON PACKAGING \$1,179 LANNETT COMPANY, INC. \$1,160 DARLINGTON SNACKS \$1,105 THE RITEDOSE CORPORATION \$1,067 UNICHEM PHARMACEUTICALS USA INC \$1,067 KIKKOMAN SALES USA, INC \$1,055 TARO PHARMACEUTICALS USA, INC \$1,026 ALVOGEN, INC. \$1,026 DAISY BRAND \$963 HANDGARDS, INC. \$963 PIRAMAL HEALTHCARE \$935 ADVANTICE HEALTH, LLC \$935 DIVERSATER HEALTHCARE, INC. \$935 HIGH LINER FOODS \$922 CIPLA USA, INC. \$865 <	HARRIS HEALTH PREMIER Q3 SPEND FY2024	
CONTINENTAL MILLS, INC. DBA THE KRUSTEAZ COMPANY \$1,378 CANVIIV, LIC. \$1,347 ALBA BIOSCIENCE, INC. \$1,320 NOVOLEX HERITAGE BAG, LIC \$1,301 SOLCO HEALTHCARE US, LIC \$1,301 SOLCO HEALTHCARE US, LIC \$1,301 SOLCO HEALTHCARE US, LIC \$1,301 ECO-PRODUCTS, INC. \$1,286 INPRO CORPORATION \$1,206 INPRO CORPORATION \$1,206 INPRO CORPORATION \$1,206 INPRO CORPORATION \$1,206 INPRO CORPORATION \$1,109 DARLINGTON SNACKS \$1,109 DARLINGTON SNACKS \$1,109 THE RITEDOSE CORPORATION \$1,067 UNICHEM PHARMACEUTICALS USA INC \$1,067 KIKKOMAN SALES USA, INC. \$1,067 ALVOGEN, INC. \$1,026 ALVOGEN, INC. \$1,026 ALVOGEN, INC. \$1,026 ALVOGEN, INC. \$933 DIVERSATE HEALTHCARE \$936 ADVANTICE HEALTH, LIC \$935 DIVERSATEK HEALTHCARE, INC. \$936 INCREASE HEALTHCARE, INC. \$930 CIPIAS CORPORATION NO. 2 CIPIA USA, INC \$865 KRUGGER INTERNATIONAL, INC. \$843 MISSION PHARMACAL USA INC. \$843 MISSION PHARMACAL OMPANY \$805 STERNO PRODUCTS \$801 PRASCO LABORATORIES \$738 RHODOES PHARMACEUTICALS \$737 EKATERRA TEA MSO USA LIC MARKETLAB, INC. \$736 SIEMEN SHEALTHCALS INC. \$736 KRUGGER INTERNATIONAL, INC. \$843 MISSION PHARMACAL COMPANY \$805 STERNO PRODUCTS \$801 PRASCO LABORATORIES \$738 KRUGGER INTERNATIONAL, INC. \$739 KRUGGER INTERNATIONAL, INC. \$730 KRUGGER INTERNAT	SUPPLIER	Q3 SPEND FY2024
CANVIIY, LLC. \$1,347 ALBA BIOSCIENCE, INC. \$1,320 NOVOLEX HERITAGE BAG, LLC \$1,310 SOLCO HEALTHCARE US, LLC \$1,301 SOLCO HEALTHCARE US, LLC \$1,301 ECO-PRODUCTS, INC. \$1,286 INPRO CORPORATION \$1,206 PEDIGO PRODUCTS INC \$1,180 MCKESSON PACKAGING \$1,179 LANNETT COMPANY, INC. \$1,169 DARLINGTON SNACKS \$1,105 THE RITEDOSE CORPORATION \$1,067 UNICHEM PHARMACEUTICALS USA, INC. \$1,057 TARO PHARMACEUTICALS USA, INC. \$1,057 ALVOGEN, INC. \$1,057 DAISY BRAND \$593 HANDGARDS, INC. \$1,017 DAISY BRAND \$938 HANDGARDS, INC. \$963 DIVERSATEK HEALTHCARE, INC. \$935 CINTAS CORPORATION NO. 2 CIPLA USA, INC SUMPASS SOLO \$921 CINTAS CORPORATION NO. 2 CIPLA USA, INC. \$936 RESERVE HEALTHCARE, INC. \$935 CIPLA USA, INC \$856 KRUGGER INTERNATIONAL, INC. \$859 GREENFIELD GLOBAL USA INC. \$859 GREENFIELD GLOBAL USA INC. \$859 KRUGGER INTERNATIONAL, INC. \$859 GREENFIELD GLOBAL USA INC. \$859 REREND PRODUCTS \$801 KRUGGER INTERNATIONAL, INC. \$859 GREENFIELD GLOBAL USA INC. \$859 TERNO PRODUCTS \$801 THERMACEUTICALS SOLO SALO SALO SALO SALO SALO SALO S	NOVA BIOMEDICAL CORPORATION	\$1,420
ALBA BIOSCIENCE, INC. NOVOLEY HERITAGE BAG, LLC \$1,310 SOLCO HEALTHCARE US, LLC \$1,310 ECO-PRODUCTS, INC. \$1,286 INPRO CORPORATION \$1,206 PEDIGO PRODUCTS INC \$1,206 MCKESSON PACKAGING \$1,179 LANNETT COMPANY, INC. \$1,169 DARLINGTON SNACKS \$1,105 THE RITEDOSE CORPORATION \$1,055 TARO PHARMACEUTICALS USA INC \$1,055 TARO PHARMACEUTICALS USA, INC. \$1,046 KIKKOMAN SALES USA, INC \$1,047 ALVOGEN, INC. \$2,040 ALVOGEN, INC. \$2,040 ALVOGEN, INC. \$3,040 ALVOGEN, INC. \$3,040 ALVOGEN, INC. \$4,040 ALVOGEN	CONTINENTAL MILLS, INC. DBA THE KRUSTEAZ COMPANY	\$1,378
NOVOLEX HERITAGE BAG, LLC S0LCO HEALTHCARE US, LLC \$1,301 ECO-PRODUCTS, INC. \$1,206 PEDIGO PRODUCTS INC \$1,180 MCKESSON PACKAGING \$1,170 LANNETT COMPANY, INC. \$1,160 DARLINGTO CORPORATION \$1,160 DARLINGTON SNACKS \$1,105 THE RITEDOSE CORPORATION \$1,067 THE RITEDOSE CORPORATION \$1,067 THE RITEDOSE CORPORATION \$1,067 TARO PHARMACEUTICALS USA INC \$1,056 TARO PHARMACEUTICALS USA, INC. \$1,046 KIKKOMAN SALES USA, INC \$1,026 ALVOGEN, INC. \$1,047 DAISY BRAND \$981 HANDGARDS, INC. \$963 PIRAMAL HEALTHCARE \$966 ADVANTICE HEALTH, LLC \$935 DIVERSATEK HEALTHCARE, INC. \$190 LINTAS CORPORATION NO. 2 \$200 CIPLA USA, INC \$865 KRUEGER INTERNATIONAL, INC. \$865 RESELEE INC. \$979 HYDROFERA, LLC \$773 RESELEE INC. \$789 PHASOC LABORATORIES \$798 RESELEE INC. \$799 RHANDES PHARMACEUTICALS \$773 REALTHCARE AS SOME AMARETILAB, INC. \$793 RHODES PHARMACEUTICALS \$773 REALTHCALS USA, INC. \$773 REALTHCALS USA, INC. \$789 HYDROFERA, LLC \$799 HYDROFERA, LLC \$790 HYDROF	CANVIIY, LLC.	\$1,347
SOLCO HEALTHCARE US, LLC ECO-PRODUCTS, INC. 15,286 INPRO CORPODATION \$1,206 INPRO CORPODATION \$1,206 INPRO CORPODATION \$1,108 MCKESSON PACKAGING \$1,179 LANNETT COMPANY, INC. \$1,169 DARLINGTON SNACKS \$1,105 THE RITEDOSE CORPORATION UNICHEM PHARMACEUTICALS USA INC \$1,055 THE RITEDOSE CORPORATION UNICHEM PHARMACEUTICALS USA, INC. \$1,046 KIKKOMAN SALES USA, INC \$1,045 KIKKOMAN SALES USA, INC \$1,047 ALVOGEN, INC. \$1,047 DAISY BRAND \$1,017 DAISY BRAND	ALBA BIOSCIENCE, INC.	\$1,320
SOLCO HEALTHCARE US, LLC ECO-PRODUCTS, INC. 15,286 INPRO CORPODATION \$1,206 INPRO CORPODATION \$1,206 INPRO CORPODATION \$1,108 MCKESSON PACKAGING \$1,179 LANNETT COMPANY, INC. \$1,169 DARLINGTON SNACKS \$1,105 THE RITEDOSE CORPORATION UNICHEM PHARMACEUTICALS USA INC \$1,055 THE RITEDOSE CORPORATION UNICHEM PHARMACEUTICALS USA, INC. \$1,046 KIKKOMAN SALES USA, INC \$1,045 KIKKOMAN SALES USA, INC \$1,047 ALVOGEN, INC. \$1,047 DAISY BRAND \$1,017 DAISY BRAND	·	
ECO-PRODUCTS, INC. \$1,286 INPRO CORPORATION \$1,206 PEDIGO PRODUCTS INC \$1,180 MCKESSON PACKAGING \$1,179 LANNETT COMPANY, INC. \$1,169 DARLINGTON SNACKS \$1,105 THE RITEDOSE CORPORATION \$1,067 UNICHEM PHARMACEUTICALS USA INC \$1,055 TARO PHARMACEUTICALS USA, INC. \$1,046 KIKKOMAN SALES USA, INC \$1,046 KIKKOMAN SALES USA, INC \$1,046 KIKKOMAN SALES USA, INC \$1,047 DAISY BRAND \$981 HANDGARDS, INC. \$983 PIRAMAL HEALTHCARE \$936 ADVANTICE HEALTH, LLC \$935 DIVERSATEK HEALTHCARE, INC. \$930 HIGH LINER FOODS \$921 CINTAS CORPORATION NO. 2 \$906 CIPLA USA, INC \$885 KRUEGER INTERNATIONAL, INC. \$885 KRUEGER INTERNATIONAL, INC. \$885 STERNO PRODUCTS \$801 MISSION PHARMACAL COMPANY \$805 STERNO PRODUCTS \$801 MISSION PHARMACAL COMPANY \$805 STERNO PRODUCTS \$773 EKATERRA TEA MSO USA LLC \$754 MARKETLAB, INC. \$736 SIEMENS HEALTHCAE DIAGNOSTICS INC. \$715 EKATERRA TEA MSO USA LLC \$754 MARKETLAB, INC. \$736 SIEMENS HEALTHCAE DIAGNOSTICS INC. \$716 MERITAGE PHARMACEUTICALS USA \$717 HERITAGE PHARMA, INC. \$663 MEDEFIL, INC. \$663 MEDTECH PRODUCTS INC \$663 MEDTECH PRODUCTS INC \$663 MEDTECH PRODUCTS INC \$663 MEDTECH PRODUCTS INC \$663 MEDTECH PRODUCTS, INC. \$663	·	
INPRO CORPORATION \$1,206 PEDIGO PRODUCTS INC \$1,180 MCKESSON PACKAGING \$1,179 LANNETT COMPANY, INC. \$1,160 DARLINGTON SNACKS \$1,105 THE RITEDOSE CORPORATION \$1,055 THE RITEDOSE CORPORATION \$1,055 TARO PHARMACEUTICALS USA, INC. \$1,046 KIKKOMAN SALES USA, INC. \$1,026 ALVOGEN, INC. \$1,026 ALVOGEN, INC. \$1,027 DAISY BRAND \$981 HANDGARDS, INC. \$963 PIRAMAL HEALTHCARE \$936 ADVANTICE HEALTH, LLC \$935 DIVERSATEK HEALTHCARE, INC. \$935 HIGH LINER FOODS \$921 CINTAS CORPORATION NO. 2 \$906 KRUEGER INTERNATIONAL, INC. \$859 KRUEGER INTERNATIONAL, INC. \$859 KRUEGER INTERNATIONAL, INC. \$843 MISSION PHARMACAL COMPANY \$805 STERNO PRODUCTS \$901 PRASCO LABORATORIES \$798 HYDROFERA, LLC \$793 ENAFORM STERNO PRODUCTS \$790 HYDROFERA, LLC \$793 ENAFORM STERNO PRODUCTS \$790 HYDROFERA, LLC \$793 ENAFORM STERNO PRODUCTS \$790 HYDROFERA, LLC \$793 ENAFORMACEUTICALS USA \$717 HERITAGE PHARMACAL LICLS USA \$717 HERITAGE PHARMACEUTICALS USA \$718	·	
PEDIGO PRODUCTS INC \$1,180 MCKESSON PACKAGING \$1,179 LANNETT COMPANY, INC. \$1,69 DARLINGTON SNACKS \$1,105 THE RITEDOSE CORPORATION \$1,067 UNICHEM PHARMACEUTICALS USA INC \$1,056 KIKKOMAN SALES USA, INC \$1,026 KIKKOMAN SALES USA, INC \$1,017 ALVOGEN, INC. \$1,017 DAISY BRAND \$981 HANDGARDS, INC. \$963 PIRAMAL HEALTHCARE \$936 ADVANTICE HEALTH, LLC \$935 DIVERSATEK HEALTHCARE, INC. \$930 HIGH LINER FOODS \$921 CINTAS CORPORATION NO. 2 \$906 CIPLA USA, INC \$865 KRUEGER INTERNATIONAL, INC. \$865 KRUEGER INTERNATIONAL, INC. \$865 GREENFIELD GLOBAL USA INC. \$843 MISSION PHARMACAL COMPANY \$805 STERNO PRODUCTS \$801 RHODES PHARMACEUTICALS \$739 REKATERRA TEA MISO USA LLC \$754 MARKETLAB, INC. \$754 SEMEMEN HEALT	·	
MCKESSON PACKAGING \$1,179 LANNETT COMPANY, INC. \$1,169 DARLINGTON SNACKS \$1,105 THE RITEDOSE CORPORATION \$1,067 UNICHEM PHARMACEUTICALS USA INC \$1,055 TARO PHARMACEUTICALS USA, INC. \$1,046 KIKKOMAN SALES USA, INC \$1,046 KIKKOMAN SALES USA, INC \$1,047 DAISY BRAND \$981 HANDGARDS, INC. \$963 PIRAMAL HEALTHCARE \$936 ADVANTICE HEALTH, LLC \$935 DIVERSATEK HEALTHCARE, INC. \$935 DIVERSATEK HEALTHCARE, INC. \$936 HIGH LINER FOODS \$921 CINTAS CORPORATION NO. 2 \$906 KRUEGER INTERNATIONAL, INC. \$865 KRUEGER INTERNATIONAL, INC. \$865 KRUEGER INTERNATIONAL, INC. \$843 MISSION PHARMACAL COMPANY \$805 STERNO PRODUCTS \$801 PRASCO LABORATORIES \$738 HYDROFERA, LLC \$754 KRAECH ALBORATORIES \$738 HYDROFERA, LLC \$754 KRAECH ALBORATORIES \$736 KRAECH ALBORATORIES \$736 KRAECH ALBORATORIES \$737 KRAECH ALBORATORIES \$736 KRAECH ALBORATORIES \$7		
LANNETT COMPANY, INC. \$1,169 DARLINGTON SNACKS \$1,105 THE RITEDOSE CORPORATION \$1,057 UNICHEM PHARMACEUTICALS USA INC \$1,055 TARO PHARMACEUTICALS USA, INC. \$1,046 KIKKOMAN SALES USA, INC \$1,026 ALVOGEN, INC. \$1,027 DAISY BRAND \$981 HANDGARDS, INC. \$963 PIRAMAL HEALTHCARE \$936 DIVERSATEK HEALTHCARE, INC. \$936 HIGH LINER FOODS \$921 CINTAS CORPORATION NO. 2 \$906 CIPLA USA, INC. \$859 GREENFIELD GLOBAL USA INC. \$859 GREENFIELD GLOBAL USA INC. \$843 MISSION PHARMACAL COMPANY \$805 STERNO PRODUCTS \$805 STERNO PRODUCTS \$805 STERNO PRODUCTS \$798 HYDROFERA, LLC \$798 RHODES PHARMACEUTICALS \$773 EKATERRA TEA MISO USA LLC \$754 MARKETLAB, INC. \$715 SIEMENS HEALTHCARE DIAGNOSTICS INC. \$715 TWI PHARMACEUTICALS USA \$717 MERISANT US, INC. <		
DARLINGTON SNACKS \$1,105 THE RITEDOSE CORPORATION \$1,067 UNICHEM PHARMACEUTICALS USA INC \$1,055 TARO PHARMACEUTICALS USA, INC. \$1,046 KIKKOMAN SALES USA, INC \$1,026 ALVOGEN, INC. \$1,017 DAISY BRAND \$983 HANDGARDS, INC. \$963 PIRAMAL HEALTHCARE \$936 ADVANTICE HEALTH, LLC \$935 DIVERSATEK HEALTHCARE, INC. \$930 HIGH LINER FOODS \$921 CIPLA USA, INC \$865 KRUEGER INTERNATION NO. 2 \$906 CIPLA USA, INC \$859 KRUEGER INTERNATIONAL, INC. \$859 GREENFIELD GLOBAL USA INC. \$843 MISSION PHARMACAL COMPANY \$805 STERNO PRODUCTS \$801 PRASCO LABORATORIES \$738 HYDROFERA, LLC \$738 KATERRA TEA MISO USA LLC \$753 MARKETLAB, INC. \$736 SIEMENS HEALTHCARE DIAGNOSTICS INC. \$719 TWI PHARMACEUTICALS USA \$717 HERITAGE PHARM		
THE RITEDOSE CORPORATION \$1,067 UNICHEM PHARMACEUTICALS USA INC \$1,057 TARO PHARMACEUTICALS USA, INC. \$1,046 KIKKOMAN SALES USA, INC \$1,026 ALVOGEN, INC. \$1,017 DAISY BRAND \$983 HANDGARDS, INC. \$936 PIRAMAL HEALTHCARE \$936 ADVANTICE HEALTH, LLC \$935 DIVERSATEK HEALTHCARE, INC. \$930 HIGH LINER FOODS \$921 CIPLA USA, INC \$865 KRUEGER INTERNATION NO. 2 \$906 CIPLA USA, INC \$859 KRUEGER INTERNATIONAL, INC. \$859 GREENFIELD GLOBAL USA INC. \$843 MISSION PHARMACAL COMPANY \$805 STERNO PRODUCTS \$801 PRASCO LABORATORIES \$798 HYDROFERA, LLC \$793 RHODES PHARMACEUTICALS \$773 KAHERRA TEA MSO USA LLC \$736 MARKETLAB, INC. \$736 SIEMENS HEALTHCARE DIAGNOSTICS INC. \$712 TWI PHARMACEUTICALS USA \$717 HERITAGE PHA	·	
UNICHEM PHARMACEUTICALS USA, INC. \$1,055 TARO PHARMACEUTICALS USA, INC. \$1,046 KIKKOMAN SALES USA, INC \$1,026 ALVOGEN, INC. \$1,017 DAISY BRAND \$981 HANDGARDS, INC. \$963 PIRAMAL HEALTHCARE \$936 ADVANTICE HEALTH, LLC \$935 DIVERSATEK HEALTHCARE, INC. \$935 HIGH LINER FOODS \$921 CINTAS CORPORATION NO. 2 \$906 CIPLA USA, INC \$865 KRUEGER INTERNATIONAL, INC. \$843 MISSION PHARMACAL COMPANY \$805 STERNO PRODUCTS \$801 PRASCO LABORATORIES \$798 HYDROFERA, LLC \$754 MARKETLAB, INC. \$736 SIEMENS PHARMACEUTICALS \$773 EKATERRA TEA MSO USA LLC \$754 MARKETLAB, INC. \$736 SIEMENS HEALTHCARE DIAGNOSTICS INC. \$719 TWIY PHARMACEUTICALS USA \$717 HERITAGE PHARMACEUTICALS INC \$636 MEDEFIL, INC. \$660 KEN'S FOODS, INC.<		
TARO PHARMACEUTICALS USA, INC \$1,046 KIKKOMAN SALES USA, INC \$1,026 ALVOGEN, INC. \$1,017 DAISY BRAND \$981 HANDGARDS, INC. \$963 PIRAMAL HEALTHCARE \$936 ADVANTICE HEALTH, LLC \$935 DIVERSATEK HEALTHCARE, INC. \$930 HIGH LINER FOODS \$921 CINTAS CORPORATION NO. 2 \$906 CIPLA USA, INC \$859 KRUEGER INTERNATIONAL, INC. \$859 GREENFIELD GLOBAL USA INC. \$843 MISSION PHARMACAL COMPANY \$805 STERNO PRODUCTS \$801 PRASCO LABORATORIES \$793 HYDROFERA, LLC \$793 RHODES PHARMACEUTICALS \$773 EKATERRA TEA MSO USA LLC \$754 MARKETLAB, INC. \$736 SIEMENS HEALTHCARE DIAGNOSTICS INC. \$715 TUYI PHARMACEUTICALS USA \$717 HERITAGE PHARMACEUTICALS USA \$717 MERISANT US, INC. \$663 CMP PHARMA, INC. \$688 MEDEFIL, INC.		
KIKKOMAN SALES USA, INC \$1,026 ALVOGEN, INC. \$1,017 DAISY BRAND \$981 HANDGARDS, INC. \$963 PIRAMAL HEALTHCARE \$935 ADVANTICE HEALTH, LLC \$935 DIVERSATEK HEALTHCARE, INC. \$930 HIGH LINER FOODS \$921 CINTAS CORPORATION NO. 2 \$966 CIPLA USA, INC \$859 KRUEGER INTERNATIONAL, INC. \$859 GREENFIELD GLOBAL USA INC. \$843 MISSION PHARMACAL COMPANY \$805 STERNO PRODUCTS \$801 PRASCO LABORATORIES \$798 HYDROFERA, LLC \$798 RHODES PHARMACEUTICALS \$773 EKATERRA TEA MSO USA LLC \$754 MARKETLAB, INC. \$736 SIEMENS HEALTHCARE DIAGNOSTICS INC. \$715 TWI PHARMACEUTICALS USA \$717 HERITAGE PHARMACEUTICALS INC. \$634 MENESANT US, INC. \$664 CMP PHARMA, INC. \$668 MEDEFIL, INC. \$668 KEN'S FOODS, INC. \$661 GRIFOLS BIOLOGICAL, INC. \$655		
ALVOGEN, INC. \$1,017 DAISY BRAND \$981 HANDGARDS, INC. \$963 PIRAMAL HEALTHCARE \$936 ADVANTICE HEALTH, LLC \$935 DIVERSATEK HEALTHCARE, INC. \$930 HIGH LINER FOODS \$921 CINTAS CORPORATION NO. 2 \$906 CIPLA USA, INC \$865 KRUEGER INTERNATIONAL, INC. \$859 GREENFIELD GLOBAL USA INC. \$843 MISSION PHARMACAL COMPANY \$805 STERNO PRODUCTS \$801 PRASCO LABORATORIES \$798 HYDROFERA, LLC \$793 RHODES PHARMACEUTICALS \$773 EKATERRA TEA MSO USA LLC \$754 MARKETLAB, INC. \$719 TWI PHARMACEUTICALS USA \$717 TWI PHARMACEUTICALS USA \$717 HERITAGE PHARMACEUTICALS INC. \$719 TWI PHARMACEUTICALS USA \$717 HERITAGE PHARMACEUTICALS INC. \$719 CMP PHARMA, INC. \$630 MERISANT US, INC. \$630 MERISANT US, INC. \$694 MEDEFIL, INC. \$630 MEDEFIL, INC. \$630 MEDEFIL, INC. \$630 MEDEFIL, INC. \$631 MEDICAL PRODUCTS, LLC \$631 MICOMPANY \$594 ACCORD HEALTHCARE INC. \$631 MICOMPANY \$594 ACCORD HEALTHCARE INC	·	
DAISY BRAND \$981 HANDGARDS, INC. \$963 PIRAMAL HEALTHCARE \$936 ADVANTICE HEALTH, LLC \$935 DIVERSATEK HEALTHCARE, INC. \$930 HIGH LINER FOODS \$921 CINTAS CORPORATION NO. 2 \$906 CIPLA USA, INC \$865 KRUEGER INTERNATIONAL, INC. \$859 KRUEGER INTERNATIONAL, INC. \$843 MISSION PHARMACAL COMPANY \$805 STERNO PRODUCTS \$801 PRASCO LABORATORIES \$798 HYDROFERA, LLC \$793 RHODES PHARMACEUTICALS \$773 KKATERRA TEA MSO USA LLC \$754 MARKETLAB, INC. \$736 SIEMENS HEALTHCARE DIAGNOSTICS INC. \$736 TWI PHARMACEUTICALS USA \$717 HERITAGE PHARMACEUTICALS INC \$63 LEADIANT BIOSCIENCES, INC. \$63 MERISANT US, INC. \$63 CMP PHARMA, INC. \$63 MEDEFIL, INC. \$63 KEN'S FOODS, INC. \$63 GRIFOLS BIOLOGICAL, INC. \$63 MEDTECH PRODUCTS INC \$63	·	
HANDGARDS, INC. \$963 PIRAMAL HEALTHCARE \$936 ADWANTICE HEALTH, LLC \$935 DIVERSATEK HEALTHCARE, INC. \$930 HIGH LINER FOODS \$921 CIPLA USA, INC \$865 KRUEGER INTERNATION NO. 2 \$906 CIPLA USA, INC \$859 GREENFIELD GLOBAL USA INC. \$843 MISSION PHARMACAL COMPANY \$805 STERNO PRODUCTS \$805 PRASCO LABORATORIES \$798 HYDROFERA, LLC \$793 RHODES PHARMACEUTICALS \$773 EKATERRA TEA MSO USA LLC \$754 MARKETLAB, INC. \$736 SIEMENS HEALTHCARE DIAGNOSTICS INC. \$719 TWI PHARMACEUTICALS USA \$717 HERITAGE PHARMACEUTICALS INC \$736 MERISANT US, INC. \$630 MERISANT US, INC. \$680 KEN'S FOODS, INC. \$661 GRIFOLS BIOLOGICAL, INC. \$657 MEDTECH PRODUCTS INC \$656 MEDTECH PRODUCTS INC \$635 MEDTECH PRODUCTS, LLC \$631 3M COMPANY \$594 <tr< td=""><td></td><td></td></tr<>		
PIRAMAL HEALTHCARE \$936 ADVANTICE HEALTH, LLC \$935 DIVERSATEK HEALTHCARE, INC. \$930 HIGH LINER FOODS \$921 CINTAS CORPORATION NO. 2 \$906 CIPLA USA, INC \$865 KRUEGER INTERNATIONAL, INC. \$859 GREENFIELD GLOBAL USA INC. \$843 MISSION PHARMACAL COMPANY \$805 STERNO PRODUCTS \$801 PRASCO LABORATORIES \$798 HYDROFERA, LLC \$793 RHODES PHARMACEUTICALS \$773 EKATERRA TEA MSO USA LLC \$754 MARKETLAB, INC. \$736 SIEMENS HEALTHCARE DIAGNOSTICS INC. \$712 TWI PHARMACEUTICALS USA \$717 HERITAGE PHARMACEUTICALS INC \$713 LEADIANT BIOSCIENCES, INC. \$703 MERISANT US, INC. \$694 CMP PHARMA, INC. \$680 KEN'S FOODS, INC. \$657 GRIFOLS BIOLOGICAL, INC. \$657 MEDTECH PRODUCTS INC \$655 MEDTECH PRODUCTS INC \$655 MEDTECH PRODUCTS, LLC \$631 3M COMPANY \$592<	27.00.07.00.00	·
ADVANTICE HEALTH, LLC DIVERSATEK HEALTHCARE, INC. \$930 HIGH LINER FOODS \$921 CINTAS CORPORATION NO. 2 \$966 CIPLA USA, INC \$865 KRUEGER INTERNATIONAL, INC. \$8849 MISSION PHARMACAL COMPANY \$801 PRASCO LABORATORIES \$798 HYDROFERA, LLC \$793 RHODES PHARMACEUTICALS EKATERRA TEA MSO USA LLC MARKETLAB, INC. \$1844 MISRIAN HEALTHCARE DIAGNOSTICS INC. \$714 HERITAGE PHARMACEUTICALS USA \$715 LEADIANT BIOSCIENCES, INC. \$715 MARISANT US, INC. \$680 MEDEFIL, INC. \$680 MEDEFIL, INC. \$680 MEDEFIL, INC. \$680 MEDEFIL, INC. \$681 MEDICAL \$683 MEDEFIL, INC. \$680 MEDEFIL, INC. \$680 MEDICAL \$683 MEDEFIL, INC. \$681 MEDICAL \$683 MEDEFIL HOLD. \$683 MEDEFIL HOLD. \$685 MEDICAL PRODUCTS INC. \$685 MEDICAL PRODUCTS INC. \$683 MEDEFIL SOLOGICAL, INC. \$685 MEDICAL PRODUCTS, LLC \$683 MIC MEDICAL PRODUCTS, LLC \$631 3M COMPANY \$594 ACCORD HEALTHCARE INC \$592	·	· · · · · · · · · · · · · · · · · · ·
DIVERSATEK HEALTHCARE, INC. \$930 HIGH LINER FOODS \$921 CINTAS CORPORATION NO. 2 \$906 CIPLA USA, INC \$855 KRUEGER INTERNATIONAL, INC. \$859 GREENFIELD GLOBAL USA INC. \$843 MISSION PHARMACAL COMPANY \$805 STERNO PRODUCTS \$801 PRASCO LABORATORIES \$798 HYDROFERA, LLC \$798 RHODES PHARMACEUTICALS \$773 EKATERRA TEA MSO USA LLC \$754 MARKETLAB, INC. \$736 SIEMENS HEALTHCARE DIAGNOSTICS INC. \$719 TWI PHARMACEUTICALS USA \$717 HERITAGE PHARMACEUTICALS INC \$715 LEADIANT BIOSCIENCES, INC. \$703 MERISANT US, INC. \$683 MEDEFIL, INC. \$683 KEN'S FOODS, INC. \$661 GRIFOLS BIOLOGICAL, INC. \$656 MEDTECH PRODUCTS INC \$656 NESTLE USA, INC. \$633 MHC MEDICAL PRODUCTS, LLC \$631 3M COMPANY \$594 ACCORD HEALTHCARE INC \$592		
HIGH LINER FOODS \$921 CINTAS CORPORATION NO. 2 \$906 CIPLA USA, INC \$865 KRUEGER INTERNATIONAL, INC. \$859 GREENFIELD GLOBAL USA INC. \$843 MISSION PHARMACAL COMPANY \$805 STERNO PRODUCTS \$801 PRASCO LABORATORIES \$798 HYDROFERA, LLC \$793 RHODES PHARMACEUTICALS \$773 EKATERRA TEA MSO USA LLC \$736 SIEMENS HEALTHCARE DIAGNOSTICS INC. \$719 TWI PHARMACEUTICALS USA \$717 HERITAGE PHARMACEUTICALS INC \$715 LEADIANT BIOSCIENCES, INC. \$703 MERISANT US, INC. \$636 MEDEFLI, INC. \$656 MEDIECH PRODUCTS INC. \$656 MEDIECH PRODUCTS INC. \$653 MEDIECH PRODUCTS INC. \$653 MEDIECH PRODUCTS, LLC \$631 MICOMPANY \$594 ACCORD HEALTHCARE INC. \$592	·	
CINTAS CORPORATION NO. 2 \$906 CIPLA USA, INC \$865 KRUEGER INTERNATIONAL, INC. \$859 GREENFIELD GLOBAL USA INC. \$843 MISSION PHARMACAL COMPANY \$805 STERNO PRODUCTS \$801 PRASCO LABORATORIES \$798 HYDROFERA, LLC \$793 RHODES PHARMACEUTICALS \$773 EKATERRA TEA MSO USA LLC \$754 MARKETLAB, INC. \$736 SIEMENS HEALTHCARE DIAGNOSTICS INC. \$719 TWI PHARMACEUTICALS USA \$711 HERITAGE PHARMACEUTICALS INC \$715 MERISANT US, INC. \$694 CMP PHARMA, INC. \$683 MEDEFIL, INC. \$683 KEN'S FOODS, INC. \$661 GRIFOLS BIOLOGICAL, INC. \$656 MESTLE USA, INC. \$656 NESTLE USA, INC. \$631 MHC MEDICAL PRODUCTS, LLC \$631 3M COMPANY \$594 ACCORD HEALTHCARE INC \$592		·
CIPLA USA, INC \$856 KRUEGER INTERNATIONAL, INC. \$843 GREENFIELD GLOBAL USA INC. \$843 MISSION PHARMACAL COMPANY \$805 STERNO PRODUCTS \$801 PRASCO LABORATORIES \$798 HYDROFERA, LLC \$793 RHODES PHARMACEUTICALS \$773 EKATERRA TEA MSO USA LLC \$754 MARKETLAB, INC. \$736 SIEMENS HEALTHCARE DIAGNOSTICS INC. \$719 TWI PHARMACEUTICALS USA \$717 HERITAGE PHARMACEUTICALS INC \$703 MERISANT US, INC. \$703 CMP PHARMA, INC. \$683 MEDEFIL, INC. \$683 KEN'S FOODS, INC. \$656 GRIFOLS BIOLOGICAL, INC. \$657 MEDTECH PRODUCTS INC \$656 NESTLE USA, INC. \$631 MHC MEDICAL PRODUCTS, LLC \$631 3M COMPANY \$592 ACCORD HEALTHCARE INC \$592		
KRUEGER INTERNATIONAL, INC. \$859 GREENFIELD GLOBAL USA INC. \$843 MISSION PHARMACAL COMPANY \$805 STERNO PRODUCTS \$801 PRASCO LABORATORIES \$798 HYDROFERA, LLC \$793 RHODES PHARMACEUTICALS \$773 EKATERRA TEA MSO USA LLC \$754 MARKETLAB, INC. \$736 SIEMENS HEALTHCARE DIAGNOSTICS INC. \$719 TWI PHARMACEUTICALS USA \$717 HERITAGE PHARMACEUTICALS INC \$715 LEADIANT BIOSCIENCES, INC. \$703 MERISANT US, INC. \$683 MEDEFIL, INC. \$683 MEDEFIL, INC. \$680 KEN'S FOODS, INC. \$661 GRIFOLS BIOLOGICAL, INC. \$657 MEDTECH PRODUCTS INC \$656 NESTLE USA, INC. \$631 MHC MEDICAL PRODUCTS, LLC \$631 3M COMPANY \$594 ACCORD HEALTHCARE INC \$592		·
GREENFIELD GLOBAL USA INC. \$843 MISSION PHARMACAL COMPANY \$805 STERNO PRODUCTS \$801 PRASCO LABORATORIES \$798 HYDROFERA, LLC \$793 RHODES PHARMACEUTICALS \$773 EKATERRA TEA MSO USA LLC \$754 MARKETLAB, INC. \$736 SIEMENS HEALTHCARE DIAGNOSTICS INC. \$719 TWI PHARMACEUTICALS USA \$717 HERITAGE PHARMACEUTICALS INC \$715 LEADIANT BIOSCIENCES, INC. \$703 MERISANT US, INC. \$680 CMP PHARMA, INC. \$680 KEN'S FOODS, INC. \$661 GRIFOLS BIOLOGICAL, INC. \$657 MEDTECH PRODUCTS INC \$656 NESTLE USA, INC. \$635 MHC MEDICAL PRODUCTS, LLC \$631 3M COMPANY \$594 ACCORD HEALTHCARE INC \$592		
MISSION PHARMACAL COMPANY \$805 STERNO PRODUCTS \$801 PRASCO LABORATORIES \$798 HYDROFERA, LLC \$793 RHODES PHARMACEUTICALS \$773 EKATERRA TEA MSO USA LLC \$754 MARKETLAB, INC. \$736 SIEMENS HEALTHCARE DIAGNOSTICS INC. \$719 TWI PHARMACEUTICALS USA \$717 HERITAGE PHARMACEUTICALS INC \$715 LEADIANT BIOSCIENCES, INC. \$703 MERISANT US, INC. \$694 CMP PHARMA, INC. \$683 MEDEFIL, INC. \$680 KEN'S FOODS, INC. \$656 GRIFOLS BIOLOGICAL, INC. \$656 MEDTECH PRODUCTS INC \$656 NESTLE USA, INC. \$635 MHC MEDICAL PRODUCTS, LLC \$631 3M COMPANY \$594 ACCORD HEALTHCARE INC \$592	·	•
STERNO PRODUCTS \$801 PRASCO LABORATORIES \$798 HYDROFERA, LLC \$793 RHODES PHARMACEUTICALS \$773 EKATERRA TEA MSO USA LLC \$754 MARKETLAB, INC. \$736 SIEMENS HEALTHCARE DIAGNOSTICS INC. \$719 TWI PHARMACEUTICALS USA \$717 HERITAGE PHARMACEUTICALS INC \$703 MERISANT BIOSCIENCES, INC. \$703 MERISANT US, INC. \$680 CMP PHARMA, INC. \$683 MEDEFIL, INC. \$680 KEN'S FOODS, INC. \$657 MEDTECH PRODUCTS INC. \$656 MESTLE USA, INC. \$635 MHC MEDICAL PRODUCTS, LLC \$631 3M COMPANY \$594 ACCORD HEALTHCARE INC \$592		
PRASCO LABORATORIES \$798 HYDROFERA, LLC \$793 RHODES PHARMACEUTICALS \$773 EKATERRA TEA MSO USA LLC \$754 MARKETLAB, INC. \$736 SIEMENS HEALTHCARE DIAGNOSTICS INC. \$719 TWI PHARMACEUTICALS USA \$717 HERITAGE PHARMACEUTICALS INC \$715 LEADIANT BIOSCIENCES, INC. \$703 MERISANT US, INC. \$694 CMP PHARMA, INC. \$683 MEDEFIL, INC. \$680 KEN'S FOODS, INC. \$650 GRIFOLS BIOLOGICAL, INC. \$650 MEDTECH PRODUCTS INC \$656 NESTLE USA, INC. \$635 MHC MEDICAL PRODUCTS, LLC \$631 3M COMPANY \$594 ACCORD HEALTHCARE INC \$592		·
HYDROFERA, LLC \$793 RHODES PHARMACEUTICALS \$773 EKATERRA TEA MSO USA LLC \$754 MARKETLAB, INC. \$736 SIEMENS HEALTHCARE DIAGNOSTICS INC. \$719 TWI PHARMACEUTICALS USA \$717 HERITAGE PHARMACEUTICALS INC \$703 MERISANT US, INC. \$703 MERISANT US, INC. \$684 CMP PHARMA, INC. \$680 KEN'S FOODS, INC. \$661 GRIFOLS BIOLOGICAL, INC. \$657 MEDTECH PRODUCTS INC \$656 NESTLE USA, INC. \$635 MHC MEDICAL PRODUCTS, LLC \$631 3M COMPANY \$594 ACCORD HEALTHCARE INC \$592		· · · · · · · · · · · · · · · · · · ·
RHODES PHARMACEUTICALS \$773 EKATERRA TEA MSO USA LLC \$754 MARKETLAB, INC. \$736 SIEMENS HEALTHCARE DIAGNOSTICS INC. \$719 TWI PHARMACEUTICALS USA \$717 HERITAGE PHARMACEUTICALS INC \$715 LEADIANT BIOSCIENCES, INC. \$703 MERISANT US, INC. \$694 CMP PHARMA, INC. \$683 MEDEFIL, INC. \$680 KEN'S FOODS, INC. \$661 GRIFOLS BIOLOGICAL, INC. \$656 MEDTECH PRODUCTS INC \$656 NESTLE USA, INC. \$635 MHC MEDICAL PRODUCTS, LLC \$631 3M COMPANY \$594 ACCORD HEALTHCARE INC \$592		· ·
EKATERRA TEA MSO USA LLC \$754 MARKETLAB, INC. \$736 SIEMENS HEALTHCARE DIAGNOSTICS INC. \$719 TWI PHARMACEUTICALS USA \$717 HERITAGE PHARMACEUTICALS INC \$715 LEADIANT BIOSCIENCES, INC. \$703 MERISANT US, INC. \$694 CMP PHARMA, INC. \$683 MEDEFIL, INC. \$680 KEN'S FOODS, INC. \$661 GRIFOLS BIOLOGICAL, INC. \$657 MEDTECH PRODUCTS INC \$656 NESTLE USA, INC. \$635 MHC MEDICAL PRODUCTS, LLC \$631 3M COMPANY \$594 ACCORD HEALTHCARE INC \$592		
MARKETLAB, INC. \$736 SIEMENS HEALTHCARE DIAGNOSTICS INC. \$719 TWI PHARMACEUTICALS USA \$717 HERITAGE PHARMACEUTICALS INC \$715 LEADIANT BIOSCIENCES, INC. \$703 MERISANT US, INC. \$694 CMP PHARMA, INC. \$683 MEDEFIL, INC. \$680 KEN'S FOODS, INC. \$661 GRIFOLS BIOLOGICAL, INC. \$657 MEDTECH PRODUCTS INC \$656 NESTLE USA, INC. \$635 MHC MEDICAL PRODUCTS, LLC \$631 3M COMPANY \$594 ACCORD HEALTHCARE INC \$592		
SIEMENS HEALTHCARE DIAGNOSTICS INC. \$719 TWI PHARMACEUTICALS USA \$717 HERITAGE PHARMACEUTICALS INC \$715 LEADIANT BIOSCIENCES, INC. \$703 MERISANT US, INC. \$694 CMP PHARMA, INC. \$683 MEDEFIL, INC. \$680 KEN'S FOODS, INC. \$661 GRIFOLS BIOLOGICAL, INC. \$657 MEDTECH PRODUCTS INC \$656 NESTLE USA, INC. \$635 MHC MEDICAL PRODUCTS, LLC \$631 3M COMPANY \$594 ACCORD HEALTHCARE INC \$592	213 11 213 11 21 21 21 21 21 21 21 21 21 21 21 21	· · · · · · · · · · · · · · · · · · ·
TWI PHARMACEUTICALS USA \$717 HERITAGE PHARMACEUTICALS INC \$703 LEADIANT BIOSCIENCES, INC. \$694 CMP PHARMA, INC. \$683 MEDEFIL, INC. \$680 KEN'S FOODS, INC. \$661 GRIFOLS BIOLOGICAL, INC. \$657 MEDTECH PRODUCTS INC \$656 NESTLE USA, INC. \$635 MHC MEDICAL PRODUCTS, LLC \$631 3M COMPANY \$594 ACCORD HEALTHCARE INC \$592		
HERITAGE PHARMACEUTICALS INC \$715 LEADIANT BIOSCIENCES, INC. \$703 MERISANT US, INC. \$694 CMP PHARMA, INC. \$683 MEDEFIL, INC. \$680 KEN'S FOODS, INC. \$661 GRIFOLS BIOLOGICAL, INC. \$657 MEDTECH PRODUCTS INC \$656 NESTLE USA, INC. \$635 MHC MEDICAL PRODUCTS, LLC \$631 3M COMPANY \$594 ACCORD HEALTHCARE INC \$592	SIEMENS HEALTHCARE DIAGNOSTICS INC.	\$719
LEADIANT BIOSCIENCES, INC. \$703 MERISANT US, INC. \$694 CMP PHARMA, INC. \$683 MEDEFIL, INC. \$680 KEN'S FOODS, INC. \$661 GRIFOLS BIOLOGICAL, INC. \$657 MEDTECH PRODUCTS INC \$656 NESTLE USA, INC. \$635 MHC MEDICAL PRODUCTS, LLC \$631 3M COMPANY \$594 ACCORD HEALTHCARE INC \$592	TWI PHARMACEUTICALS USA	\$717
MERISANT US, INC. \$694 CMP PHARMA, INC. \$683 MEDEFIL, INC. \$680 KEN'S FOODS, INC. \$661 GRIFOLS BIOLOGICAL, INC. \$657 MEDTECH PRODUCTS INC \$656 NESTLE USA, INC. \$635 MHC MEDICAL PRODUCTS, LLC \$631 3M COMPANY \$594 ACCORD HEALTHCARE INC \$592	HERITAGE PHARMACEUTICALS INC	\$715
CMP PHARMA, INC. \$683 MEDEFIL, INC. \$680 KEN'S FOODS, INC. \$661 GRIFOLS BIOLOGICAL, INC. \$657 MEDTECH PRODUCTS INC \$656 NESTLE USA, INC. \$635 MHC MEDICAL PRODUCTS, LLC \$631 3M COMPANY \$594 ACCORD HEALTHCARE INC \$592	LEADIANT BIOSCIENCES, INC.	\$703
MEDEFIL, INC. \$680 KEN'S FOODS, INC. \$661 GRIFOLS BIOLOGICAL, INC. \$657 MEDTECH PRODUCTS INC \$656 NESTLE USA, INC. \$635 MHC MEDICAL PRODUCTS, LLC \$631 3M COMPANY \$594 ACCORD HEALTHCARE INC \$592	MERISANT US, INC.	\$694
KEN'S FOODS, INC. \$661 GRIFOLS BIOLOGICAL, INC. \$657 MEDTECH PRODUCTS INC \$656 NESTLE USA, INC. \$635 MHC MEDICAL PRODUCTS, LLC \$631 3M COMPANY \$594 ACCORD HEALTHCARE INC \$592	CMP PHARMA, INC.	\$683
GRIFOLS BIOLOGICAL, INC. \$657 MEDTECH PRODUCTS INC \$656 NESTLE USA, INC. \$635 MHC MEDICAL PRODUCTS, LLC \$631 3M COMPANY \$594 ACCORD HEALTHCARE INC \$592	MEDEFIL, INC.	\$680
MEDTECH PRODUCTS INC \$656 NESTLE USA, INC. \$635 MHC MEDICAL PRODUCTS, LLC \$631 3M COMPANY \$594 ACCORD HEALTHCARE INC \$592	KEN'S FOODS, INC.	\$661
NESTLE USA, INC. \$635 MHC MEDICAL PRODUCTS, LLC \$631 3M COMPANY \$594 ACCORD HEALTHCARE INC \$592	GRIFOLS BIOLOGICAL, INC.	\$657
MHC MEDICAL PRODUCTS, LLC \$631 3M COMPANY \$594 ACCORD HEALTHCARE INC \$592	MEDTECH PRODUCTS INC	\$656
3M COMPANY\$594ACCORD HEALTHCARE INC\$592	NESTLE USA, INC.	\$635
3M COMPANY\$594ACCORD HEALTHCARE INC\$592	MHC MEDICAL PRODUCTS, LLC	\$631
ACCORD HEALTHCARE INC \$592		\$594
·	ACCORD HEALTHCARE INC	\$592
	MICRO-TECH ENDOSCOPY USA, INC.	\$576

HARRIS HEALTH PREMIER Q3 SPEND FY2024	
SUPPLIER	Q3 SPEND FY2024
CONTEC, INC.	\$570
RICHARD WOLF MEDICAL INSTRUMENTS CORP.	\$545
KATENA PRODUCTS, INC. DBA CORZA OPHTHALMOLOGY	\$540
SKLAR INSTRUMENTS	\$535
LACTALIS AMERICAN GROUP, INC.	\$512
BEYOND MEAT, INC.	\$512
CONOPCO, INC DBA UNILEVER NA FOODSOLUTIONS	\$496
JOERNS HEALTHCARE LLC	\$480
SLATE RUN PHARMACEUTICALS	\$479
MCI FOODS INC	\$472
MIZUHO ORTHOPEDIC SYSTEMS, INC.	\$471
TOLMAR, INC	\$468
HEARTLAND FOOD PRODUCTS GROUP	\$465
MYLAN PHARMACEUTICALS INC.	\$449
IMPOSSIBLE FOODS INC.	\$425
TAGI PHARMA	\$411
PERDUE FOODS LLC	\$377
SUNOPTIC TECHNOLOGIES LLC	\$375
EDENBRIDGE PHARMACEUTICALS LLC	\$373
JOHNSON & JOHNSON CONSUMER INC.	\$368
MEGAMEX FOODS, LLC	\$355
DYMA BRANDS, INC.	\$346
T MARZETTI COMPANY	\$337
METREX RESEARCH CORPORATION	\$333
HARDY DIAGNOSTICS	\$314
AUROBINDO PHARMA USA, INC.	\$300
NOVO NORDISK PHARMACEUTICALS, INC.	\$297
KIND, LLC	\$295
FURMANO FOODS, INC.	\$278
HISUN PHARMACEUTICALS USA INC.	\$269
BARILLA AMERICA INC.	\$261
GEHLS FOODS	\$259
GERI-CARE PHARMACEUTICALS CORP.	\$241
XIROMED, LLC	\$233
KING CHEESECAKE COMPANY, INC.	\$218
HERSHEY	\$207
BRANDING IRON HOLDINGS, INC	\$194
UNILEVER FOODSOLUTIONS	\$184
PERDUE FARMS INC.	\$178
LIFESTAR PHARMA LLC	\$178
MEDICURE PHARMA, INC.	\$176
KENTEC MEDICAL, INC.	\$175
KING & PRINCE SEAFOOD CORPORATION	\$174
BIMBO BAKEHOUSE, LLC	\$174
MEDTRITION, INC.	\$162
KERMA MEDICAL PRODUCTS, INC.	\$161
WORLD CENTRIC	\$147
MCCAIN FOODS USA, INC.	\$146
KETTLE CUISINE	\$140
NETTEE GOIGHTE	\$140

HARRIS HEALTH PREMIER Q3 SPEND FY2024				
SUPPLIER	Q3 SPEND FY2024			
AMD MEDICOM INC.	\$127			
THE SHERWIN-WILLIAMS COMPANY	\$113			
THE HERTZ CORPORATION	\$104			
INHARVEST, INC.	\$95			
BIONIX, LLC	\$92			
SIMPLYTHICK, LLC	\$91			
EVIDENT SCIENTIFIC, INC.	\$89			
RELIABLE-1 LABORATORIES	\$86			
ADVAGEN PHARMA LTD.	\$85			
PATRIN PHARMA INC	\$84			
MEDICAL ACTION INDUSTRIES INC.	\$82			
DAVIDS COOKIES	\$80			
RUIZ FOODS, INC.	\$73			
POST CONSUMER BRANDS	\$68			
STARKIST CO.	\$61			
PATRIOT PHARMACEUTICALS LLC	\$60			
NOVADOZ PHARMACEUTICALS LLC	\$56			
STRIDES PHARMA	\$53			
MCKEE FOODS CORPORATION	\$39			
RC BIGELOW, INC.	\$34			
THEA PHARMA INC	\$20			
HR PHARMACEUTICALS, INC. DBA HR HEALTHCARE	\$17			
INGENUS PHARMACEUTICALS, LLC	\$17			
INMAR RX SOLUTIONS, INC.	\$7			
GRAND TOTAL	\$79,436,080			

HARRIS HEALTH PREMIER	Q3 SPEND FY2024
Premier Contract Category	Q3 Spend FY2024
Services	\$15,264,120
Pharmacy	\$14,762,559
Distribution	\$12,875,258
Surgical & Imaging	\$12,590,681
Patient Care	\$10,449,416
Laboratory	\$5,182,264
Food & Nutrition	\$4,334,975
Facilities	\$2,571,880
IT/ Telecom	\$1,404,927
GRAND TOTAL	\$79,436,080





Meeting of the Board of Trustees

Thursday, October 24, 2024

Consideration of Approval of Grant Recommendations (Item C1 of the Grant Matrix)

Grant Recommendation:

- C1. Grant Agreement Restricted to the Harris Health 1st Floor Renovation of the Ben Taub Hospital Level I Trauma Center, Cath Lab, and any updates and remediations thereto
 - Grantor: Harris County Hospital District, funded by the Foundation's 2nd Capital Campaign
 - Term: 2 Years (from date the grant agreement is executed)
 - Award Amount: \$238,560.00Project Owner: Mr. Jeff Baker

Grant Agenda Items for the Harris County Hospital District dba Harris Health, Board of Trustees Report Grant Matrix: October 24, 2024

No.	Grantor	Description/Justification	Action, Basis of Recommendation	Term	Project Owner	Award Amount
C1	Harris County Hospital District Foundation, Funded by the Foundation's 2nd Capital Campaign	Consideration of Approval of a Grant Agreement between Harris Health and the Harris County Hospital District Foundation, restricted to the Harris Health 1st Floor Renovation of the Ben Taub Hospital Level I Trauma Center (Ginni and Richard Mithoff Trauma Center) and the Ben Taub Hospital Level I Trauma Center (Ginni and Richard Mithoff Trauma Center) Cath Lab, and any updates and remediations thereto.	Grant Agreement	2 Years from date the grant agreement is executed	Mr. Jeffrey Baker	\$ 238,560.00
	TOTAL AMOUNT: \$ 238					\$ 238,560.00

Page 1 of 1 10/17/2024 9:35 AM



Meeting of the Board of Trustees

Thursday, October 24, 2024

Consideration of Approval of the Re-Appointment of Dr. Sandeep Markan as Chief of Staff for Ben Taub Hospital

- 1. The renewal request is pursuant to section 5.3.1 (b) of the Operating and Support Agreement between Baylor College of Medicine and Harris Health.
- 2. The term is for time period July 1, 2024 through June 30, 2026.

Glorimar Medina, MD, MBA, FACHE

Executive Vice President / Administrator, Ben Taub Hospital

Jennifer Small, AuD, MBA, CCC-A

Executive Vice President / Administrator, Ambulatory Care Services

STATE OF TEXAS COUNTY OF HARRIS MOTION NO								
On October 24, 2024 , the Harris County Hospital District d/b/a Harris Health System (Harris Health) Board of Trustees convened in regular session at its regular meeting place. The following members of the Board were present:								
	~1 ·			Present	Absent			
Andrea Caracostis, MD, MPH	Chair	41 •						
Cody M. Pyke, MD, JD, LLM, FCLM	Vice C							
Carol Paret, BS	Secret	•	.1		П			
Afsheen Davis, JD, MPH Ingrid Robinson, MBA	Board Board							
Jim Robinson, MA, CFE	Board							
Libby Viera-Bland, AICP	Board							
Sima Ladjevardian, JD	Board							
The Board determined that a quorum was present. Among other business, a resolution on the following matter was considered: *Consideration of Approval of the Re-appointment of Dr. Sandeep Markan as Chief of Staff for Ben Taub Hospital*								
introd	duced t	he re	esolutio	n and made	e a motion that it be			
					The motion, carrying			
with it the adoption of the resolution, prevaile	ed by th	ne fo	llowing	vote:				
	7	Zes .	No	Abstain	Absent			
Andrea Caracostis, MD, MPH								
Cody M. Pyke, MD, JD, LLM, FCL	M [
Carol Paret, BS								
Afsheen Davis, JD, MPH								
Ingrid Robinson, MBA								
Jim Robinson, MA, CFE								
Libby Viera-Bland, AICP	_							
Sima Ladjevardian, JD								

HARRISHEALTH

The adopted resolution reads as follows:

Harris Health, by and through its Board of Trustees, hereby approves the re-appointment of Dr. Sandeep Markan as Chief of Staff for Ben Taub Hospital, pursuant to Section 5.3.1 (b) of the Operation and Support Agreement between Baylor College of Medicine and Harris Health, for the term of July 1, 2024 through June 30, 2026.

PASSED AND APPROVED this	24 th	of October, 2024.
		Andrea Caracostis, MD, MPH, Chair
Attest:		
Carol Darat DS Cognetani		
Carol Paret, BS, Secretary		



Meeting of the Board of Trustees

Thursday, October 24, 2024

Consideration of Approval of a Second Amendment to the Interlocal Subrecipient

Agreement Between Harris County and Harris Health for Funds to Support

Expansion of Harris Health's Food Rx and Food Farmacy Program

Administration requests approval of a second amendment to the interlocal subrecipient agreement (the "Agreement") between Harris County and Harris Health for the purpose of expanding Harris Health's Food Rx Program. The Agreement supports the opening of onsite Food Farmacies at El Franco Lee, Gulfgate, and Martin Luther King, Jr. Health Centers and community redemption models for the Cypress and Squatty Lyons Health Center patients.

Per the executed Agreement, Harris Health will receive \$663,144 from State and Federal American Rescue Plan Act of 2021 funds awarded to Harris County. The second amendment is to extend the term of the Agreement to allow for additional time to evaluate the impact of the Food Rx initiative for Harris Health patients and their families, and to modify the budget in the Statement of Work to reflect an adjustment in budget categories, at no additional cost to the County.

The proposed second amendment extends the funding end date to September, 19, 2026, at which time Harris Health will be solely responsible for supporting operation of each of these Food Farmacy and Food Rx locations.

Chethan Bachireddy

Chief Health Officer - Population

BOARD OF TRUSTEES Meeting of the Board of Trustees



Thursday, October 24, 2024

Consideration of Approval of a Second Amendment to the Population Health

Collaboration Agreement between The University of Texas

MD Anderson Cancer Center and Harris Health

Administration requests approval of a second amendment to the Population Health Collaboration Agreement (the "Agreement") between The University of Texas MD Anderson Cancer Center and Harris Health. The parties entered the Agreement dated June 11, 2o21 to jointly conduct population health quality improvement activities supporting Harris Health patients.

The proposed second amendment is to extend the term through August 31, 2025. The objectives include a continuation of Be Well Communities, funding support of \$50,000; and new work activities to advance the Texas Health Equity Alliance for Breast Cancer (THEAL) initiative.

THEAL is a multi-sector collaborative focused on reducing breast cancer disparities in Greater Houston led by MD Anderson Cancer Center. MD Anderson will provide funding of \$110,000 to support Harris Health's participation in the THEAL collaborative as a backbone member as well as the implementation of quality improvement initiatives to further identify opportunities for closing breast cancer disparities among Harris Health patients.

Chethan Bachireddy

Chief Health Officer - Population



Meeting of the Board of Trustees

Thursday, October 24, 2024

Consideration of Approval to Amend the Lease with Houston Business Development, Inc. for the Dental Center located at 5220-5250 Griggs Rd., Houston, Texas 77021

Administration recommends Board of Trustees approve a 10-year lease amendment with Houston Business Development, Inc. for the property at 5220-5250 Griggs Rd., Houston, TX 77021, which extends the current Dental Center lease through January 31, 2035.

Patrick Casey

SVP – Facilities Construction & Systems Engineering

HARRISHEALTH SYSTEM

Meeting of the Board of Trustees

BOARD OF TRUSTEES
Dental Center
Houston Business Development, Inc.
October 24, 2024
Page 2

Fact Sheet

Purpose of Lease: Dental Center

Lessor: Houston Business Development, Inc.

Lessee: Harris Health

Location of Lease Space: 5220-5250 Griggs Rd.

Pasadena, Texas 77021

Lease Space: Approximately 11,000 square feet

Lease Term: 10 years

Lease Terms	Monthly Lease Rate	Est. Monthly Operating Expenses	Est. Monthly Payment	Est. Annual Payment	Gross Annual Rate
February 1, 2025–July 31, 2025	\$13,942.50	\$2,622.36	\$16,564.86	\$198,778.31	\$18.07
August 1, 2025–January 31, 2027	\$14,859.16	\$2,701.03	\$17,560.19	\$210,722.28	\$19.16
February 1, 2027–January 31, 2029	\$16,041.66	\$2,782.06	\$18,823.72	\$225,884.65	\$20.53
Years 3-4: February 1, 2029–January 31, 2031	\$16,729.16	\$2,865.52	\$19,594.68	\$235,136.20	\$21.38
Years 7-10: February 1, 2031–January 31, 2035	\$17,490.00	\$2,951.49	\$20,441.49	\$245,297.86	\$22.30

Termination Option: Tenant may terminate the Lease on the last day of any Lease Year if either Tenant's Board of Trustees or the Harris County Commissioners Court in its sole discretion fails to approve, adequately fund or certify funds for this Lease Agreement, whether annually or otherwise, or if funding for this Agreement is removed or reduced and verification of such is provided to Landlord. Tenant agrees to provide at least 30 days prior written notice of any non-appropriation of or reduction in funding in the budget.



Meeting of the Board of Trustees

Thursday, October 24, 2024

<u>Updates Regarding Pending State and Federal Legislative and Policy Issues</u>
<u>Impacting Harris Health</u>

R. King Hillier

Senior Vice President, Public Policy & Government Relations



October 24, 2024 Board of Trustees Monthly Report

Federal Update

340B Update: After an aggressive and ultimately successful congressional advocacy push the last week of September, J&J rescinded its 340B rebate proposal on September 30th. Harris Health is grateful to Lizzy Fletcher, Randy Weber and Sylvia Garcia for signing on to the letter to HHS Secretary Becerra asking him to reject the J&J plan. 189 members (148 Ds and 41 Rs) signed the letter including 8 from Texas.

HRSA notified J&J on September 27th that their products would be pulled from the 340B program if they continued pursuing the rebate plan.

Front Line Hospital Alliance (FLHA) Update: FLHA held an additional limited D.C. Congressional Fly-in the week of the 17th to discuss site neutral policy issues and designation language.

Both House and Senate leadership staff are signaling tacit support for including the FLHA definition in a Medicaid Disproportionate Share Hospital (DSH) year-end fix.

West Texas Congressman Arrington continues to advocate for removing FLHA designated hospitals from the site neutral bill that will likely pass next year.

Dr. Porsa and King Hillier will be participating in a CEO fly-in with other FLHA CEOs the week of November 18th. We should have a better indication of what will or will not move in the lame duck session following the presidential election.

Telehealth Waiver Legislation: The House Energy and Commerce Committee in late September approved legilsation that would extend Telehealth waivers for 2 years and Hospital at Home for 5 years. The Senate is expected to approve those extensions, providing a major boost for the continuation of these important programs at Harris Health.

Federal Budget: On September 25th Congress passed a three-month stopgap spending bill.

All attention is now focused on Speaker Johnson and his narrow Republican majority to avoid a potential government shut down before December 20th. Without legislative action on the budget, the ACA Medicaid DSH cuts amounting to approximately \$2.4 billion for Texas will be implemented over a 3-year period beginning in FY 2025.

Congress returns November 12th for approximately 24 legislative days to pass an omnibus appropriations bill or longer term continuing resolution. The outcome of the presidential and congressional elections will factor significantly into these funding decisions.



State Update

Harris Health, Other Public Hospitals, Respond to Myers & Stauffer Charity Care Report: Pursuant to a Texas General Appropriations Act budget rider, the Health and Human Services Commission (HHSC) contracted with auditing firm Myers and Stauffer to report on the financial and utilization data of Texas hospitals.

Harris Health and the entire Texas hospital industry are currently reviewing a 599-page draft report containing much information and many errors. Due to reporting inconsistencies and drawing from numerous—often incompatible and/or duplicative—data sources, the report gives Harris Health no credit for the sizeable community benefit it provides to Harris County and the state.

Working with similarly situated Texas public health systems and the Teaching Hospitals of Texas, Harris Health staff are strategizing on how best to correct the record, both with the state's health agency and with lawmakers.

Fortunately, many policymakers are familiar with the tremendous community benefit Harris Health provides, despite the flaws contained in the Myers and Stauffer report.

Speaker's Race: Texas House GOP members and candidates seeking an alternative to current Speaker Dade Phelan (R-Beaumont) have coalesced behind Rep. David Cook (R-Mansfield) as their candidate of choice.

This announcement follows a closed meeting of nearly 50 GOP members and candidates—some participating by proxy—which resulted in all other GOP Speaker candidates dropping out of the race after multiple rounds of voting and throwing their support behind Cook.

Two of those members, Rep. Tom Oliverson (R-Cypress) and Rep. James Frank (R-Wichita Falls), currently chair committees with jurisdiction over issues essential to Harris Health—the House Committee on Insurance and the House Committee on Human Services, respectively.

Rep. Cook has since issued a statement listing 48 Republican colleagues supporting his bid for the Speakership.

With 150 House members, a candidate must obtain a simple majority, 76 votes, to prevail in a Speaker's Race. Complicating matters, however, is a House Republican Caucus rule stating that members of the caucus must support the Speaker candidate who first obtains the support of 3/5 of the caucus. If the Caucus adheres to this rule and the party breakdown remains consistent, it would appear Speaker Phelan has a difficult path to regain his gavel.



The current party breakdown of the House is 86 Republicans, 63 Democrats, and one vacant seat. This balance could shift slightly after the general election, but no major shifts are expected.

Despite the number of GOP members listed as supporting Cook, Phelan could still retain the Speaker's Gavel if enough of his Republican chairs remain loyal and the House Democrats support him as a bloc.

Rep. Ana-Maria Rodríguez Ramos (D-Richardson) is the lone Democrat to file for Speaker, and her candidacy could deprive Phelan of the necessary Democratic votes to reach 76. Though as the only Speaker candidate with a clear path to victory who would continue the longstanding practice of appointing chairs from the minority party, Phelan appears poised to obtain the backing of a significant number of his Democratic colleagues.

Until the 89th Legislature convenes in January 2025 and representatives cast their vote for Speaker, it remains uncertain who will lead the Texas House for the next biennium.

Texas Hospital Association Behavioral Health Council Policy Summit: In September, Harris Health staff participated in THA's Behavioral Health Council Policy Summit. We discussed behavioral health priorities THA will pursue when during the next legislative session.

One such priority is electronic emergency detention orders, or e-EDOs. Last session, hospitals successfully advocated for a bill requiring the Office of Court Administration to develop e-EDOs. The bill also explicitly gave facilities the authority to detain a person once it receives a transmitted warrant. Though the language passed, the initiative was not funded, and THA will seek about \$2 million for the biennium to fund the e-EDO system.

Another priority is Medicaid coverage for partial hospitalization programs and intensive outpatient therapy services (PHP/IOT). Though no bill passed last session, a key member, Sen. Charles Perry (R-Lubbock), has submitted a bill draft request for a potential refile. There is also ongoing discussion of an Adult Institution of Mental Disorders (IMD) Medicaid Waiver which would include Medicaid coverage for adults. Current federal law prohibits Medicaid coverage of adults, however CMS has granted these waivers to several states. These provisions could finally address the need to decompress our emergency centers and the Harris County Jail of patients/inmates in need of adult psychiatric/behavior health services.

We also spoke briefly about Harris County mental health coordination between Memorial Herman, Methodist, and Harris Health, where we collaborate on how best to treat repeat patients. San Antonio does something similar via its local Trauma EMS RAC. The next time THA's behavioral health group meets, there will be discussion around sharing best practices, or potentially advocating for a state grant program that can help support this model in the 89th session.



Upcoming Texas Legislative Interim Hearings of Interest

TEXAS SENATE

<u>State Affairs, Oct. 15, 2024</u> – Addressing homelessness: The committee will examine programs that address the homelessness crisis in Texas. Specifically, review programs like Haven for Hope and determine whether such programs could be a model throughout our state. Propose legislation to address the root causes of homelessness by expanding successful programs for cities of all sizes.

<u>State Affairs, Oct. 16, 2024</u> – Public Trust in Government: Public Trust in Government: Examine the current state of accountability, ethics, and transparency in local government. Recommend ways to bolster public trust in local government by strengthening the Public Information Act and Open Meetings Act.



Meeting of the Board of Trustees

Thursday, October 24, 2024

Review and Acceptance of the Following Report for the Healthcare for the Homeless Program as Required by the United States Department of Health and Human Services Which Provides Funding to the Harris County Hospital District d/b/a/Harris Health System to Provide Health Services to Persons Experiencing Homelessness under Section 330(h) of the Public Health Service Act

Attached for review and acceptance:

• HCHP October Operational Updates

Administration recommends that the Board accept the Healthcare for the Homeless Program Report as required by the United States Department of Health and Human Services which provides funding to the Harris County Hospital District d/b/a/ Harris Health System to provide health services to persons experiencing homelessness under Section 330 (h) of the Public Health Service Act.

Jennifer Small

Executive Vice President – Ambulatory Care Services

Health Care for the Homeless Monthly Update Report – October 2024

Jennifer Small AuD, MBA, CCC-A, Executive Vice President, Ambulatory Care Services

Tracey Burdine, Director, Health Care for the Homeless Program





Agenda

- Operational Update
 - ➤ Productivity Report
 - ➤ Consumer Advisory Report
 - ➤ Legislative Mandates Policy Revision
 - ➤ HIV Prevention Funding
 - ➤ Community Engagement
 - ➤ Quality Management Report



Patients Served

HRSA Unduplicated Patients Target:

7,250


YTD Unduplicated Patients:

5,324


HRSA Completed Visit Patients
Target:

YTD Total Completed Visits:
20,654











Consumer Advisory Council

Highlights of Council Activities from May 2024 – July 2024

- The council was informed about the HRSA Behavioral Health Service Expansion notice of funding opportunity and approved grant application.
- The council was informed about the HRSA Service Area Competition notice of funding opportunity and approved the approved grant application.
- The council reviewed and approved the revisions to the 2024 Quality Management Plan.
- The council was informed about the operations and locations of services for the new mobile units.



HCHP Revised Legislative Mandate Policy

The purpose of this policy is to outline the current limitations contained within the Consolidated Appropriations Act to ensure Harris Health's Health Care for the Homeless Program does not use federal grant funds to support prohibited activities.

Significant Changes/Updates:

- Changes to the verbiage
 - Health Care for the Homeless Program instead of Healthcare for the Homeless Program
 - Grants Policy Bulletin on Legislative Mandates in Grant Management for most recent Fiscal Year
- > Funding Acknowledgement:
 - ➤ When describing projects or programs funded in whole or in part with Federal money, Harris Health shall clearly state:
 - > The percentage of the total costs of the program or project which will be financed with Federal money
 - > The dollar amount of Federal funds for the project or program; and
 - > Percentage and dollar amount of the total costs of the project or program that will be financed by non-governmental sources.



Ending the HIV Epidemic – Primary Care HIV Prevention (One-time Funding)

- Award Date: September 3, 2024
 - Pending Board Approval
 - Funding Amount: \$37,000
 - Focus: To provide testing and preventive HIV services for people experiencing homelessness.
 - Services Provided
 - OraSure HIV test kits
 - ➤ HIV Control Kit
 - Male/Female Condoms
 - Lubricant
 - Educational Pamphlets



Ending the HIV Epidemic – Primary Care HIV Prevention

HARRIS HEALTH SYSTEM

HEALTH CARE FOR THE HOMELESS PROGRAM

HARRIS COUNTY HOSPITAL DISTRICT dba Harris Health System

One-time Funding

January 1, 2024 through December 31, 2024

SUPPLIES	Feder	al Request	Total			
OraSure HIV test kits	\$	26,400	\$	26,400		
HIV Control Kits	\$	600	\$	600		
Male condoms	\$	1,596	\$	1,596		
Female condoms	\$	5,285	\$	5,285		
Lubricant	\$	2,400	\$	2,400		
Educational pamphlets	\$	719	\$	719		
Total Supplies	\$	37,000	\$	37,000		
TOTAL DIRECT CHARGES	\$	37,000	\$	37,000		



Community Engagement

- Held Saturday, June 22, 2024
- Collaborated with Pleasant Grove Church
- Behavior health outreached to the community

Pleasant Grove Summer Health Fair



- Held Saturday, September 21, 2024
- Community Service Manager provided information on HCHP services
- Collaborated La Porte Health

La Porte Health & Safety Fair



- Held Saturday, September 28, 2024 from 10 AM – 2 PM
- Primary care services and behavioral health consults were provided to the community
- Collaborated with the African American Male Wellness Agency

Uplift Her Women's Wellness Day



- Held Saturday, October 5, 2024 from 10 AM – 12 PM
- HCHP Medical Director educated community of colorectal cancer
- Collaborated with Mt. Zion C.M.E. Church

Coffee, Tea, With Me











HARRISHEALTH

Health Care for the Homeless Quality Management Report – QTR 2 2024

LaResa A. Ridge MD, MBA, Health Care for the Homeless Medical Director,
Ambulatory Care Services



Quality Data Trending Report – Quarter 2

Health Care for the Homeles Program Quality Report 2023-2024									
Quality Measure - 2024	UDS Benchmark	HCHP Goal	2023 Q3	2023 Q4	2024 Q1	2024 Q2	1	REND LINE	
Childhood Immunization Status	>36%	50%	17%***	0%***	51%	6%***			
Cervical Cancer Screening	> 48%	70%	74%	80%	77%	75%			
Breast Cancer Screening	> 48%	50%	56%	56%	60%	62%			
Child BMI % Diet & Physical Activity Counseling	> 66%	82%	98%	100%	94%	91%			
Adult BMI/F/U Plan	> 57%	85%	96%	96%	93%	94%			
Tobacco Screening/Counseling/ Pharmacotherapy	> 79%	90%	98%	98%	98%	98%			
Statin Therapy	> 76%	80%	88%	85%	85%	82%	•		
IVD & Aspirin	> 78%	85%	88%	86%	83%*	86%	-		
Colorectal Cancer Screening	> 37%	50%	55%	56%	36%***	52%	-		
HIV Screening	> 82%	85%	95%	95%	96%	96%			
Depression Screening / F/U	> 65%	80%	80%	80%	81%	80%			
Depression Remission at 12 months	>17%	20%	3%***	0%***	18%*	16%***			
Hypertension BP < 140/90	> 62%	65%	67%	66%	67%	66%			
Diabetes A1C > 9	< 32%	45%	33%**	38%**	39%**	35%**			

^{* =} Metrics that are meeting UDS Benchmark but not HCHP goal



^{** =} Metrics that are meeting HCHP goal but not UDS Benchmark

^{*** =} Metrics that are not meeting HCHP goal or UDS Benchmark

Problem Statement: Harris Health System ensures compliance with Health Resources and Services Administration (HRSA) grant. The following 3 of 14 HRSA required quality metrics did not meet goal for Quarter 2 of 2024: Childhood Immunization Status, Depression Remission at 12 months, & Diabetes A1C > 9.

Quality Measures				Q3 (2023)			Q4 (2023)			Q1 (2024)			Q2 (2024)	
Quality Measures	UDS Benchmark	HHS Goal	July	August	September	October	November	December	January	February	March	April	May	June
Childhood Immunization Status	>36%	>50%	25%***	25%***	0%***	0%***	0%***	0%***	20%***	33%***	100%	17%***	0%***	0%***
Depression Remission at 12 months	>17%	>20%	0%***	0%***	9%***	0%***	0%***	0%***	24%	14%***	16%***	8%***	19%*	23%
Diabetes A1C > 9	<32%	<45%	34%**	32%	34%**	38%**	35%**	41%**	41%**	39%**	37%**	35%**	35%**	36%**

Plan (Root Cause-Based on analysis of the problem)-WHY?

- 1. <u>Childhood Immunizations Status:</u> Deficiency due to 1) Parents refusal to allow vaccination for their children for personal beliefs. 2) Patients present to the clinic in a uncorrectable, vaccine deficient state at the time of the initial visit. Primarily, these patients missed receiving the influenza and rotavirus vaccinations during infancy.
- 2. <u>Depression Remission at 12 months:</u> Deficiency due to 1) Failure to administer the PHQ9 within the specified time period required by the standard and 2) Patients not achieving adequate remission of depression within the specified period.
- 3. <u>Diabetes A1C > 9:</u> Deficiency due to 1) Patient's failure to comply with the order 2) Provider failure to escalate treatment regimen, 3) Patient's failure to comply with the treatment regimen

Do-(Action, Responsible Person, Implementation Date)

<u>Responsible Persons:</u> LaResa Ridge, MD (Medical Director), Sarath Roy (Operations Manager), Nichelle Easley (Nurse Manager), Jaden Jacobs (Quality Assurance Coordinator)

- 1. <u>Childhood Immunizations Status:</u> 1) Staff continues to educate parents on the importance of timely vaccinations. 2) Patients enrolled in a "catch-up schedule" to address deficient vaccines. 3)Designation of this standard as a "focus standard" for this year. (Implementation Date: May 1, 2024)
- <u>Depression Remission at 12 months:</u> 1) Best Practice Alert to trigger treatment of depression implemented 2)_Currently in bid process for a psychiatrist or hiring an internal PMHNP (Implementation Date: July 3, 2024)
- 3. <u>Diabetes A1C > 9:</u> 1)Instituted collection of lab specimen during the visit or an appointment is scheduled prior to patient's discharge from current appointment. 2) Promote aggressive escalation of treatment regimen by providers 2) Increase referrals to clinical pharmacist (Implementation date: July 29, 2024)

Check (How will you measure effectiveness)

Via analysis of the UDS Dashboard data on weekly and monthly basis

- *= Metrics that are meeting UDS Benchmark but not HCHP goal,
- ** = Metrics that are meeting HCHP goal but not UDS Benchmark
- *** = Metrics that are not meeting HCHP goal or UDS Benchmark

ACT (Effective/Ineffective): Adopt, Adapt, or Abandon

ACTIONS:

- 1.) Childhood Immunization Status: APR 24: 17%, MAY 24: 0%, JUN 24: 0% (Effective, Adapt)
- 2.) Depression Remission at 12 months: APR 24: 8%, MAY 24: 19%, JUN 24: 23%, (Effective, Adopt)
- 3.) Diabetes A1C >9: APR 24: 37%, MAY 24: 35%, JUN 24: 35% (Effective, Adapt)

HARRISHEALTH



Meeting of the Board of Trustees

Thursday, October 24, 2024

Consideration of Approval of the HCHP Consumer Advisory Report

Attached for review and approval:

• HCHP Consumer Advisory Report

Administration recommends that the Board approve the Healthcare for the Homeless Program Report as required by the United States Department of Health and Human Services which provides funding to the Harris County Hospital District d/b/a/ Harris Health System to provide health services to persons experiencing homelessness under Section 330 (h) of the Public Health Service Act.

Jehnifer Small

Executive Vice President – Ambulatory Care Services

HCHP Consumer Advisory Council Report

Highlights of Council Activities from May 2024 – July 2024:

- Members received updates on ongoing operational changes at Harris Health and the Health Care for the Homeless Program (HCHP).
- Members reviewed reports related to performance improvement, productivity, and patient satisfaction, with corresponding corrective action plans.
- The council was updated on staff changes.
- The council suggested new areas where to conduct outreach services.
- The council received updates on community engagement efforts.
- The council was informed about the HRSA Behavioral Health Service Expansion notice of funding opportunity and approved applying for this grant.
- The council was informed about the HRSA Service Area Competition notice of funding opportunity and approved applying for this grant.
- The council was informed that HRSA provided a supplemental funding award titled Quality Improvement Award Uniform Data System Plus.
- The council was informed of the name change from Harris Health System to Harris Health.
- The council reviewed and approved the revisions to the 2024 Quality Management Plan.
- The council was informed about the operations and locations of services for the new mobile units.
- The chair shared information from the council-at-large meetings.

BOARD OF TRUSTEES Meeting of the Board of Trustees



Thursday, October 24, 2024

Consideration of Approval of the HCHP Revised Legislative Mandate Policy

Attached for review and approval:

HCHP Revised Legislative Mandate Policy

Administration recommends that the Board approve the Healthcare for the Homeless Program Report as required by the United States Department of Health and Human Services which provides funding to the Harris County Hospital District d/b/a/ Harris Health System to provide health services to persons experiencing homelessness under Section 330 (h) of the Public Health Service Act.

Jehnifer Small

Executive Vice President – Ambulatory Care Services

Policy No:

Page Number:

1 of 7

Effective Date: Board Motion No

Last Review Date: Due For Revision:

POLICY AND REGULATIONS MANUAL

LEGISLATIVE MANDATES - HEALTH_CARE FOR THE

HOMELESS PROGRAM

PURPOSE:

TITLE:

To outline the current limitations contained within the Consolidated Appropriations Act to ensure the Harris Health System Health Ceare for the Homeless Program (HCHP) does not use federal grant funds to support prohibited activities.

POLICY STATEMENT:

The Health eare Care for the Homeless Program will spend federal grant funds in compliance with the Consolidated Appropriations Act that is adopted each year by the legislature.

POLICY ELABORATIONS:

Annually, the Federal government appropriates funds for its departments and programs through the Consolidated Appropriations Act. This act contains provisions that limit the use of grants funds by Health Resources and Services Administration (HRSA) grantees, like the Health eCare for the Homeless Program. The Legislative Mandates generally recur on a continuing annual basis with the passage of a new Appropriations Act, and are restated in guidance issued by the Office of Federal Assistance Management within HRSA.

I. **DEFINITIONS:**

- HARRIS HEALTH HEALTH_CARE FOR THE HOMELESS PROGRAM (HCHP): A program that provides outreach services to Homeless Individuals through Harris Health's Ambulatory Care Services Community Health Program. The HCHP also provides comprehensive primary health services at shelter-based clinics and mobile health and mobile dental units, on-site case management, financial eligibility determination, and registration for services, as well as, on-site mental health, substance abuse counseling, and residential treatment.
- B. HUMAN EMBRYO OR EMBRYOS: Any organism, not protected as a human subject that is derived by fertilization, parthenogenesis, cloning, or any other means from one or more human gametes or human diploid cells.

Printed versions of this document are uncontrolled. Please go to the Harris Health Document Control Center to retrieve an official controlled version of the document. http

POLICY AND REGULATIONS MANUAL

Policy No:

Page Number:

2 of 7

Effective Date: Board Motion No.

Last Review Date: Due For Revision:

C. LEGISLATIVE MANDATES: Provisions within the annual Consolidated Appropriations Act that restrict federal grantees from using federal grant funds, including grants received from the HRSA, to support certain specific activities.

II. **COMPLIANCE WITH HRSA MANDATES**

The Healthcare for the Homeless Program shall comply with all Legislative Mandates when spending federal grant funds. The current Legislative Mandates include the following:

- Salary Limitation
- Gun Control
- Anti-Lobbying
- Acknowledgment of Federal Funding
- Restriction on Abortions
- Exceptions to Restriction on Abortions
- Ban on Funding Human Embryo Research
- Limitation on Use of Funds for Promotion of Legalization of Controlled Substances
- Restriction of Pornography on Computer Networks
- Restriction on Distribution of Sterile Needles
- Confidentiality Agreements
- A. HRSA's Legislative Mandates will be reviewed annually by the Director of the HCHP, who may seek assistance from the Harris County Attorney's Office, and, if changes to the Legislative Mandates are made, Harris Health policies shall be revised accordingly to include such changes and any new requirements from the Consolidated Appropriations Act. This revised policy will be approved by the Board of Trustees.
- B. The HCHP Director will be responsible for ensuring that staff receive any training required based on Legislative Mandate changes.
- C. Harris Health will incorporate the Legislative Mandates into its audit of the HCHP Program.
- D. Harris Health shall:

Printed versions of this document are uncontrolled. Please go to the Harris Health Document Control Center to retrieve an official controlled version of the document. http://

POLICY AND REGULATIONS MANUAL

Policy No:

Page Number:

3 of 7

Effective Date: Board Motion No

Last Review Date: Due For Revision:

1. Set the salary limitation for charging of salaries to federal grant funds at a rate not to exceed the Executive Level II salary in the federal government;

- 2. Not use any HRSA funds:
 - To advocate or promote gun control; a.
 - For publicity or propaganda purposes; or for the preparation, distribution, or use b. of any kit, pamphlet, booklet, publication, electronic communication, radio, television, or video presentation designed to support or defeat the enactment of legislation before the Congress or any State or local legislature or legislative body, except in presentation to the Congress or any State or local legislature itself, or designed to support or defeat any proposed or pending regulation, administrative action, or order issued by the executive branch of any State or local government, except in presentation to the executive branch of any State or local government itself, other than for normal and recognized executive legislative relationships, for publicity or propaganda purposes;
 - To pay the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before the Congress or any State government, State legislature or local legislature or legislative body, other than for normal and recognized executive-legislative relationships or participation by an agency or officer of a State, local or tribal government in policymaking and administrative processes within the executive branch of that government;

NOTE: The prohibitions in subsections b. and c. shall include any activity to advocate or promote any proposed, pending or future Federal, State or local tax increase, or any proposed, pending, or future requirement or restriction on any legal consumer product, including its sale or marketing, including but not limited to the advocacy or promotion of gun control.

- For any abortion or for Health Benefits Coverage that includes coverage of d. abortion. This limitation does not:
 - Apply to an abortion (1) if the pregnancy is the result of an act of rape or incest; or (2) in the case where a woman suffers from a physical disorder,

Printed versions of this document are uncontrolled. Please go to the Harris Health Document Control Center to retrieve an official controlled version of the

Policy No:

Page Number:

4 of 7

Effective Date: Board Motion No.

Last Review Date: Due For Revision:

POLICY AND REGULATIONS MANUAL

physical injury, or physical illness, including a life-endangering physical condition caused by or arising from the pregnancy itself, that would, as certified by a physician, place the woman in danger of death unless an abortion is performed;

- ii. Prohibit the expenditure by a State, locality, entity or private person of State, local, or private funds; OR
- Restrict the ability of any managed care provider from offering abortion 111. coverage or the ability of a State or locality to contract separately with such a provider for such coverage with State funds (other than a State's or locality's contribution of Medicaid matching funds);
- Make funds available to a Federal agency or program, or to a State or local government, if such agency, program, or government subjects any institutional or individual Health Care Entity to discrimination on the basis that the Health Care Entity does not provide, pay for, provide coverage of, or refer for abortions;
- For the creation of a Human Embryo or Embryos for research purposes; f.
- Any activity that promotes the legalization of any drug or other substance included in schedule 1 of the schedules of controlled substances except for normal and recognized executive-congressional communications. This limitation shall not apply when there is significant medical evidence of a therapeutic advantage to the use of such drug or other substance or that federally sponsored clinical trials are being conducted to determine therapeutic advantage;
- h. To purchase any sterile needles for the hypodermic injection of any illegal drug. Nor, to carry out any program of distributing sterile needles or syringes for the hypodermic injection of any illegal drug;
- To maintain or establish a computer network unless such network blocks the viewing, downloading, and exchanging of pornography. The foregoing shall not limit the use of funds necessary for any federal, state, tribal, or local law enforcement agency or any other entity carrying out criminal investigations, prosecution, or adjudication activities;

Printed versions of this document are uncontrolled. Please go to the Harris Health Document Control Center to retrieve an official controlled version of the document. http

POLICY AND REGULATIONS MANUAL

Policy No:

Page Number:

5 of 7

Effective Date: Board Motion No.

Last Review Date: Due For Revision:

To fund a contract, grant, or cooperative agreement with an entity that requires employees or contractors of such entity seeking to report fraud, waste, or abuse to sign internal confidentiality agreements or statements prohibiting or otherwise restricting such employees or contractors from lawfully reporting such waste, fraud, or abuse to a designated investigative or law enforcement representative of a Federal department or agency authorized to receive such information.

E. Funding Acknowledgement:

When issuing statements, press releases, requests for proposals, bid solicitations and other documents describing projects or programs funded in whole or in part with Federal money, Harris Health shall clearly state:

- 1. The percentage of the total costs of the program or project which will be financed with Federal money;
- 2. The dollar amount of Federal funds for the project or program; and
- 3. Percentage and dollar amount of the total costs of the project or program that will be financed by non-governmental sources.

Formatted: Numbered + Level: 1 + Numbering Style: 1, 2, 3, ... + Start at: 1 + Alignment: Left + Aligned at: 0.25" + Indent at: 0.5"

Formatted: Font: 14 pt

Formatted: Indent: Left: 0.5"

Formatted: Numbered + Level: 1 + Numbering Style: 1, 2, 3, ... + Start at: 1 + Alignment: Left + Aligned at: 0.25" + Indent at: 0.5"

Printed versions of this document are uncontrolled. Please go to the Harris Health Document Control Center to retrieve an official controlled version of the document. http



POLICY AND REGULATIONS MANUAL

Policy No:

Page Number:

6 of 7

Effective Date: Board Motion No.

Last Review Date: Due For Revision:

REFERENCES/BIBLIOGRAPHY:

Grants Policy Bulletin on Legislative Mandates in Grant Management for most recent Fiscal Y<u>ear 2022</u>

Health Center Program Compliance Manual - Health Resources and Services Administration (HRSA), Bureau of Primary Healthcare

OFFICE OF PRIMARY RESPONSIBILITY:

Harris Health System Health Ceare for the Homeless Program

Printed versions of this document are uncontrolled. Please go to the Harris Health Document Control Center to retrieve an official controlled version of the document. https://document.

HARRISHEALTH SYSTEM

POLICY AND REGULATIONS MANUAL

Policy No:

Page Number:

7 of 7

Effective Date: Board Motion No.

Last Review Date: Due For Revision:

REVIEW/REVISION HISTORY:

_ , ,	, 10101, 11101		
Effective Date	Version # (If Applicable)	Review/ Revision Date (Indicate Reviewed or Revised)	Approved by:

Printed versions of this document are uncontrolled. Please go to the Harris Health Document Control Center to retrieve an official controlled version of the document. https://apps.hchd.local/sites/dcc



Meeting of the Board of Trustees

Thursday, October 24, 2024

Consideration of Approval of the HCHP HIV Prevention Funding

Attached for review and approval:

• HCHP HIV Prevention Funding

Administration recommends that the Board approve the Healthcare for the Homeless Program Report as required by the United States Department of Health and Human Services which provides funding to the Harris County Hospital District d/b/a/ Harris Health System to provide health services to persons experiencing homelessness under Section 330 (h) of the Public Health Service Act.

Jehnifer Small

Executive Vice President – Ambulatory Care Services

Harris Health
H80CS00038
BUDGET NARRATIVE
Ending the HIV Epidemic – Primary Care HIV Prevention
One-time Funding
January 1, 2024 through December 31, 2024

EXPENSES:

	Fee	deral			
SUPPLIES	Rec	quest	Total		
OraSure HIV test kits: \$1,100/kit (100					
tests in each kit) $x 24 = $26,400$	\$	26,400	\$	26,400	
HIV Control Kits: \$25/kit x 24 = \$600	\$	600	\$	600	
Male condoms: \$79.80/case x 20 =					
\$1,596	\$	1,596	\$	1,596	
Female condoms: $$755/box x 7 = $5,285$	\$	5,285	\$	5,285	
Lubricant: $$96/case \times 25 = $2,400$	\$	2,400	\$	2,400	
Educational pamphlets = \$719	\$	719	\$	719	
Total Supplies	\$	37,000	\$	37,000	

		_	
TOTAL DIRECT CHARGES	\$ 37,000	\$	37,000

OraSure HIV test kits will be used to provide HIV testing to people experiencing homelessness. Condoms and lubricant will be used to encourage safer sex practices.

PCHP funds will be used separately and distinctly from other health center awards.



Meeting of the Board of Trustees

Thursday, October 24, 2024

Executive Session

Review of the Community Health Choice, Inc. (CHCI) and Community Health Choice Texas, Inc. (CHCT) financial performance for the eight months ending August 2024, pursuant to Tex. Gov't Code Ann. §551.085.

Anna Mateja

Chief Financial Officer

Community Health Choice, Inc.

Community Health Choice Texas, Inc.

Victoria Nikitin

EVP & Chief Financial Officer

Victoria Nikitin

Harris Health



Meeting of the Board of Trustees

- Pages 145-150 Were Intentionally Left Blank -

BOARD OF TRUSTEES Meeting of the Board of Trustees



Thursday, October 24, 2024

Executive Session

Discussion Regarding Expansion of Clinical Service Lines, Pursuant to Tex. Gov't Code Ann. §551.072 and Tex. Gov't Code Ann. §551.085.

Louis G. Smith, Jr.

Sr. EVP/Chief Operating Officer



Meeting of the Board of Trustees

- Pages 152-157 Were Intentionally Left Blank -



Meeting of the Board of Trustees

Thursday, October 24, 2024

Executive Session

Consultation with Attorney Regarding Settlement of Claim with Johnston, LLC, Pursuant to Tex. Gov't Code Ann. §551.071 and Possible Action Upon Return to Open Session.

Sara Thomas

Chief Legal Officer/Division Director Harris County Attorney's Office

Harris Health System



Meeting of the Board of Trustees

- Pages 159-160 Were Intentionally Left Blank -



Meeting of the Board of Trustees

Thursday, October 24, 2024

Executive Session

Report by the Executive Vice President, Chief Compliance and Risk Officer, Regarding Compliance with Medicare, Medicaid, HIPAA and Other Federal and State Health Care Program Requirements, Including Status of Fraud and Abuse Investigations, Pursuant to Tex. Health & Safety Code Ann. §161.032.

Carolyn Jones Carolynn Jones, JD, CHC

Executive Vice President, Chief Compliance and Risk Officer



Meeting of the Board of Trustees

- Pages 162-172 Were Intentionally Left Blank -